Official Protocol Title: 
NCT number:  [STUDY_ID_REMOVED]  
Document Date:  14-Sep-2020A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, 
Double-Blind Clinical Trial to Study the Safety and Efficacy of 
Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in 
Pediatric Subjects with Complicated Urinary Tract Infection, 
Including Pyelonephritis
Product:   MK-7625A 1
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTHIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., 
WHITEHOUSE STATION , NJ, U.S.A.
SPONSOR:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc. 
(hereafter referred to as the Sponsor or Merck)
One Merck Drive
P.O. Box 100
Whitehouse Station , New Jersey , 08889-0100, U.S.A.
Protocol-specific Sponsor Contact information can be found in the Investigator Trial File 
Binder(or equivalent) .
TITLE:
A Phase 2, Randomized, Active Comparator -Controlled, Multicenter, Double -Blind Clinical 
Trial to Study  the Safet y and Efficacy  of Ceftolozane/Tazobactam (MK -7625A) Versus 
Meropenem in Pediatric Subjects with Complicated Urinary Tract Infection, I ncluding 
Pyelonephritis
IND NUMBER:   104,490
EudraCT NUMBER:   2016-004153-32 
   05L60Q
Product:   MK-7625A 2
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTABLE OF CONTENTS
DOCUMENT HISTORY ..................................................................................................... 10
SUMMARY OF CHANGES ................................................................................................ 11
1.0TRIAL SUMMARY .................................................................................................. 17
2.0TRIAL DESIGN........................................................................................................ 18
Trial Design ........................................................................................................... 18
Trial Diagram ........................................................................................................ 20
3.0OBJECTIVE(S) & HYPOTHESIS(ES) .................................................................. 20
Primary Objective(s) & Hypothesis(es) .............................................................. 20
Secondary Objective(s) & Hypothesis(es) ........................................................... 21
Exploratory Objectives ......................................................................................... 21
4.0BACKGROUND & RATIONALE .......................................................................... 21
Background ........................................................................................................... 21
Pharmaceutical and Therapeutic Background .................................................... 21
Ceftolozane/Tazobactam .............................................................................. 21
Complicated Urinary  Tract Infection........................................................... 23
Completed Preclinical and Clinical Trials of Ceftolozane/Tazobactam .............24
Ongoing Clinical Trials of Ceftolozane/Tazobactam ......................................... 25
Information on Other Trial -related Therap y....................................................... 26
Rationale ................................................................................................................ 26
Rationale for the Trial and Selected Subject Population .................................... 26
Rationale for Sample Size ............................................................................ 27
Rationale for Dose Selection/Regimen ............................................................... 28
Rationale for Ceftolozane/Tazobactam Dosage ........................................... 28
Rationale for the Use of Comparator ........................................................... 32
Rationale for Comparator Dosage ............................................................... 32
Rationale for Duration of Therap y and Optional Ora l Step-Down 
Antibiotic Therap y....................................................................................... 33
Rationale for Endpoints ...................................................................................... 33
Rationale for Safety  Endpoints .................................................................... 33 
   05L60Q
Product:   MK-7625A 3
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Rationale for Efficacy  Endpoints ................................................................ .34
4.2.3.2.1 Clinical Outcome .................................................................................. 35
4.2.3.2.2 Microbiological Outcome ..................................................................... 36
Rationale for Pharmacokinetic Endpoints ................................................... 38
Benefit/Risk ........................................................................................................... 38
5.0METHODOLOGY ................................................................................................... 39
Entry Criteria ........................................................................................................ 39
Diagnosis/Condition for Entry  into the Trial ...................................................... 39
Subject Inclusion Criteria .................................................................................... 39
Subject Exclusion Criteria .................................................................................. 42
Trial Treatment(s) ................................................................................................ 44
Intravenous Trial Treatments .............................................................................. 44
Optional Oral Step- down Therap y...................................................................... 46
Trial Treatments: Administrative Considerations ............................................... 47
Dose Selection .................................................................................................... 47
Dose Selection (Preparation) ....................................................................... 47
Timing of Dose Administr ation.......................................................................... 48
Trial Blinding...................................................................................................... 48
Randomization ...................................................................................................... 48
Stratification .......................................................................................................... 48
Concomitant Medications/Vaccinations (Allowe d & Prohibited) .................... 49
Rescue Medications & Supportive Care ............................................................. 49
Diet/Activity/Other Considerations ..................................................................... 49
Subject Withdrawal/Discontinuation Criteria ................................................... 49
Discontinuation of Treatment ............................................................................. 49
Withdrawal from the Trial .................................................................................. 51
Subject Replacement Strategy ............................................................................. 51
Beginning and End of the Trial ........................................................................... 51
Clinical Criteria for Early Trial Termination ................................................... 51
6.0TRIAL FLOW CHART ........................................................................................... 52
7.0TRIAL PROCEDURES ........................................................................................... 55 
   05L60Q
Product:   MK-7625A 4
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Trial Procedures ................................................................................................... 55
Administrative Procedures .................................................................................. 55
Informed Consent/Assent ............................................................................. 55
7.1.1.1.1 General Informed Consent/A ssent........................................................ 55
Inclusion/Exclusion Criteria ........................................................................ 56
Subject Identification Card .......................................................................... 56
Medical History ........................................................................................... 56
Prior and Concomitant Medications Review ............................................... 56
7.1.1.5.1 Prior Medications .................................................................................. 56
7.1.1.5.2 Concomitant Medications ..................................................................... 57
Assignment of Screening Number ............................................................... 57
Assignment of Treatment/Randomization Number ..................................... 57
Trial Compliance (Medication) .................................................................... 57
Clinical Procedures/Assessments ........................................................................ 57
Body Weight, Height and Vital Signs .......................................................... 57
Physical Examination ................................................................................... 58
Assessment of Clinical Signs and S ymptoms of Complicated Urinary  
Tract Infection, Including P yelonephritis .................................................... 58
Adverse Event Monitoring ........................................................................... 58
Assessment of Clinical Out come................................................................ .58
Assessment of Microbiological Outcome .................................................... 59
Assessment of Composite Clinical and Microbiological Outcome .............59
Assessment of Emergent Infection.............................................................. 59
Laboratory  Procedures/Assessments .................................................................. 59
Laboratory  Safety Evaluations (Hematology  and Chemistry )..................... 59
Urine Microscop y........................................................................................ 60
Pregnancy  Testing........................................................................................ 61
Assessment of Creatinine Clearance ............................................................ 61
Urine Samples for Culture ........................................................................... 61
Blood Samples for Culture ........................................................................... 62
Pharmacokinetic Evaluations ....................................................................... 63
Other Procedures ................................................................................................ .63
Withdrawal/Discontinuation ........................................................................ 63 
   05L60Q
Product:   MK-7625A 5
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Lost to Follow -up......................................................................................... 64
Unblinded Pharmacist.................................................................................. 64
Subject Blinding/Unblinding ....................................................................... 64
Calibration of Critical Equipment ................................................................ 65
Visit Requirements .............................................................................................. 65
Screening...................................................................................................... 65
Randomization Visit .................................................................................... 65
Clinical Assessment Visits on I ntravenous Study  Treatment ...................... 66
End of IV Treatment Visit ........................................................................... 66
Clinical Assessment Visit on Oral Step -down Therap y.............................. 66
End of Treatment Visit ................................................................................. 66
Test of Cure Visit......................................................................................... 67
Last Follow -up Visit.................................................................................... 67
Subjects Who Prematurely Discontinue From Study Treatment or the 
Trial.............................................................................................................. 67
Assessing and Recording Adverse Events .......................................................... 67
Definition of an Overdose for This Protocol and Reporting of Overdose to 
the Sponsor .......................................................................................................... 68
Reporting of Pregnancy  and Lactation to the Sponsor ....................................... 68
Immediate Reporting of Adverse Events to the Sponsor .................................... 69
Serious Adverse Events ............................................................................... 69
Events of Clinical I nterest............................................................................ 70
Evaluating Adverse Events ................................................................................. 70
Sponsor Responsibility  for Reporting Adverse Events ...................................... 73
TRIAL GOVERNANCE AND OVERSIGHT ................................................... 73
Executive Oversight Committee ......................................................................... 73
Data Monitoring Committee ............................................................................... 73
8.0STATISTICAL ANALYSIS PLAN ........................................................................ 73
Statistical Analysis Plan Summary..................................................................... 74
Responsibility for Analyses/In -house Blinding .................................................. 75
Hypotheses/Estimation......................................................................................... 76
Analysis Endpoints ............................................................................................... 76
Safety Endpoints ................................................................................................ .76 
   05L60Q
Product:   MK-7625A 6
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Adverse Events ............................................................................................ 76
Laboratory  Data........................................................................................... 76
Vital Signs.................................................................................................... 77
Efficacy Endpoints .............................................................................................. 77
Secondary  Efficacy Endpoints ..................................................................... 77
Exploratory  Efficacy Endpoints ................................................................... 77
Pharmacokinetic Endpoints ................................................................................ 78
Analysis Populations ............................................................................................. 78
Safety Anal ysis Populations ............................................................................... 78
Efficacy Analysis Populations ............................................................................ 78
Statistical Methods ................................................................................................ 79
Statistical Methods for Safet y Analyses............................................................. 79
Statistical Methods for Efficacy  Analyses.......................................................... 81
Summaries of Baseline Characteristics, Demographics, and Other Anal yses....83
Analyses of Baseline Characteristics and Demographics ............................ 83
Population Pharmacokinetic A nalyses......................................................... 84
Interim Analyses................................................................................................... 84
Multiplicity ............................................................................................................ 84
Sample Size and Power Calculations .................................................................. 84
Subgroup Analyses ............................................................................................... 85
Compliance (Medication Adherence) .................................................................. 85
Extent of Exposure ................................................................................................ 86
9.0LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES ................................................................................................................. 86
Investigational Product ........................................................................................ 86
Packaging and Labeling Information ................................................................ .87
Clinical Supplies Disclosure ................................................................................. 88
Storage and Handling Requirements .................................................................. 88
Discard/Destruction/Returns and Reconciliation .............................................. 88
Standard Policies ................................................................................................... 88
10.0ADMINISTRATIVE AND REGULATORY DETAILS ....................................... 88
Confidentiality ....................................................................................................... 88 
   05L60Q
Product:   MK-7625A 7
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Confidentiality  of Data....................................................................................... 88
Confidentiality  of Subject Records ..................................................................... 89
Confidentiality  of Investigator Information ........................................................ 89
Confidentiality  of IRB/IEC I nformation ............................................................. 89
Compliance with Financial Disclosure Requirements ....................................... 90
Compliance with Law, Audit and Debarment ................................................... 90
Compliance with Trial Registration and Results Posting Requirements ........92
Quality Management System ............................................................................... 92
Data Mana gement................................................................................................ .92
Publications ........................................................................................................... 93
11.0LIST OF REFERENCES ......................................................................................... 95
12.0 APPENDICES ......................................................................................................... 100
Merck Code of Conduct for Clinical Trials ...................................................... 100
Approximate Blood Volumes Drawn/Collected by Trial Visit ....................... 102
List of Abbreviations and Def initions of Terms ............................................... 103
13.0SIGNATURES ......................................................................................................... 106
Sponsor's Representative ................................................................................... 106
Investigator .......................................................................................................... 106 
   05L60Q
Product:   MK-7625A 8
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialLIST OF TABLES
Table 1 Ceftolozane Exposure and Target Attainment Summary for Simulated Adult 
and Pediatric Subjects ................................ ................................ ............................ 30
Table 2 Tazobactam Exposure and Target Attai nment Summary  for Simulated Adult 
and Pediatric Subjects ................................ ................................ ............................ 31
Table3Clinical Outcome Categories ................................ ................................ .................. 36
Table4Microbiological Outcome Categories ................................ ................................ .....37
Table5Composite Clinical and Microbiological Outcome Categories .............................. 37
Table6Emergent Infection Categories ................................ ................................ ............... 38
Table 7 Intravenous Trial Trea tments................................ ................................ .................. 45
Table 8 Recommended Oral Step -down Therap y Options ................................ .................. 47
Table 9 Laboratory  Safety Evaluations ................................ ................................ ................ 60
Table 10 Evaluating Adverse Events ................................ ................................ .................... 71
Table11Efficacy Analysis Populations ................................ ................................ ................ 79
Table12Analysis Strategy for Safety  Parameters ................................ ................................ 81
Table13Analysis Strategy  for Efficacy  Variables ................................ ............................... 82
Table14Estimated Two-sided 95% Confidence Intervals Based on Different Assumed 
Observed Rates of Efficacy  Endpoints ................................ ................................ ...83
Table15Estimated Treatment Differences and Two-sided 95% Confidence Intervals.......85
Table16Product Descriptions ................................ ................................ .............................. 87
Table17Approximate Blood Volumes Collected by  Trial Visit ................................ ........102 
   05L60Q
Product:   MK-7625A 9
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialLIST OF FIGURES
Figure1Trial Diagram ................................ ................................ ................................ ......20 
   05L60Q
Product:   MK-7625A 10
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialDOCUMENT HISTORY
Document Date of Issue Overall Rationale
Amendment 3 14-SEP-2020 Due to enrollment challenges in the 
remaining age groups in both thistrial in 
pediatric subjects with cUTI 
(MK-7625A-034) and also in the 
companion trial in pediatric subjects with 
cIAI (MK -7625A-035), individual study  
age group minimum requirement s for 
Groups 3-5 were removed in both studies, 
and the overall combined enrollment 
minimum targets for Groups 3 and 5 were 
also reduced to facilitate more timely  
availability  of these important pediatric 
datato healthcareproviders and patients. 
These changes do not impact the key  goals 
or scientific validity  of either study .
Amendment 2 26-APR-2019 Enrollment targets for Groups 3 -5 were 
applied across the present trial in pediatric 
subjects with cUTI (MK -7625A-034) and 
the companion trial in pediatric subjects 
with cIAI (MK -7625A-035).
Amendment 1/Ukraine specific amendment 30-APR-2018 Country-specific amendment to exclude 
enrollment of subjects <3 months old 
(Group 5) in Ukraine.
Original proto col 21-MAR-2017 Not applicable . 
   05L60Q
Product:   MK-7625A 11
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialSUMMARY OF CHANGES
PRIMARY REASON(S)FOR THIS AMENDMENT:
Section Number (s) Section Title(s) Description of Change (s)Rationale
1.0
2.1
4.2.1.1
5.2.1
5.4Trial Summary
Trial Design
Intravenous Trial Treatments
Subject Inclusion Criteria
StratificationRemoved minimum number of 
at least 4 subjects per study  
(MK-7625A-034 and MK -
7625A-035) in Groups 3, 4, 
and 5.
Reduced minimum enrollment 
targets for Groups 3 and 5 
across both studies.Due to enrollment challenges 
in the remaining age groups, 
individual study  age group 
minimum requirement s for 
Groups 3-5 were removed in 
both the MK-7625A-034 and 
MK-7625A-035 studies.  
Additionally , the overall 
combined enrollment 
minimum targets for Groups 3 
and 5 were reduced to facilitate 
more timely  availability  of 
these important pediatric data
to healthcareproviders and 
patients. These changes do not 
impact the key  goals or 
scientific validity  of either 
study. 
   05L60Q
Product:   MK-7625A 12
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialADDITIONAL CHANGE (S)FOR THIS AMEN DMENT:
Section Number (s) Section Title (s) Description of Change (s)Rationale
1.0
5.1.2
5.1.3
5.10
6
7.1.1.1
7.1.1.1.1
7.1.1.3
7.1.5.1
7.2
7.2.2
7.2.3.1
7.2.3.2Trial Summary
Subject Inclusion Criteria
Subject Exclusion Criteria
Beginning and End of the Trial
Trial Flow Chart
Informed Consent/Assent
General Informed 
Consent/Assent
Subject Identification Card
Screening
Assessing and Recording 
Adverse Events
Reporting of Pregnancy  and 
Lactation to the Sponsor
Serious Adverse Events
Events of Clinical I nterestUpdated text for informed 
consent processUpdated to align with Merck 
standard protocol template 
   05L60Q
Product:   MK-7625A 13
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialSection Number (s) Section Title (s) Description of Change (s)Rationale
10.1.2
Confidentiality  of Subject 
Records
4.2.3.2.2 Microbiological Outcome Removed language that 
emergent infections are 
considered to have an 
unfavorable microbiological 
response.As microbiological outcome is 
meant to capture the persistence 
or eradication specifically  of the 
baseline pathogen, emergent 
infections will not contribute to 
the microbiological outcome. 
This change aligns with other 
studies in the ZERBAXA 
program, wherein emergent 
infections are distinct from the 
overall microbiological 
outcome endpoint and are 
described separatel y in the 
CSR.
Table 6 “Emergent Infection 
Categories”Added “and through the TOC 
visit” to the definition of new 
infection. To clarify  the window in which 
new infections will be recorded.  
   05L60Q
Product:   MK-7625A 14
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialSection Number (s) Section Title (s) Description of Change (s)Rationale
5.1.3 Subject Exclusion Criteria For chronic administration of 
systemic corticosteroids that 
could qualify  as an 
immunosuppressing condition 
at screening, added the non -
weight-based definit ion for 
participants weighing >20 kg. To align the pediatric -specific 
definition of 
immunosuppression due to 
corticosteroid use with other 
protocols in the ZERBAXA 
program.
5.2.5
6.0Timing of Dose 
Administration
Trial Flow Chart Added text clarify ing 
maximum duration of 
antibiotics. To clarify  that the final day of 
study treatment may  extend into 
Day 15 to accommodate 
different start and stop times of 
the IV study treatment and/or 
dosing schedules of the oral 
step-down therapy.
5.8.1 Discontinuation of Treatment Added “required for IV study  
treatment only ” to 
discontinuation criteria for 
development of moderate or 
severe impairment of renal 
function. The lower limit of 
50mL/min/1.73 m2only 
applies to 
ceftolozane/tazobactam an d not 
to the various optional oral step -
down treatment options. 
   05L60Q
Product:   MK-7625A 15
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialSection Number (s) Section Title (s) Description of Change (s)Rationale
5.10 Beginning and End of the TrialText defining the end of the 
trial as the last subject’s last 
visit or contact was changed to 
defining the end of the trial as 
when the last data is availa ble 
in either study , MK-7625A-
034 or MK -7625A-035, 
whichever occurs later.Updated to reflect the fact that 
the safety data will be combined 
for analysis across the 2 studies, 
thus the final anal ysis cannot 
begin until both studies are 
completed and final data from 
both trials are available.
7.1.4.4 Subject Blinding/Unblinding Updated template text to 
describe who may  be 
unblinded following 
unblinding .This revision will allow greater 
flexibility  when describing who 
may become unblinded to a 
single participant’ s treatment 
following an unblinding and 
allows the principal 
investigator, site personnel, and 
Sponsor personnel to conduct 
appropriate follow -up medical 
care for the participant once an 
emergency  unblinding has taken 
place.
8.11
8.12Compliance (Medication 
Adherence)
Extent of ExposureUpdated the IV study 
treatment and o verall study  
treatment (including oral step-
down therap y) compliance 
definition and how exposures 
will be summarized.It is clinically informative to 
know the compliance and extent 
of exposure for treated subjects.  
In addition, subjects overall 
study treatment exposure is an 
important criterion to evaluate 
the CE anal ysis population.  
   05L60Q
Product:   MK-7625A 16
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialSection Number (s) Section Title (s) Description of Change (s)Rationale
Global Global Minor editorial and document 
formatting revisions.Minor syntax and grammar 
edits made for clarit y and 
correctness. 
   05L60Q
Product:   MK-7625A 17
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential1.0TRIAL SUMMARY
Abbreviated Title Ceftolozane/tazobactam (MK -7625A) v ersus Meropenem in Pediatric 
cUTI
Sponsor Product Identifiers MK-7625A
Ceftolozane/tazobactam
TrialPhase 2
Clinical Indication Treatment of complicated urinary tract infection (cUTI), including 
pyelonephritis
Trial Type Interventional
Type of control Active control without placebo
Route of administration Intravenous (IV) with optional oral step -down therapy
Trial Blinding Double-blind
Treatment Groups Subjects will be randomized to the experimental 
(ceftolozane/tazobactam) or comparator (meropenem) treatment arm 
to receive IV study treatme nt administered as a 60 -minute(±10 
minutes) infusion as follows:
Group 1(Ages 12 to <18 years, n ≥50combined with Group 2 ):
Ceftolozane 1 g and tazobactam 0.5 g IV every 8 h oursOR
Meropenem 20 mg/kg (maximum1g/dose) IV every 8 hours
Group 2(Ages 6 to <12 years, n ≥50 combined with Group 1):
Ceftolozane 20 mg/kg and tazobactam 10 mg/kg(maximum 
ceftolozane 1g and tazobactam 0.5 g/dose)IV every 8 h oursOR
Meropenem 20 mg/kg (maximum1g/dose) IV every 8 hours
Group 3(Ages 2 to <6 years, n≥57 combined with same age group in 
MK-7625A-035):
Ceftolozane 20mg/kg and tazobactam 1 0mg/kg(maximum 
ceftolozane 1 gand tazobactam 0.5 g/dose)IV every 8 h oursOR
Meropenem 20 mg/kg (maximum 1g/dose) IV every 8 hours
Group 4(Ages 3 months to <2 years, n ≥24 combined with same age 
group in MK-7625A-035):
Ceftolozane 20mg/kg and tazobactam 1 0mg/kg(maximum 
ceftolozane 1g and tazobactam 0.5 g/dose)IV every 8 h oursOR
Meropenem 20 mg/kg (maximum 1g/dose) IV every 8 hours
Group 5(Ages birth [>32 w eeks gestation al ageand ≥7 days 
postnatal] to <3 months, n ≥21combined with same age group in MK-
7625A-035):
Ceftolozane 20 mg/kg and tazobactam 10 mg/kg(maximum 
ceftolozane 1g and tazobactam 0.5 g/dose)IV every 8 h oursOR
Meropenem 20 mg/kg* (maximum 1g/dose) IV every 8 hours
*NOTE: Some literature supports a higher meropenem dosage (up to 
30mg/kg every 8 h ours) for subjects 14 days to <3 months of age, 
therefore meropenem dosing up to 30 mg/kg every 8 h oursmay be 
used for subjects 14 days to <3 months of age at the investigator’s 
discretion.
NOTE:In Ukraine, enrollment w ill be limited to subjects 3 months to 
< 18 years of age (Groups 1 -4). Enrollment of subjects < 3 months of 
age(Group 5) is not applicable at Ukrainian study sites. 
   05L60Q
Product:   MK-7625A 18
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialNumber of trial subjects Approximately 240 (combined across MK-7625A-034 and MK -
7625A-035)subjects w ill be enrolled.
Estimated duration of trial The Sponsor estimates that the trial w ill require approximately 3 years
from the time the first subject (or their legally acceptable 
representative) provides documented informed consent/assent until the 
last subject’s last study -related contact
Duration of Participation Each subject will participate in the trial for approximately 5 to 7 
weeks from the time the subject or subject’s legal representative 
provides documented informed consent  until the last subject’s last 
study-related contact. Afte r a screening phase of up to 48 hours, each 
subject w ill receive study treatment (IV only or IV + oral )for a 
minimum of 7 to a maximum of 14 days. After the end of treatment, 
each subject enters a follow-up phase consisting of a Test of Cure 
(TOC) Visit 5 to 9 days after the last dose of study treatment and a 
Last Follow -up (LFU) Visit 28 to 35 days after the last dose of study 
treatment .
A list of abbreviations used in this document can be found in Appendix 12.3.
2.0TRIAL DESIGN
Trial Design
This is a Phase 2 randomized, active comparator -controlled, multicenter, double-blind trial 
evaluating the safet y and efficacy of ceftolozane/tazobactam (MK -7625A) versus meropenem 
in pediatric subjects from birth (defined as >32 weeks gestational age and ≥7 days postnatal) 
to <18 years of age with cUTI, including p yelonephritis.
MK-7625A-035 is a companion Phase 2randomized, double-blind trial of 
ceftolozane/tazobactam (plus metronidazole) versus meropenem in pediatric subjects with 
cIAI;MK-7625A-034 and MK-7625A-035 will be pooled together for a combined safety 
database. Thus,approximately 240subjects(combined acrossMK-7625A-034 and MK-
7625A-035)will be stratified by age to receive study treatment. Afterminimum enrollment 
targets for each age group are met (202subjects total), additional subjects (combined across
MK-7625A-034 and MK -7625A-035)will be enrolled in any  of the 5age groups.
In MK-7625A-034, subjects will be randomized in a 3:1 ratio to receive IV 
ceftolozane/tazobactam or meropenem. After receiving at least 9 doses of double-blind IV 
study treatment, subjects in either treatment arm may be switched to open-label, standard-of-
careoral step-down antibiotic therapy  at the investigator’s discretion. Oral step -down therap y 
is considered study treatment. Recommendations for oral step-down therapy are provided in 
Section 5.2.2 –Optional Oral Step- down Therap y.
The total duration of study treatment (IV only or IV + oral) is a minimum of 7 days and a 
maximum of 14 day s.Randomization Ratio 3:1for ceftolozane/tazobactam: meropenem . 
   05L60Q
Product:   MK-7625A 19
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialSubjects will be randomized to the experimental (ceftolozane/tazobactam) or comparator 
(meropenem) treatment arm to receive IV study treatment administered as a 60-minute 
(±10minutes) infusion as follows:
Group 1(Ages 12 to <18 y ears, n≥50 combined with Group 2):
Ceftolozane 1 g and tazobactam 0.5 g IV every  8 hours OR
Meropenem 20 mg/kg (maximum of 1 g/dose) IV every 8 hours
Group 2(Ages 6 to <12 y ears, n≥50 combined with Group 1):
Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g and tazobactam
0.5 g/dose) IV every 8 hours OR
Meropenem 20 mg/kg (maximum of 1 g/dose) IV every 8 hours
Group 3(Ages 2 to <6 y ears, n≥57 combined with same age group in MK-7625A-035):
Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g and tazobactam
0.5 g/dose) IV every 8 hours OR
Meropenem 20 mg/kg (maximum of 1 g/dose) IV every 8 hours
Group 4(Ages 3 months to <2 years, n≥24 combined with same age group in MK-7625A-035 ):
Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g and tazobactam
0.5 g/dose) IV every 8 hours OR
Meropenem 20 mg/kg (maximum of 1 g/dose) IV every 8 hours
Group 5(Ages birth [>32 weeks gestational age and ≥7 days postnatal] to <3 months, 
n≥21combined with same age group in MK-7625A-035):
Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g and tazobactam
0.5 g /dose) IV every 8 hours OR
Meropenem 20 mg/kg* (maximum of 1 g/dose) IV every 8 hours
*NOTE: There is literature that supports a higher meropenem dosage (up to 30 mg/kg every 8 
hours) for subjects 14 days to <3 months of age. Therefore,meropenem dosing up to 30 mg/kg 
every 8 hours may be used for subjects 14 days to <3 months of age at the investigator’s 
discretion.
NOTE: In Ukraine, enrollment will be limited to subjects 3 months to < 18 years of age (Groups 
1-4). Enrollment of subjects < 3 months of age(Group 5) is not applicable at Ukra inian study  
sites. 
Clinical and microbiological assessments will be performed at the following visits:
End of IV Treatment Visit(EOIV)
End of Treatment Visit(EOT)
Test of Cure Visit(TOC)
NOTE: For subjects who receive IV study treatment only(without optional oral step-down 
therapy), a separate assessment does not need to be performed at the EOT Visit; the EOIV 
Visitwill serve as the EOT Visit.
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit windows, are outlined in the Trial Flow Chart - Section 6 .0. Details of each 
procedure are provided in Section 7.0 – Trial Procedures. 
   05L60Q
Product:   MK-7625A 20
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Trial Diagram
The trial design is depicted in Figure1.
Figure1Trial Diagram
3.0OBJECTIVE(S) & HYPOT HESIS(ES)
In male and female subjects from birth (>32 weeks gestational age and ≥7 days postnatal) to 
<18 years of age with cUTI:
Primary Objective(s) & Hypothesis (es)
To evaluate the safety and tolerability  of ceftolozane/tazobactam compared with that of 
meropenem
 
   05L60Q
Product:   MK-7625A 21
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Secondary Objective(s) & Hyp othesis(es)
1.To evaluate the efficacy of ceftolozane/tazobactam compared with that of meropenem 
with respect to clinical response at the EOT and TOC Visit s
2.To evaluate the efficacy  of ceftolozane/tazobactam compared with that of meropenem 
with respect to per -subject microbiological response at the EOT and TOC Visit s
Exploratory Objectives
1.To evaluate the pharmacokinetics (PK) of ceftolozane and tazobactam
2.To evaluate the efficacy ofceftolozane/tazobactam compared with that of meropenem 
with respect to clinical response at the EOIV Visit
3.To evaluate the efficacy of ceftolozane/tazobactam compared with that of meropenem 
with respect to per -subject microbiologic alresponse at the EOIV Visit
4.To evaluate the efficacy  of ceftolozane/tazobactam compared with that of meropenem 
with respect to per-pathogen microbiologic alresponse at the EOIV, EOT, and TOC 
Visits
5.To evaluate the efficacy  of ceftolozane/tazobactam compared with that of meropenem 
with respect to composite response (clinical response and per-subject microbiological 
response) at the EOIV, EOT, and TOC Visits
NOTE: For subjects who receive IV study treatment only (without optional oral step-down 
therapy), a separate assessment does not need to be performed at the EOT Visit; the EOIV 
Visitwill serve as the EOT Visit.
4.0BACKGROUND & RATIONA LE
Background
Refer to the Investigator’s Brochure (IB)/approved labeling for detailed background 
information on ceftolozane/tazobactam.
Pharmaceutical and Therapeutic Background
Ceftolozane/Tazobactam
Ceftolozane/tazobactam, a novel combination of ceftolozane and the β-lactamase inhibitor 
(BLI), tazobactam, is used to treat serious bacterial infections. Ceftolozane is a member of the 
cephalosporin class of antibiotics, which is well characterized in ter ms of safety , efficacy, and 
general antimicrobial profile. While ceftolozane alone represents an important therapeutic 
option for the treatment of infections caused by Pseudomonas aeruginosa , the efficacy of 
ceftolozane for the treatment of suspected gram-negative infections in general could be 
compromised by the spread of extended- spectrum β-lactamase (ESBL)-producing bacteria. 
Combining ceftolozane with a BLI such as tazobactam broadens its in vitro spectrum of  
   05L60Q
Product:   MK-7625A 22
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialactivity to include many  drug-resistant Ente robacteriaceae and is thereb y likely to improve its 
clinical utility  against gram -negative bacteria.
Ceftolozane (both alone and in combination with tazobactam) exhibits time -dependent killing 
activity against various gram-negative organisms, including drug-resistant P. aeruginosa . 
Ceftolozane/tazobactam has been shown to be active against strains of P. aeruginosa that are 
resistant to carbapenems, cephalosporins, fluoroquinolones, and/or aminoglycosides, 
including the majority of multidrug -resistant (MDR) isolates. The in vitro activity of 
ceftolozane/tazobactam against the majority of ESBL-producing gram-negative bacilli and 
important anaerobic pathogens such as Bacteroides fragilis is greater than that of ceftolozane 
alone. Ceftolozane/tazobactam has no a ctivity against enterococci and staphy lococci.
Compared withother cephalosporins, ceftolozane requires a lower percentage of time above 
the minimum inhibitory  concentration (T>M IC)of 8 µg/mL to achieve bacteriostasis (21% to 
29%) or 1-log killing (27% to35%) in animal models. Additionally , ceftolozane/tazobactam 
was superior to piperacillin/tazobactam against ESBL-producing Escherichia coli in a mouse 
sepsis model.
Clinical trials in adults have demonstrated that the PK of ceftolozane/tazobactam is linear 
across a wide range of doses (up to 4.5 g [3 g ceftolozane/1.5 g tazobactam] as a single -dose), 
distributes primarily  to the extracellular fluid, has a relatively  short terminal elimination half -
life (approximately  2to 3hours for ceftolozane and 1 hourfor tazobactam), and has low 
protein-binding (approximately  16% to 21% for ceftolozane and 30% for tazobactam). In 
adults, at the approved dose of 1.5 g, the mean (coefficient of variation [%CV]) values for area 
under the concentration -timecurve (AUC) on Day 1 were172 (14) and 24.4 (18) µg•h/mL for 
ceftolozane and tazobactam, respectivel y. The mean (%CV) values for maximum observed 
concentration (Cmax)on Day 1 were69.1 (11) and 18.4 (16) µg/mL for ceftolozane and 
tazobactam , respectively . As ceftolozane/tazobactam is primarily removed from the systemic 
circulation by renal excretion, dose adjustments are necessary  in some subjects with renal 
impairment.
The safety and efficacy  of ceftolozane/tazobactam was demonstrated in Phase 3 trials in adult 
subjects with cUTI or complicated intra -abdominal infection (cIAI). In these Phase 3 trials, the 
overall incidence of treatment -emergent adverse events (TEAEs) was similar in the 
ceftolozane/tazobactam and comparator treatment arms. Ceftolozane/tazobactam was found to 
be noninferior to thecomparator in these Phase 3 trials.
In summary , ceftolozane is a novel cephalosporin antibiotic that, in combination with apotent 
BLI,tazobactam, has broad-spectrum antibacterial coverage against Enterobacteriaceae, 
including ESBL-producing strains, and MDR P. aeruginosa . Ceftolozane/tazobactam is 
approved for use in adult patients with cUTI, including pyelonephritis, and cIAI (in 
combination with metronidazole) at a dose of 1.5 g (1 g ceftolozane/0.5 g tazobactam) every 
8hours. Both in vitro and in vivo safety and efficacy data support its continued clinical 
investigation in the pediatric population. 
   05L60Q
Product:   MK-7625A 23
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Complicated Urinary Tract Infection
Incommunity  and hospital settings, urinary tract infections (UTIs) are among the most 
common infections encountered in pediatric patients [1] [2] [3]. Urinary tract infection is 
defined as microorga nism colonization in the normally  sterile urinary  tract (bacteriuria) in the 
presence of urinary symptoms [4]. The frequency of bacteriuria is highest in young children 
and elderly men and women; however, symptomatic infection occurs most frequently in 
females 15 to 29 y ears of age [4] . The incidence of UTI  in the pediatric population is reported 
to be highest overall in the first year of life; the incidence decreases substantially  in boys after 
infancy, but increases in girls as they  get older [5] [6] .
Classification of UTI is performed according to the anatomical site of infection, and 
distinguishes between lower tra ct infections of the bladder (cy stitis) or urethra (urethritis) and 
upper tract infections of the ureter, collecting system, and renal parenchyma (pyelonephritis) 
[7]. Further classification subdivides the condition into uncomplicated UTI and cUTI. 
Complicated UTI that does not involve the upper urinary tract is often referred to as 
complicated lower UTI (cLUTI). Complicated UTI is characterized b y white blood cells inthe 
urine (pyuria) and a documented microbial pathogen on culture of urine or blood, accompanied 
by local and systemic signs and symptoms, including fever, chills, malaise, flank pain, back 
pain, and/or costovertebral angle (CVA) pain or tenderness, that occur in the presence of a 
functional or anatomical abnormality  of the urinary tract or in the presence of catheterization 
[8]. Diagnosis of cUTI is therefore made irrespective of the severity or location of theinfection.
As a result of predisposing anatomical or functional abnormalities of the urinary  tract, cUT I is 
associated with a higher risk of recurrent infection and relapse in comparison to uncomplicated 
UTI [7] [9]. Conditions that increase the risk of cUTI include the presence of an indwelling 
urinary catheter, increased residual urine after voiding (eg, neurogenic bladder), obstructive 
uropathies such as nephrolithiasis or fibrosis, azotemia caused by intrinsic renal disease, and 
urinary retention, including retention caused by benign prostatic hypertrophy  [8]. In the 
pediatric population, the nature of the UTI is presumed complicated when confirmed in 
neonates and infants, owing to the high correlation between functional or anatomical 
abnormalities of the urinary  tract and concurrent bacteremia, which ultimately  leads to higher 
risk of renal scarring and long -term morbidity  in this population [10] [11] .
In the pediatric population , obstruction and urinary tract dysfunction are among the most 
frequent causes of UTI [2]. Vesicouretic reflux is the most common obstructive anomaly 
detected in pediatric patients being investigated with their first UTI  [12]. Other circumstances 
that affect UT I risk in pediatric patients include lack of circumcision in males, non-retractable 
foreskin (phimosis), labial adhesions, sexual activity, chronic constipation, systemic disorders
(eg, immunological compromise , diabetes mellitus, sickle cell anemia), dysfunctional voiding, 
neuropathic bladder, and other congenital urinary tract abnormalitie s such as urethral valves, 
pelvi-ureteric junction obstruction, and non-obstructive urinary stasis (eg, prune belly 
syndrome) [1] [2] [13] .
Symptoms commonl y associated with UTI in adults, such as dysuria, frequency , hesitancy , 
and flank plain, are unreliable in pediatric patientsyounger than 2 years of age. Urinary tract 
infection complaints in this age group are often nonspecific and may include fever, irritability,  
   05L60Q
Product:   MK-7625A 24
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentiallethargy, poor feeding, gastrointestinal distress, and incontinence; fever represents the most 
common presentation in young pediatric patients[5] [6]. Pediatric patientsolder than 2 years 
of age tend to exhibit more specific s ymptoms in accordance with adult UTI, and may present 
with or without fever [2]. The clinical presentation of cUTI may range from simple catheter-
associated UTI to severe obstructive acute pyelonephritis with imminent urosepsis [2]. The 
nonspecific presentation of cUTI together with the high prevalence of UTI in the pediatric 
population dictate a high index of suspicion for UTI in pediatric patientspresenting with 
nonspecif ic symptoms of infection [14] .
Urinary tract infections in pediatric patients are associated with significantly higher morbidit y 
and more severe long-term sequelae, including impaired renal function and progression to end-
stage renal disease, in comparison to UTIs in adultpatients [15]. Furthermore, UTIs in 
prepubertal girls have been linked to potential complications in subsequent pregnancy  [15]. 
Renal scarring represents the most significant difference in disease pathophysiology between 
theadult and pediatric populations; pediatric patientsyounger than 2 years of age are more 
likely to be predisposed to damage, given their developmental stage. Sequelae associated with 
renal scarring can include hypertension, proteinuria, renal damage, and chronic renal failure, 
which may  necessitate dialy sis treatment in adulthood [16] .
Across all pediatric age groups, E. coliis the most common cause of UTI, followed by 
Klebsiella spp., Proteus mirabilis, other Enterobacteriaceae, Enterococcus spp., P.aeruginosa, 
and Staphylococcus saprophyticus [17] [18]. Uncomplicated UTIs are most commonly caused 
by E. coli, whereas a broader range of microorganisms may be r esponsible for cUTIs [7] [19]. 
Furthermore, cUTIs are associated with an increased likelihood of drug resistance in the 
infecting microorganisms, which can further complicate treatment and lead to high mortality 
rates [7]. Drug resistance in pediatric patients with cUTI is attributed to recurrent infection, 
instrumentation, and exposure to multiple courses of antibiotics [7].
Empiric antimicrobial therapy for cUTI should be sufficientl y broad spectrum to cover the 
most commonly  isolated pathogens. Treatment should be individualized for the subject, based 
on subject tolerance, clinical presentation, prior antimicrobial use and urine culture reports, 
and known or suspected institutional susceptibilities [5] [20].
Completed Preclinical and Clinical Trials of Ceftolozane/Tazobactam
Refer to the IB/approved labeling for detailed information on preclinical and completed 
clinical trials ofceftolozane/tazobactam .
The primary data supporting the efficacy of ceftolozane/tazobactam in the cUTIindication was 
derived from 2 large, identical, global, multicenter, randomized, double-blind, active-
controlled Phase 3 trials (CXA-cUTI-10-04 [MK-7625A-004] and CXA-cUTI-10-05 [MK-
7625A-005]). In both trials, adult subjects were randomized 1:1 to receive either 
ceftolozane/tazobactam 1.5 g (ceftolozane 1g/tazobactam 0.5 g) IV every 8  hours or 
levofloxacin IV once daily administered for 4 to 14 days. The results indicated that 
ceftolozane/tazobactam was noninferior to levofloxacin in the treatment of cUTI in adults[21]. 
   05L60Q
Product:   MK-7625A 25
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialIn the treatment of adult subjects with nosocomial pneumonia ( NP)(MK-7625A-008), 
ceftolozane/tazobactam 3 g (2 g ceftolozane and 1 g tazobactam) IV every  8 hours 
demonstrated noninferiority  compared with meropenem 1 g IV every  8 hours for FDA and 
EMA primary  and keysecondary  efficacy endpoints. Overall, both treatment groups 
demonstrated comparable per -pathogen clinical cure and microbiological eradication rates at 
the TOC visit against comm only isolated pathogens, including P. aeruginosa, 
Enterobacteriaceae, and Haemophilus influenzae .
The pediatric development program for ceftolozane/tazobactam include da pediatric PK and 
safety trial of ceftolozane/tazobactam, CXA-PEDS-13-08 (MK-7625A-010)[22].This was a 
Phase 1, multicenter, single-dose, noncomparative , open-label trialin pediatric subjects with 
proven or suspected gram -negative infection or for peri -operative proph ylaxis. This study  had 
6age-based cohorts and enrolled a total of 43 subjects; 37 (86.0%) received study  drug.Dose
selections of ceftolozane/tazobactam for each age group (Group 1: ages ≥12 to 18 years, 
Group 2: ages ≥7 to 12 years, Group 3: ages ≥2 to 7 years, Group 4: ages ≥3 months to 2 
years, Group 5: 32weeks gestation, 7 day s postnatal to 3months, and Group 6: 32 weeks 
gestation, 7 days postnatal to 3 months) were projected to achieve exposures similar to those 
observed in adults who received the approved dose forcUTI and cIAI. Ceftolozane and 
tazobactam PK parameters were generall y comparable across Groups 1 to 4 (ages 3 months to 
<18 years). Subjects in Groups 5 and 6 (birth [7 days postnatal] to <3 months of age) had a 
lower CL than older children; however, there was no consistent trend in the weight-normalized 
CL across Groups 1to 6. Data from MK-7625A-010were used to determine appropriate doses 
for the present trial, as detailed in Section 4.2.2.1 –Rationale for Ceftolozane/Tazobactam 
Dosage.
Ceftolozane/tazobactam administered as a single, age- based dose was generally well tolerated
in MK-7625A-010. Overall, 11 subjects (29.7%) experienced a total of 26 TEAEs.  No severe 
TEAEs or TEAEs leading to disconti nuation of study treatment were reported, and there we re 
no deaths during the trial. Two subjects had nonserious treatment -related TEAEs (1 subject in 
Group 1 with dizziness and 1 subject in Group 3 [30/15 mg/kg dose] with bradycardia and 
tachycardia). Three subjects had SAEs (1 subject from Group 1 with pneumonia, 1 subject 
from Group 2 with infective pulmonary  exacerbation of cystic fibrosis, and 1 subject from 
Group 4 [30/15 mg/kg dose] with device-related sepsis), which were all deemed unrelated to 
trial treatment. No subject in Groups 5 or 6 experienced a treatment -related TEAE or SAE. No 
clinically significant laboratory  abnormalities or changes in electrocardiograms were observed 
after administration of ceftolozane/tazobactam.
Ongoing Clinical Trials of Ceftolozane/Tazobactam
Refer to the IB for detailed information for ongoing clinical trials of ceftolozane/tazobactam.  
In addition to the present trial, the current clinical development program for 
ceftolozane/tazobactam includes 4ongoing/planned clinical studies:1) a Phase 3, randomized, 
double-blind, active comparator -controlled study comparing ceftolozane/tazobactam plus 
metronidazole versus meropenem in adult Chinese subjects with cIAI, 2) a Phase 2, 
randomized, double-blind, active comparator -controlled study comparing 
ceftolozane/tazobactam plus metronidazole versus meropenem in pediatric subjects with cI AI,  
   05L60Q
Product:   MK-7625A 26
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential3) a Phase 1, open-label, noncomparative study evaluating the safety, tolerability , and PK of 
ceftolozane/tazobactam in pediatric subjects with NP, and 4) a Phase 1, non-randomized, 
single-arm, single-site, fixed-sequence open-label, PK, safety, and tolerability  study of 
ceftolozane/tazobactam in healthy Chinese subjects .
Information on Other Trial -related Therapy
Subjects in the comparator arm of the presenttrial (MK- 7625A-034)will receive IV 
meropenem ( Table 7). Meropenem is a carbapenem antibiotic and is approved for treatment of 
cUTI in pediatric ( 3months of age and older) and adult patients[23]. There is no evidence of 
increased risk for any adverse drug reaction in pediatric patients based on the limited available 
data. See Section 4.2.2.2–Rationale for the Use of Comparator and 4.2.2.3–Rationale for 
Comparator Dosagefor additional details on the efficacy and safety of meropenem in the 
treatment of cUTI.
Meropenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in gram-
positive and gram -negative bacteria through binding to penicillin -binding proteins . Like other 
β-lactam antibiotics, the T>MIC for meropene m has been shown to best correlate with efficacy. 
In preclinical models, meropenem demonstrated activity when plasma concentrations 
exceeded the MIC of the infecting organisms for approximately  40% of the dosing interval.
Rationale
Rationale for the Trial and Selected Subject Population
As described in Section 4.1.1.2–Complicated Urinary Tract Infection, UTIs are among the 
most common infections encountered in pediatric patients and are associated with an increased 
likelihood of drug resistance, a higher risk of recurrence and relapse, and higher morbidity  and 
more severe long-term sequelae than in adult patients. Hence, there is a medical need to 
investigate the use of newer antibacterial agents, such as ceftolozane/tazobactam, in the 
pediatric population.
Ceftolozane/tazobactam has activity against the most commonly  encountered pathogens 
associated with pediatric cUTIs and may be a valuable treatment option empirically  and for 
the treatment of ESBL-producing Enterobacteriaceae and MDR P. aeruginosa. While
ceftolozane/tazobactam has been demonstrated to be safe and effective in the treatment of 
cUTIs in adults, the safety and efficacy of ceftolozane/tazobactam have not been established 
in pediatric subjects with cUTI. Therefore, the study of ceftolozane/taz obactam in pediatric 
subjects with cUTI is warranted.
Clinical trials have indicated that ceftolozane is welltolerated and generally safe in healthy 
adult subjects, adult subjects with varying degrees of renal impairment, and adult subjects with 
cUTI or cIAI. The Phase 1 PK and safety trial in pediatric subjects (CXA-PEDS-13-08 
[MK-7625A-010]; see Section 4.1.2 –Completed Preclinical and Clinical Trials of 
Ceftolozane/Tazobactam employedan adaptive trial design wherein enrollment of Groups 1 to 
4 (ages 3months to <18 years) was conducted in parallel but enrollment of Groups 5 and 6 
(ages birth to <3 months) did not begin until PK assessments and subject safet y data from the  
   05L60Q
Product:   MK-7625A 27
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialolder age groups were reviewed. Data from this trial revealed that ceftolozane/tazobactam 
doses resulting in exposures similar to those observed in adult subjects with cUTI or cIAI were 
safe and well tolerated in pediatric subjects.
The present trial (MK -7625A-034) will enroll pediatric subjects from birth to <18 yea rs of age
(from 3 months to < 18 yearsof agein Ukraine) who present with cUTI, including 
pyelonephritis, to establish the safety and efficacy of ceftolozane/tazobactam in this 
population. The pediatric dosing recommendations (see Section 4.2.2.1-Rationale for 
Ceftolozane/Tazobactam Dosagefor rationale for dose selection) were developed using data 
from subjects from birth (>32 weeks gestational age and≥7 days postnatal) to <18 years of 
age; no data were available from subjects ≤32 weeks gestational age or <7 day s postnatal to 3 
months of age . Neonatal renal function is closely  related to both gestational age and postnatal 
age. Because serum creatinine fluctuates in the first week of life, the revised Schwartz equation
[24], which will be used to calculate renal function in this population, is not recommended for 
use until after the first week of life. Therefore, the present trial defines “birth” as >32 weeks 
gestational age a nd ≥7 day s postnatal.
Because ceftolozane/tazobactam was welltolerated in the Phase 1 pediatric PK and safety trial
(CXA-PEDS-13-08 [MK-7625A-010]), parallel enrollment into active and comparator groups 
is considered appropriate forthe present trial. Investigators, Sponsors, trialpersonnel, and 
subjects will all be blinded to prevent bias in treatment allocation and in the assessment of 
safety and efficacy. Likewise, randomization will be used to produce similar treatment arms
and reduce bias.
Rationale for Sample Size
This trial is being conducted to establish the safet y and tolerability  of ceftolozane/tazobactam 
in pediatric subjects with cUTI. The efficacy of ceftolozane/tazobactam in pediatric subjects
with cUTI  may be extrapolated from the corresponding adult trials . Therefore, the calculation 
of cumulative sample size for this trial is based on obtaining sufficient data to evaluate the
safety of this drug in pediatric subjectsby combining safety data from the present trial and 
MK-7625A-035 (thecompanion trial in pediatric subjects with cIAI)(see Section 8.9—Sample 
Size and Power Calculations) . Combining subjects across both studies is intended to provide 
flexibility  and enable timely enrollment of the trials. This is an exploratory  trial and is not 
powered to test formal hy potheses.
Approximately 240 subjects (combined acrossMK-7625A-034 and MK-7625A-035)will 
receive study treatment (approximately  180 ceftolozane/tazobactam -treated and 60 
comparator -treated subjects). After the minimum enrollment targets for each age group are met
(202 subjects total), additional subjects (combined acrossMK-7625A-034 and MK-7625A-
035)will be enrolled in any  of the 5 age groups. 
   05L60Q
Product:   MK-7625A 28
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Rationale for Dose Selection/Regimen
Rationale for Ceftolozane/Tazobactam Dosage
The proposed ceftolozane/tazobactam pediatric doses were projected using a population PK 
approach using data from 13 clinical studies (12 adult studies and 1 pediatric study). The PK 
analysis showed that 2 -compartment models best described the concentration -time profiles of 
ceftolozane and tazobactam. The fit of the models was improved by including allometric 
scaling using body weight as a covariate on clearance (CL), central volume of distribution 
(Vc), peripheral volume of distribution (Vp), and intercompartmental clearance (Q, for 
tazobactam only). In the final models, renal function (estimated glomerular filtration rate 
[eGFR]) was included as a covariate on CL for ceftolozane. For tazobactam, presence of 
infection (as a categorical variable: Presence or absence) was also a significant covariate on 
CL for tazobactam. Tazobactam CL for subjects was estimated to be 67.7% of the CL for those 
without infection. Infection status did not appear to be a significant covariate on the PK of 
ceftolozane.
The final PK models for ceftolozane and tazobactam were used to simulate the AUC from 0 to 
8 hours (AUC0-8) and the Cmaxin pediatric subjects with infections on Day 3, which was shown 
to provide steady-state exposures. To provide a benchmark for evaluating the safety of 
ceftolozane and tazobactam in simulated pediatric subjects, Day 3 plasma exposure parameters 
for adult subjects were simulated. For predicting efficacy of the doses, probability  of target 
attainment (PTA) after the first dose for adult subjectsand 5 pediatric age groups wasalso 
simulated.
The criteria used in evaluating the appro priateness of doses were:
The 95th percentile of pediatric ceftolozane and tazobactam exposures (AUC and 
Cmax) on Day 3 not exceeding the corresponding 95th percentile of adult exposures; 
and 
The ceftolozane Day  1 PTA (initial dose) ≥90% based on concentr ations exceeding 
an MIC of 4 µg/mL (the Clinical and Laboratory Standards Institute [ CLSI]
breakpoint) for at least 30% of the dosing interval and a tazobactam Day  1 PTA 
≥90% based on concentrations exceeding a threshold concentration of 1 µg/mL for at 
least 20% of the dosing interval.
Similar to other β-lactams, the PK target that best correlates with in vivo efficacy for 
ceftolozane is the percentage of the dosing interval during which the free concentration of 
ceftolozane in plasma exceeds the MIC (% fT>MIC). A % fT>MIC of 30% was selected as the 
criterion because data from a neutropenic mouse thigh infection model showed that the 
%fT>MIC ranged from 26.7%to 35.3% for a 1-log kill [25]. The CLSI breakpoints are 
2µg/mL for Enterobacteriaceae and 4 µg/mL for Pseudomonas aeruginosa . The higher 
breakpoint of 4 µg/mL  was chosen to ensure cove rage for both organisms.
Because tazobactam does not have intrinsic antibacterial activity, an MIC cannot be 
determined. Instead, the threshold drug concentration (C t) needed to effectively  neutralize the 
β-lactamase enz yme produced by  bacteria is used for target attainment [26]. Time above a C t 
   05L60Q
Product:   MK-7625A 29
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialof 1µg/mL for free tazobactam exposures of 20%, which is supported by data from a mouse 
model and clinical studies, was used.
Based on the exposure and PTA criteria described above, the simulations in pediatric subjects 
indicated that the following doses are appropriate for evaluation in this trial:
12 to <18 y ears of age: Ceftolozane 1 g with tazobactam 0.5 gvia a 60-minute (±10 
minutes) IV infusion every 8 hours
<12 years of age: Ceftolozane 20 mg/kg with tazobactam 10 mg/kg via a 60 -minute 
(±10 minutes) IV infusion every  8 hours (not to exceed a dose of ceftolozane 1 gand 
tazobactam 0.5 g)
The ceftolozane and tazobactam exposures and PTA for adult and pediatric subjects at these 
doses are summarized in Table 1andTable 2, respectivel y. As shown in these tables, the 
selected doses provide exposures for the age groups that do not exceed the corresponding 95th 
percentile of adult exposures and achieve PTAs ≥90%. 
   05L60Q
Product:   MK-7625A 30
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTable 1 Ceftolozane Exposure and Target Attainment Summary for Simulated Adult and Pediatric Subjects
Parameter StatisticAdult Subjects 
(n=1000)Pediatric Age Groupa
1
1000 mg 
(n=1200)2 
20 mg/kg 
(n=1000)3 
20 mg/kg 
(n=1000)4 
20 mg/kg 
(n=1000)5 
20 mg/kg 
(n=1200)
Age (years) Mean (SD) 53.57 (19.09) 15.00 (1.74) 9.52 (1.45) 4.51 (1.45) 0.80 (0.44) 0.13 (0.07)
Median 56.00 14.99 9.53 4.53 0.71 0.12
5th, 95th 22.0, 81.0 12.3, 17.7 7.3, 11.8 2.2, 6.7 0.3, 1.7 0.0, 0.2
AUC0-8
(μg h/mL), Day 3Mean (SD) 213.36 (171.91) 172.11 (78.76) 176.08 (69.92) 153.13 (60.32) 162.04 (63.15) 157.36 (65.19)
Median 176.00 160.00 161.00 141.00 149.00 147.00
5th, 95th 95.3, 388.0 73.2, 319.0 90.3, 315.0 77.0, 268.0 81.2, 276.5 71.3, 282.5
Cmax(μg/mL), Day 3 Mean (SD) 69.66 (45.09) 86.04 (36.25) 92.68 (29.84) 82.37 (23.96) 74.37 (19.33) 62.06 (15.18)
Median 56.10 80.35 86.90 79.35 72.40 60.15
5th, 95th 32.9, 154.0 37.8, 154.0 53.1, 150.0 47.8, 125.0 45.9, 109.0 39.9, 89.4
Target attainmentb
Day1N(%) 1000 (100.0) 1188 (99.0) 995 (99.5) 992 (99.2) 1000 (100.0) 1196 (99.7)
5th, 95th = 5th, 95th percentiles; AUC0-8=area under the concentration -time curve from time of drug administration (time 0) to 8hours; C max=maximum 
observed concentration; h = hours; N = number of subjects achieving target attainment; n = number of subjects; SD = standard deviation
aAge Group1, 12yearsage<18years; Age Group 2,7yearsage<12years; Age Group 3,2yearsage<7years; Age 
Group4,3monthsage<2years; Age Group 5,7days postnatal age<3months.
bFor ceftolozane, minimum effective concentration is4μg/mL and target is attainment of this concentration for 30% of the 8 -hourdosing interval. 
   05L60Q
Product:   MK-7625A 31
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTable 2 Tazobactam Exposure and Target Attainment Summary  for Simulated Adult and Pediatric Subjects
Parameter StatisticAdult 
Subjects 
(n=
1000)Pediatric Age Groupa
1 
500 mg
(n=1200)2 
10 mg/kg
(n=1000)3
10 mg/kg
(n=1000)4 
10 mg/kg
(n=1000)5 
10 mg/kg
(n=1200)
Age (years) Mean (SD) 46.37 (18.72) 15.00 (1.74) 9.52 (1.45) 4.51 (1.45) 0.80 (0.44) 0.13 (0.07)
Median 44.00 14.99 9.53 4.53 0.71 0.12
5th, 95th 20.0, 78.0 12.3, 17.7 7.3, 11.8 2.2, 6.7 0.3, 1.7 0.0, 0.2
AUC0-8 
(μgh/mL), Day 3Mean (SD) 80.71 
(148.87)37.12 (23.29) 38.02 (24.49) 30.22 (19.18) 29.87 (19.05) 26.77 (16.50)
Median 29.80 31.20 32.30 26.10 25.00 22.30
5th, 95th 15.4, 379.0 12.4, 83.1 12.3, 84.5 10.2, 62.9 10.0, 63.5 8.4, 57.3
Cmax(μg/mL), Day 
3Mean (SD) 30.30 (34.73) 27.92 (14.51) 29.19 (14.69) 24.04 (11.78) 21.69 (10.54) 18.37 (8.81)
Median 17.70 24.75 26.45 21.80 19.50 16.80
5th, 95th 10.3, 108.0 10.7, 54.6 11.7, 57.7 9.6, 46.1 8.5, 42.2 7.6, 35.2
Target attainmentb
Day1N(%) 1000 (100.0) 1169 (97.4) 978 (97.8) 950 (95.0) 958 (95.8) 1116 (93.0)
5th, 95th = 5th, 95th percentiles; AUC0-8,area under the concentration -time curve from time of drug administration (time 0) to 8hours; C max,maximum 
observed concentration; N, number of subjects achieving target attainment; n, number of subjects; SD, standard deviation
aAge Group 1, 12yearsage<18years; Age Group 2,7yearsage<12years; Age Group 3,2yearsage<7years; Age 
Group4,3monthsage<2years; Age Group 5,7days postnatal age<3months.
bFor tazobactam, threshold concentration is1μg/mL and target is attainment of this concentration for 20% of the 8 -hourdosing interval. 
   05L60Q
Product:   MK-7625A 32
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialVarying age-appropriate volumes of a fixed concentration of ceftolozane/tazobactam will be 
administered IV to achieve the intended dose in each pediatric subject. The same IV 
formulation will be used across all age groups .
Rationale for t he Use of Comparator
The comparator medication, meropenem, was selected because it is approved in the European 
Union (EU)for the treatment of pediatric patients in this indication and based on its clinical 
utility and safet y profile in patients with cUTI [23].
A consensus does not exist for standard of care treatment of cUTI in the pediatric population. 
However, the carbapenem class of antibiotics, including meropenem, is a reliable treatment 
option for cUTI in adults [2]. Meropenem monotherap y has been studied and used extensivel y 
in the treatment of cUTI in adults, and is recommended in the evidence-based guidelines for 
adults developed by an expert panel as an option for cUTI [2] [23] [27][28] [29] [30]. 
Meropenem and other carbapenems have also been shown to be safe and effective in the 
treatment of UTIs in pediatric patients [31] [32] [33] [34] [35] [36] [37 ] [38] [39] . The safety 
profile of meropenem has bee n demonstrated to be similar in adult and pediatric subjects [23] 
[40].
In addition, the use of meropenem in this trial will allow for an adequately -sized safety 
database when data from this trial are pooled withdata from the companion Phase 2trial of 
ceftolozane/tazobactam (plus metronidazole) in pediatric subjects with cIAI 
(MK-7625A-035), which also utilizes meropenem as the comparator (see Section 4.2.1.1-
1.1.1.1Rationale for Sample Size). Available Phase 3 comparative safety data for 
ceftolozane/tazobactam versus meropenem from trials in adultswith cIAI[41]will allow for 
comparison of the safety profiles of ceftolozane/tazobactam and meropenem in pediatric and 
adult subjects.
In the Phase 3 trials of ceftolozane/tazobactam in adults with cUTI (CXA-cUTI-10-04 
[MK-7625A-005] and CXA-cUTI-10-05 [MK-7625A-006]), the active comparator was a 
fluoroquinolone (levofloxacin) [21]. However, fluoroquinolones may not be appropriate as 
comparators in the pediatric population due to concerns about increased musculoskeletal AEs 
in pediatric patients who receivefluoroquinolones compared withother classes of antibiotics 
[42]. In addition, rising rates of fluoroquinolone resistance among common uropathogens have 
rendered this class of antibacterial agents a questionable choice for initial empiric therapy in 
certain parts of the world [21] [33] [43] .
Rationale for Comparator Dosage
The meropenem dose for Groups 1through5 (20 mg/kg IV every 8 hours [maximum of 
1g/dose]) was chosen for this trial based on the approved dosage regimen for the treatment of 
cUTI for pediatric patients 3 months to 18 y ears of age [23] .
Safety and efficacy  data of meropenem in pediatric patients under 3 months of age are limited, 
and the optimal dose regimen for this age group has not been identified. However, a trial in 
200 critically ill preterm and term infants (<91days of age) with suspected or confirmed IAI  
   05L60Q
Product:   MK-7625A 33
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialdemonstrated that meropenem was safe and well tolerated at the 20 mg/kg dose [44].Limited 
data on the PK of meropenem suggest that drug disposition in young infants may differ 
significantl y from that in adults, likely related to developmental differences in renal function 
and differences in body composition seen in young infants. As a result, some sources 
recommend higher meropenem doses (up to 30 mg/kg IV every 8 hours) for the treatment of 
serious infections in neonates [45]. In order to accommodate potential variations in standard 
of care dosing, the protocol allows for a range of weight-based dosing schemesbetween 20 
mg/kg and 30 mg/kg forsubjects in Group 5(birth [defined as >32 weeks gestational age and 
≥7 days postnatal] to <3 months of age).
To ensure blinding, each dose of meropenem will be administered as a 60-minute 
(±10minutes) infusion (versus the 30 -minute infusion noted in the EUProduct Circular [23])
to match the duration of infusion of ceftolozane/tazobactam. As described in Section 4.1.4–
Information on Other Trial-related Therapy, the efficacy of meropenem, like other β-lactam 
antibiotics, is dependent on the T>MI C of the pathogens being treated. Therefore, the efficacy 
of meropenem is not affected by prolonging the infusion. In addition, infusions of meropenem 
longer than 1 hour have been administered to patients with satisfactory  results and without 
additional safet y or tolerability risk [46].
Therefore, the Sponsor believes the dosage regimen of meropenem in this trial isa clinically 
appropriate andacceptable comparator with which to evaluate the safety and efficacy of 
ceftolozane/tazobactam in pediat ric cUTI.
Rationale for Duration of Therapy and Optional Oral Step -Down Antibiotic 
Therapy
Appropriate duration of therapy for pediatric cUTI treatment remains controversial, butmost 
guidelines suggest 7 to 14 days of antibiotic therapy with the option of switching from 
parenteral to oral antibiotics when the patient is afebrile and/orimproving [1] [2] [5][14]. 
Thus, subjects in the present trial will receive 7 to14 days of study treatment with thepotential 
to receive oral step- down therap y after IV study treatment, in alignment with standard clinical 
practice for cUTI.
After receiving at least 9 doses of IV study treatment, subjects may be switched to oral step-
down therapy at theinvestigator ’s discretionbased on the subject’s clinical condition (Section 
5.2.2–Optional Oral Step- down Therap y). The requirement of72 hours (9 doses) of IV study 
treatment allows for evaluation of the safety, efficacy, and PK of ceftolozane/tazobactam while 
minimizing the need for prolonged hosp italization and IV access .
Rationale for Endpoints
Rationale for Safety Endpoints
To evaluate the safety and tolerability  of ceftolozane/tazobactam in pediatric subjects, the 
incidence, severity, and type of AEs will be tabulated (see Section 7.2–Assessing and 
Recording Adverse Events). 
   05L60Q
Product:   MK-7625A 34
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialLaboratory  data will be summarized by the type of laboratory  test. Descriptive statistics of 
temperature, heart rate, respiratory  rate, and blood pressure (s ystolic and diastolic) values and 
changes from baseline will be summarized at each scheduled time point.
Subjects may be asked to return for unscheduled visits in order to perform additional safety 
monitoring.
See Section 8.4.1–Safety Endpoints for details about the analysis ofsafety endpoints and 
Section 8.5.1 – Efficacy Endpoints for details about the safet y analysis population .
Rationale for Efficacy Endpoints
Because the mechanism of action and the potency of ceftolozane/tazobactam should be the 
same across all ages, adult and pediatric PK data can be compared to extrapolate the efficacy 
of ceftolozane/tazobactam fromadult subjects to pediatric subjects. Therefore, efficacy is 
evaluated as secondary  andexploratory  objectives in this trial. There are no prespecified 
statistical hypotheses for this trial. The trial is not powered to statistically  compare the efficacy 
of ceftolozane/tazobactam versus meropenem.
The secondary  efficacy endpoints are:
Clinical success rate at the EOT and TOC Visits, defined as the proportion of s ubjects 
in the anal ysis population who have a clinical response of cure.
Per-subject microbiological eradication rate at the EOT and TOC Visits, defined as the 
proportion of subjects in the analysis population who have an overall outcome of 
microbiological eradication.
The exploratory  efficacy endpoints are:
Clinical success rate at the EOIV Visit, defined as the proportion of subjects in the 
analysis population who have a clinical response of cure or partial improvement.
NOTE: At EOIV, clinical success is defined as cure or partial improvement. At EOT 
and TOC, clinical success is defined as cure. The definition for clinical success at the 
EOIV Visitincludes partial improvement to accommodate those subjects with partial 
improvement who are switched to oral step- down therap y at this time point. 
Per-subject microbiological eradication rate at the EOIV Visit.
Per-pathogen microbiological eradication rate at the EOIV, EOT, and TOC Visits, 
defined as the proportion of pathogens in the analysis population that have an outcome 
of microbiological eradication.
Composite success (clinical success and per-subject microbiological eradication) rate 
at the EOIV, EOT, and TOC Visits.
NOTE: For subjects who receive IV study treatment only (without optional oral step-down 
therapy), a separate assessment does not need to be performed at the EOT Visit; the EOIV 
Visitwill serve as the EOT Visit . 
   05L60Q
Product:   MK-7625A 35
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential4.2.3.2.1 Clinical Outcome
Investigators will determine clinical outcomes at the EOIV, EOT, and TOC Visits according 
to the definitions inTable3. Subjects with failure or indeterminate outcomes will be 
considered to have an unfavorable clinical response. Subjects with no study-qualifying 
baseline urine culture must be withdrawn from study treatment by the investigator 
immediately ; no clinical outcome assessments of these subjects are required (see Section 5.1.2 
–Subject Inclusion Criteria) .
For subjects who receive only IV study treatment and are notswitched to oral step-down 
therapy, the EOIV assessment serves as the EOT assessment and these subjects do not have a 
separate EOT assessment. Subjects who are switched to oral step -down therapy will have b oth 
an EOIV and EOT assessment.
At EOIV, clinicalsuccess is defined as cure or partial improvement. At EOT and TOC, clinical 
success is defined as cure. Subjects with failure or indeterminate clinical outcomes will be 
considered to have an unfavorable clinical response.
Failure will be carried forward; subjects who are assessed as a failure prior to the TOC Visit
should have “failure” recorded on the TOC Visitelectronic case report form (eCRF). These 
subjects should attend the TOC Visit but will not have a new clinical outcome assessment at 
this visit.
Subjects who discontinue IV study  treatment or discontinue from the trial prior to receiving 9 
doses of IV study treatment for reasons other than those meeting the definition of failure will
be assessed with a clinical outcome of indeterminate. See also Section 5.8 – Subject 
Withdrawal/Discontinuation Criteria, Section 7.1.4.1 – Withdrawal/Discontinuation, and 
Section 7.1.5. 9 –Subjects Who Prematurely  Discontinue From Study  Treatment or the Trial. 
   05L60Q
Product:   MK-7625A 36
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTable3Clinical Outcome Categories
Outcome Definition
Cure Complete resolution or marked improvement in signs and symptoms of 
the cUTI or return to preinfection signs and symptoms ,such that no 
further antibiotic therapy (IV or oral) is required for the treatment of 
the cUTI.
Partial improvement
(only at the EOIV Visitfor subjects 
who switch to oral step -down 
therapy)Partial resolution of signs and symptoms of the cUTI such that no 
further IV antibiotic therapy is required for the treatment of the cUTI; 
however, additional or al step-down therapy is required.
Failure Any of the following is considered a clinical outcome of failure:
Persistence or reappearance of 1 or more sign or symptom of 
infection that requires alternative non studytreatment for the 
current cUTI
New signs or symptoms of infection that require alternative 
nonstudytreatment for the treatment of a cUTI due to an 
appropriate gram -negative uropathogena
Requirement of antibiotic therapy beyond the protocol -defined 
treatment duration of 14 days
Death related to cUTI
Indeterminate Trial data are not available for evaluation of efficacy for any reason, 
including death during the trial period unrelated to the cUTI or 
extenuating circumstances which preclude classification as cure, partial 
improvement, or failure (eg, subject is lost to follow -up).
cUTI = complicated urinary tract infection; EOIV = End of IV Treatment; IV = intravenous
aRefer to Section 7.1.3.5– Urine Samples for Culturefor more detail about appropriate gram-negative 
uropathogens.
4.2.3.2.2 Microbiological Outcome
All microbiological outcomes will be based on laboratory  results and determine d by the 
Sponsor. Investigators are not responsible for assessment of microbiological out comes.
Per-subject Microbiological O utcome
An overall microbiological response will be determined for each subject based on the 
individual microbiological response for each baseline pathogen. Microbiological response 
categories are eradication, persistence , and indeterminate as defined inTable4.Eradication 
will be considered a favorable microbiological response; in order for the subject to have a 
favorable overall microbiological response (ie, eradication), each baseline pathogen must have 
a favorable microbiological outcome. 
   05L60Q
Product:   MK-7625A 37
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTable4Microbiological Outcome Categories
OutcomeaDefinitiona
Eradication A postbaseline urine culture shows all uropathogens found at baseline 
at ≥105CFU/mL are reduced to <104CFU/mL.
Persistence A postbaseline urine culture shows the uropathogen(s) found at 
baseline at ≥105CFU/mL persist(s)at ≥104CFU/mL.
Indeterminate No appropriate urine culture result available.
CFU = colony-forming units
aThe per-pathogen microbiological outcome will be determined for each uropathogen isolated by the 
Sponsor from a baseline study-qualifying culture.
b.Eradication w ill be considered a favorable microbiological response.
Composite Clinical and Microbiological Outcome
Composite clinical and microbiological outcomes will be determined as cure, failure, or 
indeterminate as defined in Table5. If one of the outcomes is failure(clinical) or persistence 
(microbiological) and the other is indeterminate, the composite response of the subject will be 
considered failure. If one of the outcomes is cure(clinical) or eradication (microbiological)
and the other is indeterminate, the composite response of the subject will be considered 
indeterminate .
Table5Composite Clinical and Microbiological Outcome Categories
Outcome Definition
Cure Clinical response is clinical success and per-subject microbiological 
response is eradication.
Failure Clinical response is clinical failure and/or per -subject microbiological 
response is persistence. If one of the outcomes is failure (clinical) or 
persistence (microbiological) and the other is indeterminate, the 
composite response of the subject w ill be considered failure.
Indeterminate Clinical response is indeterminate and/or per- subject microbiological 
response is indeterminate. Ifone of the outcomes is cure (clinical) or 
eradication (microbiological) and the other is indeterminate, the 
composite response of the subject w ill be considered indeterminate.
Per-pathogen Microbiological Outcome
The per-pathogen microbiological outcome will be determined for each uropathogen isolated 
by the Sponsor from a baseline study-qualifying culture (seeTable4).Eradication will be 
considered a favorable microbiological response. 
   05L60Q
Product:   MK-7625A 38
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialEmergent Infection
Pathogens isolated after baseline will be assessed for the outcome ofsuperinfection or new 
infection, as defined in Table6. 
Table6Emergent Infection Categories
Outcome Definition
Superinfection A urine culture grows ≥105CFU/mL of an appropriate gram-negative
uropathogenaother than the baseline uropathogen(s) during the course 
of study treatment.
New infection A urine culture grows ≥105CFU/mL of an appropriate gram-negative
uropathogenaother than the baseline uropathogen(s) after 
administration of the last dose of stu dy treatment and through the 
TOC visit .
CFU = colony -forming units
aRefer to Section 7. 1.3.5–Urine Samples for Culture for more detail about appropriate gram -negative
uropathogens.
See Section 8.4.2 -Efficacy Endpointsfor details about efficacy analysesand Section 8.5.2-
Efficacy Analysis Populations for details about the efficacy analysis populations.
Rationale for Pharmacokinetic Endpoints
Whole blood samples (250µL) will be collected at the time points specified in Section 6.0 –
Trial Flow Chart for determination of plasma concentrations of ceftolozane ,tazobactam ,and
tazobactam M1. Specific information about PK sample collection is provided in 
Section7.1.3.7–Pharmacokinetic Evaluations . These sample s will provide pediatric PK data 
in the target population and will support further evaluation of the PK profiles of ceftolozane 
and tazobactam by confirming whethersubjects achieve percentage of dosing interval during 
which free concentration of drug ( ceftolozane) exceeds the MIC (%fT>MIC)of at least 30% 
(for an MIC of 4 µg/mL) for ceftol ozane and percentage of dosing interval during which free 
concentration of drug (tazobactam) exceeds the Ct (%fT>Ct)of at least 20% (for a threshold 
concentration of 1 µg/mL) for tazobactam .
Pharmacokinetic data mayalso aid in the assessment of the clinical relationship between 
ceftolozane and tazobactam plasma concentrations and efficacy  in the pediatric population.
See Section 8.4.3 – Pharmacokinetic Endpoints for details about analysis of PK endpoints .
Benefit/Risk
It cannot be guaranteed that subjects in clinical trials will directly benefit from treatment during 
participation, as clinical trials are designed to provide informatio n about the safety and 
effectiveness of an investigational medicine. 
   05L60Q
Product:   MK-7625A 39
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialThis trial will include pediatric subjects who require IV antibiotics for treatment of cUTI. If 
randomized to receive ceftolozane/tazobactam, subjects will receive an antibiotic regimen t hat 
is active against organisms commonly  isolated from pediatric patients with cUTI and that has 
proven to be effective in large -scale clinical trials for the treatment of cUTI in adults (Section 
4.1.1.1–Ceftolozane/Tazobactam ). Subjects who are randomiz ed to the comparator arm will 
receive meropenem, an antibacterial agent approved for treatment of cUTI in pediatric patients
3 months of age and older and adults (Section 4.1.4–Information on Other Trial-Related 
Therapy).
Although potentially  more frequent than the standard of care, the planned study procedures 
(see Section 6.0 –Trial Flow Chart) are generall y typical procedures performed for this patient 
population. Trial procedures, including the number of blood draws for PK sampling, are 
limited in order to minimize risk. Additional burden may be incurred due to visits after release 
from the hospital; however, the procedures performed at these visits are generall y not likely to 
lead to significant harm (eg, blood draws, urine collection, physical examinations, and vital 
signs) and are necessary  to support a robust evaluation of the safety and efficacy of the 
investigational drug.
Additional details regarding specific benefits and risks for subjects participating in this clinical 
trial may be found in the accompan ying ceftolozane/tazobactam IB and Informed Consent 
documents.
5.0METHODOLOGY
Entry Criteria
Diagnosis/Condition for Entry into the Trial
Male andfemalesubjects frombirth(defined as >32 weeks gestational age and≥7 days 
postnatal) to <18 years of age with cUT Iwill be enrolled in this trial.
Subject Inclusion Criteria
In order to be eligible for participation in this trial, the subject must:
1.Have a legal ly acceptable representative who provides documented informed 
consent/assentfor the trial.
2.Be a male or female from birth (defined as >32 weeks gestational age and ≥7 days 
postnatal) to <18 years of age.
NOTE: In Ukraine, enrollment age of a male or female subject is limited to 3 months 
to < 18 years (Groups 1 -4). Subjects < 3 months old(Group 5) are not permitted to 
enroll into the study  at Ukraine sites.
3.Be able to comply  with the protocol for the duration of the trial.
4.Require IV antibacterial therap y for the treat ment of cUTI.
5.Have a pretreatment baseline urine culture specimen obtained within 48 hours before 
the start of administration of the first dose of study treatment and preferably  prior to  
   05L60Q
Product:   MK-7625A 40
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialadministration of any potentially  therapeutic antibiotics. Specimen is to be obtained 
by suprapubic aspiration, clean intermittent urethral catheterization, indwelling 
urethral catheter, or mid-streamclean catch.
NOTE: Subjects may  be enrolled in this trial and start IV study  treatment before the 
investigator knows the results of the baseline urine culture ; however, subjects without 
documented ≥105colony-forming units (CFU)/mL of a n appropriate gram-negative 
uropathogen cultured from a baseline urine specimen must discontinue study  
treatment immediatel y following cultur e result.
6.Have pyuria, defined as dipstick analy sis positive for leukocy te esterase, OR :
a)If ≥1 year of age: White blood cell ( WBC)count >10 cells/µL  in unspun urine or 
≥10cells/high power field in spun urine
b)If <1year of age: WBC count >5 cells/µL in unspun urine or ≥5 cells/high power 
field in spun urine
7.Have clinical signs and/or sy mptoms of cUTI (p yelonephritis or cLUTI) at the
Screening V isit.
a)For pyelonephritis, subjects must have at least 2 of the following new or 
worsening signs and/or sy mptoms:
i. If 0 to <2 y ears of age:
-Fever (as defined by  the investigator)
-Failure to thrive
-Recent weight loss
-Irritability
-Poor feeding
-Lack of normal level of activity
-Abdominal tenderness on phy sical examination
-Vomiting
-Jaundice
ii. If 2 to <18 years of age:
-Fever (as defined by  the investigator)
-Dysuria
-Urinary urgency
-Urinary frequency
-New-onset urinary  incontinence
-Suprapubic pain ,flank pain, or abdominal pain
-Suprapubic tenderness or CVA tenderness on ph ysical examination
-Nausea or vomiting
OR
b)For cLUTI, subjects must have at least 2 of the new or worsening signs and/or 
symptoms listed above AND must have at least 1 of the following complicating 
factors:
-Obstructive uropathy
-Congenital, functional, or anatomic abnormality  of the urogenital tract 
   05L60Q
Product:   MK-7625A 41
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential-Temporary  indwelling urinary  catheter
-Bladder instrumentation within <24 hours
-Recurrent UTI ( ≥2 events within a 12-month period) 
8.Meet one of the following categories:
a)The subject is a male who is not of reproductive potential, defined as a male who 
has azoospermia (whether due to being prepubertal, having had a vasectomy, or 
an underl ying medical condition) .
b)The subject is a female who is not of reproductive potential, defined as a female 
who either: (1) Has not undergone menarche; (2) has had a h ysterectomy and/or 
bilateral oophorectomy , bilateral salpingectom y, or bilateral tubal 
ligation/occlusion at leas t 6 weeks prior to screening , or (3) has a congenital or 
acquired condition that prevents child -bearing.
c)The subject is a female or a male of reproductive potential who agrees to avoid 
becoming pregnant or impregnating a partner during screening, while receiving 
study treatment, and for at least 30 day s after the last dose of study  treatment by  
complying with one of the following: (1) Practice abstinenceafrom heterosexu al 
activity OR (2) use (or have their partner use) acceptable contraception during 
heterosexual activity . Acceptable methods of contraception areb:
Single method ( 1of the following is acceptable):
Intrauterine device (IUD)
Vasectomy of a female subject’s male partner 
Contraceptive rod implanted into the skin
Combination method (requires use of 2 of the following):
Diaphragm with spermicide (cannot be used in conjunction with cervical 
cap/spermicide)
Cervical cap with spermicide (nulliparous females only)
Contraceptive sponge (nulliparous females only)
Male condom or female condom (cannot be used together)
Hormonal contraceptive: Oral contraceptive pill (estrogen/progestin pill or 
progestin-only pill), contraceptive skin patch, vaginal contraceptive ring, 
or subcutaneous contraceptive injection
aAbstinence (relative to heterosexual activity) can be used as the sole method 
of contraception if it is consistently  employed as the subject’s preferred and 
usual lifesty le and if considered acceptable by  local regulatory  agencies and 
Ethics Review Committees ( ERCs)/Institutional Review Boards ( IRBs). 
Periodic abstinence (e g,calendar, ovulation, sy mptothermal, postovulation 
methods, etc.) and withdrawal are not acceptable methods of contraception.
bIf a contraceptive method listed above is restricted by  local 
regulations/guidelines, then it does not qualify  as an acceptable method of 
contraception for subjects participating at sites in this country /region. 
   05L60Q
Product:   MK-7625A 42
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential9.Meet the following criteria for a female subject who is of reproductive potential:
a)The subject is not pregnant (as confirmed b y serum pregnancy  test at screening) 
and not planning to become pregnant within 30 days of the last day  of study 
treatment administration,
AND
b)The subject is nonlactating.
Subject Exclusion Criteria
The subject must be excluded from participating in the trial if the subject:
1.Is currently participating in or has participated in an interventional clinical trial with an 
investigational compound or device within 30 days prior to the first dose of study 
treatment in this current trial.
2.Has previously participated in any trial of ceftolozane or ceftolozane/tazobactam or has 
enrolled previousl y in the current trial and been d iscontinued.
3.Has a history  or current evidence of an y condition, therap y, laboratory  abnormality , or 
other circumstance that, in the opinion of the investigator, might expose the subject to 
increased risk by  participating in the trial, confound the results of the trial, or interfere 
with the subject’s participation for the full duration of the trial.
4.Has a history of any moderate or severe hypersensitivity  (eg, anaphylaxis), allergic 
reaction, or other contraindication to any of the following: β-lactam antibiotics 
(eg,penicillins, cephalosporins and carbapenems), or β-lactamase inhibitors 
(eg,tazobactam, sulbactam, clavulanic acid, avibactam).
NOTE: A history of mild rash to any of these agents is not a contraindication to 
enrollment.
5.Hasa history of a cUTI within the past 1yearprior to randomization that is caused by  
a pathogen known to be resistant to either IV study  treatment.
6.Has a concomitant infection at the time of randomization that requires nonstudy 
systemic antibacterial therapy in addition to IV study treatment or oral step-down 
therapy (medications with only gram-positive activity [eg, vancomycin, linezolid] are 
allowed). 
   05L60Q
Product:   MK-7625A 43
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential7.Has received potentially therapeutic antibacterial therapy (eg, with gram-negative 
activity),including bladder infusions with topical urinary antiseptics or antibacterial 
agents,for a duration of more than 24 hours during the 48hours preceding the first 
dose of study  treatment.
NOTE: Provided all other eligibility  criteria are met, including obtaining a baseline 
study-qualifying urine culture, the following subjects may be enrolled; however, 
subjects without documented ≥105CFU/mL of an appropriate gram-negative
uropathogen must discontinue study treatment immediately  following culture results :
a)Subjects with an active cUTIwho received at least 48 hours of a prior antibiotic 
regimen, if in the opinion of the investigator there is evidence they are failing 
the prior antibiotic regimen.
b)Subjects who are receiving antibiotic prophylaxis for cUTI who present with 
signs and symptoms consistent with an active new cUTI due to an appropriate 
gram-negative uropathogen.
8.Has any of the following:
a)Intractable UTI or pyelonephritis infection at baseline that the Investigator 
anticipates would require more than 14 day s of study  treatment
b) Confirmed fungal urinary tract infection at time of randomization with ≥103
fungal CFU/mL
c)Permanent indwelling bladder catheter or instrumentation including 
nephrostomy
d)Current urinary catheter that is not scheduled to be removed before the end of 
all study treatment (intermittent straight catheterization during the study 
treatment period is acceptable)
e)Complete, permanent obstruction of the urinary  tract
f)Suspected or confirmed perinephric or intrarenal abscess
g)Documented ileal loop reflux
h)Suspected or confirmed prostatitis, urethritis, or epididy mitis
i)Trauma to pelvis/urinary  tract
9.Has moderate orsevere impairment of renal function, defined as an estimated creatinine 
clearance ( CrCL)<50mL/min/1.73 m2based on the revised Schwartz equation [24]or 
requirement for peritoneal dialy sis, hemodial ysis, or hemofiltration.
10.Has one or more of the following laboratory  abnormalities in a specimen obtained at 
baseline:
a)Absolute neutrophil count (ANC)<1000/mm3
b)Aspartate aminotransferase ( AST) oralanine aminotransferase (ALT)≥3 × the 
upper limit of normal (ULN)
c)Total bilirubin ≥2 × ULN (if 7 to ≤28 days of ageand breastfeeding, total 
bilirubin >10 mg/dL OR ≥2 × ULN)
11.Has a seizure disorder or is anticipated to be treated with divalproex sodium or valproic 
acid during the course of study treatment.
12.Is receiving, or is expected to receive, an y of the following medications: 
   05L60Q
Product:   MK-7625A 44
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentiala)Immunosuppressive agents
NOTE: Short-term treatment with systemic (IV or oral) steroids of <1 week 
duration (eg, treatment for an acute asthma exacerbation or acute skin 
condition) is allowed. Topical steroids for the treatment of skin conditions are 
also allowed.
b)Valproic acid or divalproex sodium 
c)Probenecid
13.Has any rapidly progressing disease or immediately  life-threatening illness including 
acute hepatic failure, respiratory  failure, or septic shock.
14.Has an immunocompromising condition, including established AIDS, hematological 
malignancy , or bone marrow transplantation, oris receiving immunosuppressive 
therapy including cancer chemotherap y, medications for prevention of organ 
transplantation rejection, or chronic administration of systemic corticosteroids (defined 
as the systemic equivalent of ≥2mg/kg total daily dose of prednisone for participants 
≤20kg, or >40mg of prednisone per day for participants >20kg, administered 
continuously  for more than 14days in the 30days prior to the first dose of 
ceftolozane/tazobactam)
15.Has a history of malignancy  ≤5 years prior to providing documented informed consent, 
except for adequately treated basal cell or squamous cell skin cancer or in situ cervical 
cancer.
16.Planned receipt of suppressive/proph ylactic antibiotics with gram-negative activity 
after completion of study treatment.
NOTE: Based on site level standard of care, subjects at increased risk of recurrent 
pyelonephritis or cUTI (eg, vesico -ureteral reflux Grade 3 through 5) wherein there is 
a clear benefit to low -dose antibiotic prophy laxis, may  be enrolled.
17.Is or has an immediate family  member ( e.g., spouse ,parent/legal guardian, siblingor 
child) who is investigational site or Sponsor staff directly involved with this trial.
Trial Treatment(s)
The treatments to be used i n this trial areoutlined below in Table 7and Table 8. 
Intravenous Trial Treatment s
The IVtreatment regimens to be used in this trial are outlinedin Table 7.
After receiving at least 9 doses of double -blind IV study treatment, subjects in either treatment 
armmay be switched to open-label, standard-of-careoral step-down antibiotic therapy at the
investigator ’s discretion (Section 5.2.2–Optional Oral Step-down Therapy).Total antibiotic 
duration (IV onl y or IV + oral) is a minimum of 7 anda maximum of 14 day s.
NOTE: In Ukraine, enrollment will be limited to subjects 3 months to < 18 years of age 
(Groups1-4). Study treatments for Group 5 are not applicable at Ukrainian sites. 
   05L60Q
Product:   MK-7625A 45
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTable 7 Intravenous Trial Treatment s
Drug Dose/PotencyDose 
FrequencyaRoute of 
AdministrationbTreatment 
PeriodbUse
Age Group 1 ( 12to <18 years [n≥50combined with Group 2 ])c
Ceftolozane
/tazobactamCeftolozane 1 g 
and tazobactam 
0.5gEvery 8 h ours IV 7-14 days Experimental
Meropenem 20mg/kg 
(maximum 
1g/dose)Every 8 h ours IV 7-14 days Active
comparator
Age Group 2 (6 to <12 years [n≥50 combined with Group 1])c
Ceftolozane
/tazobactamCeftolozane 
20mg/kg and 
tazobactam 
10mg/kg
(maximum 
ceftolozane 1 g 
and tazobactam 
0.5 g/dose)Every 8 h ours IV 7-14 days Experimental
Meropenem 20mg/kg 
(maximum 
1g/dose)Every 8 h ours IV 7-14 days Active
comparator
Age Group 3 (2 to <6 years [n ≥57 combined with sam e age group in MK -7625A-035])c
Ceftolozane
/tazobactamCeftolozane 
20mg/kg and 
tazobactam 
10mg/kg
(maximum 
ceftolozane 1 g 
and tazobactam 
0.5 g/dose)Every 8 h ours IV 7-14 days Experimental
Meropenem 20 mg/kg 
(maximum 
1g/dose)Every 8 h ours IV 7-14 days Active
comparator
Age Group 4 (3 m onths to <2 years [n ≥24combined with sam e age group in MK-7625A-035])c
Ceftolozane
/tazobactamCeftolozane 
20mg/kg and 
tazobactam 
10mg/kg
(maximum 
ceftolozane 1 g 
and tazobactam 
0.5 g/dose)Every 8 h ours IV 7-14 days Experimental
Meropenem 20 mg/kg 
(maximum 
1g/dose)Every 8 h ours IV 7-14 days Active
comparator 
   05L60Q
Product:   MK-7625A 46
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialDrug Dose/PotencyDose 
FrequencyaRoute of 
AdministrationbTreatment 
PeriodbUse
Age Group 5 (Birthdto <3 months [n ≥21combined with same age group in MK -7625A-035])c
Ceftolozane
/tazobactamCeftolozane 
20mg/kg and 
tazobactam 
10mg/kg
(maximum 
ceftolozane 1 g 
and tazobactam 
0.5 g/dose)Every 8 h ours IV 7-14 days Experimental
Meropenem 20 mg/kg 
(maximum 
1g/dose)eEvery 8 h ours IV 7-14 days Active
comparator
IV = intravenous
aEach dose of ceftolozane/tazobactam or meropenem is administered as a 60- minute (±10 minutes)
infusion. Ceftolozane/tazobactam and meropenem are to be dosed every 8 h ours(±1 hour) after the 
previous infusion. The second IV dose has a ±4 -hourwindow for dosing to facilitate adjustment of th e IV 
dosing schedule (once every 8 hours) to be performed throughout the IV dosing period.
bAfter receiving at least 9 doses of double- blind IV study treatment, subjects may be switched to open -
label, stand ard-of-care, oral step -down therapy at the investigator’s discretion. The total duration of study 
treatment (IV only or IV + oral) is a minimum of 7 days and a maximum of 14 days.
cThe total minimum number of subjects in the 5age groups combined acrossMK-7625A-034 and MK -
7625A-035is 202. After the minimum enrollment targets for each age group are met, additional subjects 
(combined acrossMK-7625A-034 and MK -7625A-035)will be enrolled in any of the 5age groups.
dBirth is defined as >32 w eeks gestational age and ≥7 days postnatal.
eSome literature supports a higher meropenem dosage (up to 30 mg/kg every 8 h ours) for subjects 14 days 
to <3 months of age, therefore meropenem dosing up to 30 mg/kg every 8 h oursmay be used for subjects 
14 days to <3 months of age at the investigator’s discretion.
Optional Oral Step -down Therapy
After receiving at least 9 doses of double-blind IV study treatment, subjects may  be switched 
to open-label, standard-of-care, oral step-down antibiotic therapy  at the investigator’s 
discretion. Total antibiotic duration (IV onl y or IV + oral) is a minimum of 7 to a maximum of 
14 days. Optional oral step -down therap y is considered stud y treatment in this trial.
Oral step-down therapy should be guided by culture results and consistent with the local 
standard of care. Table 8lists recommended options for oral step- down therapy . 
   05L60Q
Product:   MK-7625A 47
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTable 8 Recommended Oral Step -down Therap yOptions
Antibiotic or Antibiotic Classa
β-lactam/β-lactamase inhibitor combination
Cephalosporin
Quinolone
Nitrofurantoin
Trimethoprim or trimethoprim/s ulfamethoxazole
aThe choice of oral step -down therapy should be guided by culture results and based on local antibiotic 
susceptibility patterns.
NOTE: Regimens not listed above must be approved by the Sponsor.
Trial Treatments: Administrative Considerations
Trial treatment should beginas soon as possible after randomization and at the latest within 
24hours of randomization. There should be no medically  inappropriate delay in randomization 
and subsequent stud y treatment.
All supplies indicated inTable 7andTable 8will be provided centrally by the Sponsor or 
locally by the trial site, subsidiary  or designee, depending on local country operational or 
regulatory  requirements.
For any commercially  available product that is provided by the trial site, subsidiary  or designee 
every attempt will be made to source these supplies from a single lot/batch number. The trial 
site is responsible for recording the lot number, manufacturer, and expiry  date for any  locally 
purchased product as per local guidelines unless otherwise instructed b y the Sponsor .
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution and usage of trial 
treatments in accordance with the protocol and an y applicable laws and regulations.
Dose Selection
Dose Selection (Preparation)
The following doses are to be used in this trial:
12 to <18 years of age: Ceftolozane 1 g with tazobactam 0.5 gvia a 60-minute 
(±10minutes) IV infusion every  8 hours
<12 years of age: Ceftolozane 20 mg/kg with tazobactam 10 mg/kg via a 60-minute
(±10 minutes) IV infusion every 8 hours (not to exceed a dose of ceftolozane 1 g and 
tazobactam 0.5 g) 
   05L60Q
Product:   MK-7625A 48
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialThe rationale for selection of doses to be used in this trial is provided in Section 4.2.2–
Rationale for Dose Selection/Regimen . The dosing calculations and drugpreparation are 
described in detail inthe pharmacy  manual.
Timing of Dose Administration
Ceftolozane/tazobactam and meropenem are to be dosed every 8 hours (±1 hour)afterthe 
previous infusion. The second IV dose has a ±4-hour window for dosing to facilitate 
adjustment of the dosing schedule (once every 8 hours) to be carried out throughout t he IV 
dosing period.
The final day of study treatment may extend into Day 15 to accommodate different start and 
stop times of the I V study treatment and/or dosing schedules of the oral step -down therap y.
Trial Blinding 
A double-blindingtechnique with in-house blinding will be used.  Ceftolozane/tazobactam and 
meropenem will be packaged identically so that blinding is maintained. The subject, the 
investigator and Sponsor personnel or delegate(s) who are involved in the treatmentor clinical 
evaluation of the subjects are unaware of the group assignments.
An unblinded pharmacist will prepare IV study treatment. In addition, infusion bags, IV lines, 
and any other dispensing devices will be covered as needed to maintain blinding .
The standard-of-careoral step-down therapy used at the discretion of the investigator after 
completion of IV study  treatment will not be blinded.
Specific blinding procedures required for this study can be found in the p harmacy manual.
See Section 7.1.4.4, Subject Blinding/Unblinding, for a description of the method of 
unblinding a subject during the trial, should such action be warranted.
Randomization
Treatment randomization will occur centrally using aninteractive voice response system / 
integrated web response sy stem (IVRS/I WRS).There are 2treatment arms.  Subjects will be 
assigned randomly in a3:1ratio to ceftoloza ne/tazobactam or meropenem , respectivel y.
Stratification
Treatment randomization will be stratified across 5age groups as defined in Section 2.1–Trial 
Design.After the minimum enrollment targets in Section 2.1 for each age group are met ( 202 
subjects total), additional subjects (combined acrossMK-7625A-034 and MK-7625A-035) 
will be enrolled in an y of the 5 age groups. 
   05L60Q
Product:   MK-7625A 49
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Concomitant Medications /Vaccinations (Allowed & Prohibited)
Medications specifically  prohibited in the exclusion criteria are not allowed during the ongoing 
trial. If there is a clinical indication for an y medication specificall y prohibited during the trial, 
discontinuation from trial therapy may be required. The investigator should discuss any 
questions regarding this with the Sponsor Clinical Director. The final decision on any 
supportive therapy rests with the investigator and/or the subject’s primary physician; however, 
the decision to continue the subject on trial therapy requires the mutual agreement of the 
investigator, th e Sponsor, and subject/ subject’s legal representative.
The following concomitant medications/therapies are not permitted in this study :
Immunosuppressive agents
NOTE: Short-term treatment with systemic (IV or oral) steroids of <1 week duration 
(eg, treatment for an acute asthma exacerbation or acute skin condition) is allowed. 
Topical steroids for the treatment of skin conditions are also allowed.
Valproic acid or divalproex sodium
Probenecid
Concomitant systemic antibacterial agents with gram-negative activity, other than 
1dose of prophylactic antibiotic, are not permitted while the subject is receiving IV 
study treatment or oral step-down therapy. Use of such agents for any reason other than 
the subject being considered a clinical failure must be discussed with the Sponsor 
Clinical Director before administration.
Bladder infusions with topical urinary antiseptics or antibacterial agents are not 
permitted. Subjects who require such therap y will be considered clinical failures.
All other concomitant medications necessary  for the health and well-being of the subject are 
permitted.
Rescue Medications & Supportive Care
No rescue or supportive medications are specified to be used in this trial.
Diet/Activity/Other Considerations
Intravenous study treatment may be administered without regard to food , alcohol,or caffeine 
consumption, tobacco use, oractivity.Oral step-down study therapymay have different dietary
considerations from IV study treatment and should be administered according to the product 
label.
Subject Withdrawal/Discontinuation Criteria
Discontinuation of Treatment
Discontinuation of IV study treatment or oral step-down therapydoes not represent withdrawal 
from the trial. 
   05L60Q
Product:   MK-7625A 50
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialAs certain data on clinical events beyond study treatment discontinuation areimportant to the 
study, they must be collected through the subject’s last scheduled follow-up, even if the subject 
has discontinued study treatment .  Therefore, all subjects who discontinue t rial treatment prior 
to completion of the treatment periodwill still continue to participate in the trial as specified 
in Section 6.0 – Trial Flow Chart and Section 7.1.5.9–Subjects Who Prematurel y Discontinue
from Study  Treatment or the Trial.
Subjects may discontinue study treatment at any time for an y reason or be dropped from study 
treatment at the discretion of the investigator should any untoward effect occur.  In addition, a 
subject may be discontinued from study treatment by the investigator or the Sponsor if study 
treatment is inappropriate, the trial plan is violated, or for administrative and/or other safety 
reasons.  Specific details regarding procedures to be performed at study treatment
discontinuation are provided in Section 7.1.4 –Other Procedures.
A subject must be discontinued from IV study treatment or oral step-down therapy but 
continue to be monitored in the trial for an y of the following reasons:
○The subject or subject’s lega lly acceptable representative requests to discontinue study  
treatment .
oLack of study-qualifying baseline urine culture. Subjects whose baseline urine culture does 
not qualify as defined in Section 7.1.3 – Laboratory Procedures/Assessments must be 
discontinued from study treatment by the investigator immediately . At the time study 
treatment is discontinued, all EOT Visitprocedures must be completed and recorded in the 
eCRF. No clinical response assessments or follow-up urine cultures are required for this 
category of subjects; however, these subjects should return to the trial site for the TOC 
Visit5 to 9 days after administration of the last dose of study treatment, and return or be 
contacted for the LFU Visit28 to 35 days after administration of the last dose of study 
treatment to complete safety assessments including assessment of AEs, recording 
concomitant medications, and collection of standard safety laboratory  data. Collection of 
standard safety laboratory  data is required at LFU only if abnormal values existed at the 
prior visit.
oThe subject has a medical condition or personal circumstance which, in the opinion of the 
investigator and/or Sponsor, places the subject at unnecessary  risk from continued 
administration of study  treatment .
oDevelopment of moderate orsevere impairment of renal function, including an estimated 
CrCL <50mL/min/1.73 m2based on the revised Schwartz equation [24]or requirement for 
peritoneal dial ysis, hemodialy sis,or hemofiltration (required for IV study treatment onl y).
oTheinvestigator feels it is in the best interest of the subject to disconti nue for any reason, 
including, but not limited to, the need for nonstudy antibacterial therapy due to insufficient 
therapeutic effect of the study  treatment .
oSafety issues:
Occurrence of an AE or clinically significant laboratory  abnormality  that, in the opinion 
of the Investigator, warrants the subject’s permanent discontinuation from IV study 
treatment or oral step-down therapy. In the event that IV study treatment or oral step- 
   05L60Q
Product:   MK-7625A 51
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialdown therapy is discontinued due to the occurrence of an AE, the trialsite should notify 
the Sponsor as soon as possible.
Suspected or confirmed pregnancy  or breastfeeding during the IV study treatment or 
oral step-down therapy administration period. Female subjects whose pregnancy  test 
becomes positive during study treatment must be followed through the immediate 
postnatal period or until termination of the pregnancy .
Discontinuation from studytreatment is “permanent.” Once a subject is discontinued, he/she 
shall not be allowed to restart study  treatment .
Withdrawal from the Trial
A subjectmust be withdrawn from the trial if the subjector subject’s legally acceptable 
representative withdraws consent fr om the trial.
If a subjectwithdraws from the trial, they will no longer receivestudy treatment or be followed 
at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the trial 
including the procedures to be performed should a subject repeatedly fail to return for 
scheduled visits and/or if the study site is unable to contact the subject, are outlined in Section 
7.1.4 –Other Procedures.
Subject Replacement Strategy
A subject whodiscontinues from study treatment or withdraws from the trialwill not be 
replaced.
Beginning and End of the Trial
The overall trial begins when the first subject (or their legally acceptable representative) 
provides documented informed consent.  The overa ll trial ends when the last data areavailable 
in either MK -7625A-034 or MK-7625A-035 (whichever is later).
Clinical Criteria for Early Trial Termination
The clinical trial may be terminated early if the extent (incidence and/or severity) of emerging 
effects/clinical endpoints is such that the risk/benefit ratio to the trial population as a whole is 
unacceptable.  In addition, further recruitment in the trial or at (a) particular trial site(s) may 
be stopped due to insufficient compliance withthe protocol, GCP and/or other applicable 
regulatory  requirements, procedure -related problems or the number of discontinuations for 
administrative reasons is too high. 
   05L60Q
Product:   MK-7625A 52
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential6.0TRIAL FLOW CHART
TrialPeriod: Screening Treatment (7 to 14 days)aFollow-up
Visit Number: 1 2 3 to 16 17 18 19 20 21
Visit Title:ScreeningbRandomizationbIV Clinical 
Assessmentsa,bEOIVc
(all 
subjects)Oral Clinical 
Assessmentd,e
(only for IV to 
oral switch)EOTd
(only for 
IV to oral 
switch)TOC
(all subjects)LFUf
(all subjects)
Scheduled Day or Timing: 48 h Day 1Day 2 up to Day 
15<24 h 
after last 
IV dose(after ≥7 days 
on oral step -
down therapy)<48h after 
last oral 
dose 5 to 9 days 
after final 
dose28 to 35 days 
after final 
dose
Administrative Procedures
Informed consent X
Inclusion/e xclusion criteria X
Subject identification card X X
Medical history X
Prior or concomitant medication review X X X X X X X X
Randomize to treatment (prior to 
administration of study treatment)X
Administer ceftolozane/tazobactam IV or 
meropenem IV every 8 hX X
Standard-of-careoral step-down therapyaX
Clinical Procedures/Assessments
Body weight X Xg,hXg,hXgXg,hXg
Height X
Vital signs (heart rate, respiratory rate, blood 
pressure, and temperature)X X X X X X X Xg,i
Full physical examination X
Directed physical examination XjX X X X Xg,i
Sign/symptom assessment X X X X X X X
AE monitoringkX X X X X X X
Assess clinical outcome X X X 
   05L60Q
Product:   MK-7625A 53
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTrialPeriod: Screening Treatment (7 to 14 days)aFollow-up
Visit Number: 1 2 3 to 16 17 18 19 20 21
Visit Title:ScreeningbRandomizationbIV Clinical 
Assessmentsa,bEOIVc
(all 
subjects)Oral Clinical 
Assessmentd,e
(only for IV to 
oral switch)EOTd
(only for 
IV to oral 
switch)TOC
(all subjects)LFUf
(all subjects)
Scheduled Day or Timing: 48 h Day 1Day 2 up to Day 
15<24 h 
after last 
IV dose(after ≥7 days 
on oral step -
down therapy)<48h after 
last oral 
dose 5 to 9 days 
after final 
dose28 to 35 days 
after final 
dose
Laboratory Procedures/Assessments
Blood for hematology and chemistry safety 
evaluationsX XjXlX XlX Xg,i
Coombs test (direct) X X
Urine microscopy for pyuria X XmXmXm
Serum pregnancy testnXnXn
Assessment of CrCL X XgXgXgXg
Urine for culture and susceptibility testing X XmXmXm
Verify urine culture resultoXo
Blood for culture and susceptibility testinggXgXgXg
Blood for PK analyses (Day 3 only [after ≥6 
doses of IV study treatment])pXo
AE = adverse event; CFU = colony -forming units; CrCL = creatinine clearance; eCRF = electronic case report form; EOIV = End of IV Treatment; EOT = End of 
Treatment; h = hour (s); IV = intravenous; LFU = Last Follow -up; PK = pharmacokinetic (s); SAE = serious adverse event; TOC = Test of Cure
aAfter receiving at least 9 doses of double -blind IV study treatment, subjects in either treatment arm may be switched to open -label, standard -of-careoral step-
down antibiotic therapy at the investigator’s discretion. Total duration of study treatment (IV only or IV + oral) is a minimum of 7 days and a maximum of 
14days, except the final day of study treatment may extend into Day 15 to accommodate different start and stop times of the IV study treatment and/or dosing 
schedules of the oral step -down therapy. From Day 1 through the last day of IV study treatment, each subject’s assessments should be performed at a consistent 
time of day (eg, every morning) on each calendar day, as much as p ossible. Subjects cannot go home on IV study treatment. If subjects are sw itched to oral 
step-down therapy, the oral step -down therapy must be initiated <24 hours after stopping IV study treatment.
bScreening, randomization, and first dose of study treatm ent may all occur on the same day. Assessments (eg, laboratory procedures, vital signs) performed prior 
to providing documented informed consent may be used if collected during the routine care of the patient, so long as they were conducted within 48 ho ursprior 
to the start of administration of the first dose of IV study treatment.
cFor subjects who receive only IV study treatment and are not switched to oral step -down therapy, the EOIV Visitserves as the EOT Visitand these subjects do 
not have a separate EOT Visit. Subjects who are switched to oral step -down therapy will have both an EOIV and EOT Visit .
dOnly for subjects who are switched to oral step -down therapy. 
   05L60Q
Product:   MK-7625A 54
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialeAnOral Clinical Assessment Visit should be pe rformed once if a subject receives ≥7 days oforal step-down therapy. This visit can be performed ±24 hours 
after 7 days of oral step -down therapy. Subjects who receive <7 days of oral step -down therapy will not undergo the Oral Clinical Assessment Visit.Any AE 
thatcomes to the attention of the investigator before the Oral Clinical Assessment Visit should be recorded at this visit, but any SAE must be reported within 
24 hours. The Oral Clinical Assessment V isit will be the same whether the subject is sti ll in the hospital or has been discharged to home. 
fThe LFU Visit willbe conducted by telephone; h owever,ifthe subject has abnormal laboratory values or AEs that require follow -up, an in-person visit is 
required.
gIf clinically indicated.
hAs needed to calculate CrCL or changes in weight -based dosing, if the subject’s weight is expected to change over the co urse of IV study treatment.
iTo be performed only if LFU Visitis conducted in person instead of by telephone.
jProcedures to be completed on Day 3 and then once weekly while the subject is receiving study treatment (IV or oral) .
kThe reporting period f or AEs is outlined in Section7.2. All serious adverse events will be follow ed until resolution, stabilization, withdraw al of consent, or 
death.
lIf blood samples for chemistry and hematology safety evaluations were collected within 24 hours prior to this Visit, blood samples for these evaluations are not 
required.
mThe use of sterile urine collection bags is allow ed for young children who are unable to provide mid -stream clean catch urine specimens at the EOIV, EOT, and 
TOC Visits. However, urine microscopy must be performed to detect pyuria in the urine sample; if pyuria is not present (as defined per inclusion criteria # 6), 
then any bacterial growth may be considered a contaminant rather than a true superinfection or new  infection. 
nFemale subject s of child-bearing potential only. A urine pregnancy test instead of a serum pregnancy test may be done at the TOC Visit, if deemed clinically 
appropriate by the investigator.
oVerify results from urine culture (sample obtained at screening) at the first Clinical Assessment Visitat which results are available. Subjects who are not 
documented as having ≥105CFU/mL of a n appropriate gram- negative uropathogen cultured from a screening urine specimen must discontinue from the trial 
immediately upon receipt of the culture result. At the time study treatment is discontinued, all EOT Visitprocedures must be completed and recorded in the 
eCRF.
pBlood samples for ceftolozane ,tazobactam , and tazobactam M1 concentration assays will be collected from all subjects over one 8 -hourdosing period on Day 
3 of the treatment period after administration of at least 6 doses of IV study treatment (see Section 7.1.3. 7 –Pharmacokinetic Evaluations ). OnDay 3, 250 µL 
of blood w ill be collected at the following times: At the end of infusion ( collected within 10 min utesafterthe end of total dose administration ); between 2.5 and 
3.5h post start of infusion; and between 5.0and 6.0hourspost start of infusion but prior to the start of the next dose of study treatment. If sampling on Day 3 is 
logistically difficult, sampling may be performed at comparable time points after Day 3 in subjects who are continuing to rec eive IV study treatment . Plasma 
will be separated from blood and sent to the central laboratory for PK testing. Procedures for collection, processing, storag e, and shipment of PK samples from 
blood (plasma) will be provided separately in a laboratory manual. Actual whole blood s ample collection dates and times should be recorded on the appropriate 
eCRF. 
   05L60Q
Product:   MK-7625A 55
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential7.0TRIAL PROCEDURES
Trial Procedures
The Trial Flow Chart -Section 6.0summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary  to perform 
these procedures at unscheduled time points if deemed clinically necessary by the investigator.
Furthermore, additional evaluations/testing may  be deemed necessary  by the investigator and 
or the Sponsor for reasons related to subject safety. In some cases, such evaluation/testing may 
be potentiall y sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations may 
require that additional informed consent,and assent if applicable, be obtained from the subject.  
In these cases, such evaluations/testing will be performed in accordance with those regulations.
Administrative Procedures
Informed Consent /Assent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent, and assent if applicable, from each potential subjector 
each subject’s legally acceptable representative prior to participating in this clinical trial.If 
there are changes to the subject’s status during the trial (e.g.,health or age of majority 
requirements ), the investigator or medically qualified designee must ensure the appropriate 
documented consent/assentis in place. 
7.1.1.1.1 General Informed Consent/Assent
Informed consent/assent given by the subject or their legally  acceptable representative must be 
documented on a consent/assent form. The form must include the trial protocol number, trial 
protocol title, dated signature, and agreement of the subject (or his/her legally acceptable 
representative) and of the person conducting the consent discussion.
A copy of the signed and dated informed consent/assentform should be given to the subject 
(or their legall y acceptable representative) before participation in the trial.
The initial informed consent/assent form, any subsequent revised informed consent/assent
form and any written information provided to the subject must receive the IRB/IEC’s 
approval/favorable opinion in advance of use.  The subject or his/her legally acceptable 
representative should be informed in a timely manner if new information becomes available 
that may be relevant to the subject’s willingness to continue participation in the trial.  The 
communication of this information will be provided and documented via a revised 
consent/assentform or addendum to the original consent/assentform that captures the subject’s 
or the subject’s legally  acceptable representative’s dated signature.
Specifics about a trial and the trial population are to be included in the trial informed 
consent/assent form.   
   05L60Q
Product:   MK-7625A 56
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialInformed consent will adhere to IRB/IECrequirements, applicable laws and regulations and 
Sponsor requirements .  The assent, as applicable ,will adhere toIRB/ERC requirements, 
applicable laws and regul ations,and Sponsor requirements .
Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by  the investigator or qualified designee 
to ensure that the subject qualifies for the trial.
Subject Identification Card
All subjects will be given a Subject Identification Card identifying them as participants in a 
research trial. The card will contain trial site contact information (including direct telephone 
numbers) to be utilizedin the event of an emergency . The investigator or qualified designee 
will provide the subject with a Subject Identification Card immediately  after the subject 
provides documented informed consent/assent.At the time of treatment 
allocation/randomization, site personnel will add the treatment/randomization number to the 
Subject Identification Card.
The subject identification card also contains contact information for the emergency  unblinding 
call center so that a health care provider can obtain information about trial 
medication/vaccination in emergency  situations where the investigator is not availa ble.
Medical History
A medical history will be obtained by  the investigator or qualified designee. I n addition to the 
evaluation of a subject’s medical history in terms of study eligibility, all medical conditions 
present during the 5 years prior to study entry will be documented at the Screening Visiton 
the appropriate eCRF. Any history of prior cUT I episodes or conditions that may predispose a 
subject to the development of cUTI will also be documented on the appropriate eCRF, even if 
the prior episode orpredisposing condition was diagnosed more than 5 years prior to study 
entry.
Prior and Concomitant Medications Review
7.1.1.5.1 Prior Medications
At Screening, the investigator or qualified designee will review prior medication use and 
record prior medication takenby the subject within 7 days before the first dose of trial 
medication (or within 14 days before the first dose of trial medication for all antibacterial 
agents, and within 30 days before the first dose of trial medication for any other investigational 
drug). For subjects who are breastfeeding, prior medication use by the subject’s mother will 
be recorded similarl y.
Any blood or blood product transfusions in the previous 48 hours before first dose of trial 
medication will be recorded. 
   05L60Q
Product:   MK-7625A 57
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential7.1.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by the subject 
during the trial (from the first dose of trial medication to the last trial evaluation). For subjects 
who are breastfeeding, concomitant medication use by the subject’s mother will be recorded 
similarly.
Assignment of Screening Number
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior to randomization .  Each subject will be assigned 
only one screening number.  Screening numbers must not be re -used for different subjects.
Specific details on the Screening Visitrequirements are provided in Section 7.1.5.1-
Screening .
Assignment of Treatment/ Randomization Number
All eligible subjects will be randomly allocated and will receive a treatment/ randomization 
number.  The treatment/ randomization number identifies the subject for all procedures 
occurring after randomization.  Once a treatment/randomization number is assigned to a 
subject, it can never be re -assigned to another subject.
A single subject cannot be assigned more than 1 treatment/ randomization number.
Trial Compliance (Medication)
Interruptions from the protocol specified IV study treatment for ≥2 consecutive dosesor 
≥3nonconsecutive doses require consultation between the investigator and the Sponsor and 
written document ation of the collaborative decision on subject management.
Clinical Procedures/Assessments
Clinical procedures and assessments will occur as specified in Section 6.0 –Trial Flow Chart. 
This section provides additional details.Clinical procedure/assessmen t data will be recorded 
in source documents and the appropriate location in the eCRF.
Body Weight, Height and Vital Signs
The investigator or qualified designee will record body weight (kg) and height (cm) as 
indicated in Section 6.0 – Trial Flow Chart. Body weight will be measured without shoes,
jacket, or diaper (in subjects using diapers) .
The investigator or qualified designee will record vital signs (heart rate, respiratory  rate, blood 
pressure, and temperature [oral, tympanic, rectal, axillary, or temporal] ) as indicated in Section 
6.0 –Trial Flow Chart. Systolic and diastolic blood pressure will be measured on the same arm. 
Heart rate and blood pressure will be measured simultaneously . 
   05L60Q
Product:   MK-7625A 58
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Physical Examination
The investigator or qualified designee will performfull ordirected physical examinations as 
indicated in Section 6.0 – Trial Flow Chart. The investigat or or qualified designee willalso 
perform a full or directed physical examination at other times at the investigator’s discretion, 
if an AE or abnormality is suspected.
Thefullphysical examination will includeexamination of body systems(including, but not 
limited to,general appearance, skin, neck, eyes, ears, nose, throat, breast, lungs, heart, 
abdomen, back, l ymph nodes, extremities, and nervous sy stem).
The directed physical examination should be based on the subject’s condition and 
circumstances, at the investigator’s discretion. The directed physical examination should note 
any changes in the subject’s condition (body  systems) since the last examination and does not 
preclude examination of any  of the body  systems as clinically  indicated.
Changes in physical examination findings (abnormalities) that the investigator considers 
clinically significantwill be recorded on the medical history eCRF page if observed prior to 
administration of the first dose of IV study treatment. Changes in physical examination 
findings (abnormalities) that the investigator considers clinically  significant must be recorded 
as AEsif observed after the start of the first dose of IV stud y treatment .
Assessment of Clinical Signs and Symptoms ofComplicated Urinary Tract 
Infection , Including Pyelonephritis
The clinical signs and symptoms of cUTI, including pyelonephritis (see Section 5.1.2-Subject 
Inclusion Criteria, Criterion 7)will be evaluated at the visits specified in Section 6.0 –Trial 
Flow Chart.The signs and symptoms of cUTI will be assessed at Screening by clinical 
examination. Specific findings (eg, fever, failure to thrive, recent weight loss, irritability , poor 
feeding, lack of normal level of activity, abdominal pain/tenderness, vomiting, dysuria, urinary 
urgency,etc.) will be assessed and noted as absent, present, or not able to assess/not done.
At visits after Screening , the investigator will assess each observed sign or symptom according 
to the categories above. The clinical signs and symptoms of cUTI are not considered AEs, 
unless a sign or s ymptom qualifies as a nSAE.
Adverse Event Monitoring
Assessment and recording of AEs is described in Section 7.2–Assessing and Recording 
Adverse Events. All SAEswill be followed until resolution, stabilization, withdrawal of 
consent, or death.
Assessment of Clinical Outcome
At the visits indicated in Section 6.0 –Trial Flow Chart, the investigator or qualified designee 
will assign the subject’s clinical outcome to a category  (cure,partial improvement, failure, or 
indeterminate) as described in Section 4.2.3.2 –Rationale for Efficacy  Endpoints. 
   05L60Q
Product:   MK-7625A 59
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Assessment of Microbiological Outcome
All microbiological outcomes will be assessed by the Sponsor based on culture resultsas 
eradication, persistence, or indeterminate, as defined in Section 4.2.3.2–Rationale for Efficacy 
Endpoints. Investigators are not responsible for assessment of microbiological outcomes .
Assessment of Composite Clinical and Microbiological Outcome
Composite response (clinical success and microbiological eradication) will be categorized as 
cure, failure, or indeterminate, as defined in Section 4.2.3.2–Rationale for Efficacy Endpoints.
Investigators are not responsible for assessment of composite clinical and microbiological 
outcomes .
Assessment of Emergent Infection
Emergent pathogens (ie, those isolated after Screening) will be assessed by the Sponsor for the 
outcome of superinfection or new infection, as defined in Section 4.2.3.2–Rationale for 
Efficacy Endpoints. Investigators are not responsible for assessment of emergent infection s.
Laboratory Procedures/Assessments
Details regarding specific laboratory  procedures/assessments to be performed in this trial are 
provided below. Laboratory  procedure/assessment data will be recorded in source documents 
andthe appropriate location in the eCRF.
The total amount of blood to be drawn/collected over the cou rse of the trial (from screening to 
the last trial evaluation), including approximate bloodvolumes drawn/colle cted by visit per 
subject can be found in Appendix 12.2 –Approximate Blood Volumes Drawn/Collected by 
Trial Visit .
Laboratory Safety Evaluation s (Hematology and Chemistry)
At the visits specified in Section 6.0 – Trial Flow Chart, blood samples will be obtained for
theindicated laboratory tests (hematology andchemistry ;Table 9).See Appendix 12.2–
Approximate Blood Volumes Drawn/Collected by Trial Visitfor the maximum expected blood 
volumes needed forlaboratory  tests.
At Screening, blood samples will be collected for laboratory  safety evaluations to determine 
trial eligibility , as follows: serum creatinine , ANC, AST,ALT, and total bilirubin. These
laboratory  safety evaluations for trial eligibility  will be performed bythelocal laboratory . A 
blood sample will also be collected at Screening for the direct Coombs test, which the site will 
send to the central laboratory for testing .
Bloodsamples collected for laboratory  safety evaluations after the Screening Visitwill be 
tested bythelocallaboratory . At the EOIV Visit, a blood samplewill be collected for the direct 
Coombs test,which the site will send to the centrallaboratory for testing.The blood sample 
for direct Coombs test maybe drawn on Day 3 (with the blood samples for chemistry  and 
hematology  safety evaluations) if the EOIV V isit is planned for Day  4. 
   05L60Q
Product:   MK-7625A 60
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialBloodsamplesfor laboratory  safety evaluations will be collected without regard to meals or 
study treatment.
Table 9 Laboratory  Safety Evaluations
Hematology Chemistry
Hematocrit Albumin
Hemoglobin Alkaline phosphatase
Platelets ALT
Leukocytes (total and differential) AST
Direct Coombs test Bicarbonate
Calcium
Chloride
Creatinine
Glucose
Phosphorus
Potassium
Sodium
Total bilirubin
Direct bilirubin, if total bilirubin is >ULN
Total protein
BUN
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; ULN = 
upper limit of normal
NOTE: All laboratory safetyevaluations will be performed by the local laboratory, except the direct Coombs 
test; sites will send blood samples for the direct Coombs test to the central laboratory for testing.
Urine Microscopy
Urine will be colle cted for microscopy , including WBC count to assess pyuria as specified in 
Section 6.0 – Trial Flow Chart. Urine microscop y will be performed by the local laboratory .
Pyuria is defined as dipstick anal ysis positive for leukocy te esterase, OR :
If ≥1 year of age: WBC count >10 cells/µL in unspun urine or ≥10 cells/high power 
field in spun urine
If <1 year of age: WBC count >5 cells/µL in unspun urine or ≥5 cells/high power field 
in spun urine
Urine may be collected by suprapubic aspiration, clean intermittent urethral catheterization, 
indwelling urethral catheter, or mid -streamclean catch. Urine specimens obtained f rom Foley 
bags are not allowed for the study -qualifying baseline urine culture specimen .
The use of sterile urine collection bags is allowed for young children who are unable to provide 
mid-stream clean catch urine specimens at the EOIV, EOT, and TOC Visits. However, urine 
microscop y must be performed to detect p yuria in the urine sample; if p yuria is not present (as  
   05L60Q
Product:   MK-7625A 61
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialdefined per inclusion criteria #6), then any  bacterial growth may  be considered a contaminant 
rather than a true superinfection or new infection.
Pregnancy Testing
Pregnancy  testing will be performed by the local laboratory  on female subjectsof child-bearing 
potential at the visits specified in Section 6.0 – Trial Flow Chart.Prior to randomization, the 
investigator will ensure serum pregnancy tests are negative in female subjects of child -bearing 
potential.
A urine pregnancy test instead of a serum pregnancy test may be done at the TOC Visitby the 
local laboratory , if deemed clinically  appropriate by  the investigator.
Assessment of Creatinine Clearance
Blood samples for serum creatinine will be obtained as indicated in Section 6.0 – Trial Flow 
Chartandevaluated by the local laboratory . The subject’s CrCLwill be estimated using the 
serum creatinine value , height, and the revised Schwartz equation [24], as follows :
Glomerular filtration rate (GFR)(mL/min per 1.73 m2) = 0.413 *H/Scr, where
GFR = glomerular filtration rate (mL/min per 1.73 m2)
H = height (cm)
Scr= serum creatinine (mg/dL)
Forsubjectswith unstablerenal function (CrCLis close to 50 mL/min/1.73 m2) while receiving 
IV study treatment, obtain serum creatinine value and monitor CrCLat least daily. Subjects 
with CrCL<50 mL/min/1.73 m2must be discontinued from the IV study treatment .
Urine Samples for Culture
A baselineurine samplefor culture must be obtained within 48 hoursbefore the start of 
administration of the first dose of study treatment and preferably prior to administration of any 
potentially  therapeutic antibiotics .If more than 1 appropriatel y collected urine culture sample
isobtained before the initiation of study treatment , the specimen obtained closest to the time
of the administration of the first dose of study treatment will be considered the Screening
specimen.
Urine specimens areto be obtained by suprapubic aspiration, clean intermittent urethral 
catheterization, indwelling urethral catheter, or mid-stream clean catch .Urine specimens
obtained from Foley bags are not allowedfor the study-qualifying baseline urine culture 
specimen.
The use of sterile urine collection bags is allowed for young children who are unable to provide 
mid-stream clean catch urine specimens at the EOIV, EOT, and TOC Visits. However, urine 
microscop y must be performed to detect p yuria in the urine sample; if p yuria is not present (as 
defined per inclusion criteria #6), then any  bacterial growth may  be considered a contaminant 
rather than a true superinfection or new infection. 
   05L60Q
Product:   MK-7625A 62
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialA baseline study-qualifying urine culture must contain 1 and not more than 2 gram-negative 
bacterial isolates at ≥105CFU/mL each,as follows:
For non-catheterized subjects, if more than 2 bacterial isolates are identified from a 
single urine specimen, the culture will be suspected contaminated unless a pathogen of 
≥105CFU/mL is also isolated from the blood culture at the Screening Visit. 
For catheterized subjects, if more than 1bacterial isolate isidentified from a single 
urine specimen, the culture will be suspected contaminated unless a pathogen of 
≥105CFU/mL is also isolated from the blood culture at the Screening Visit. 
The full list of appropriate gram-negative uropathogens will be provided in a laboratory 
manual. The following pathogens will not be considered causative pathogens of cUTI 
in this trial:
oCoagulase -negative Staphylococci
oNon-Group D Streptococci
NOTE: The Lancefield category [47]is shown below as reference :
Group A: Streptococcus pyogenes
Group B: S. agalactiae
Group C and G: S. equi, S. canis
Baseline urine cultureresults(sample obtained at Screening) will be verified at the first 
Clinical Assessment Visit at which results are available. Subjects who are not documented as 
having ≥105CFU/mL of an appropriate gram-negative uropathogen cultured from a screening 
urine specimen must discontinue from the trial immediately  upon receipt of the culture result. 
At the time study treatment is discontinued, all EOIV/EOT Visitprocedures must be completed 
and recorded. Subjects should return to the trial site for the TOC Visit5 to 9 days after 
administration of the last dose of study  treatment and return or be contacted for the LFU Visit
28 to 35 days after administration of the last dose of study treatment to complete safety 
assessmen ts. Last Follow-upVisit procedures must be completed 28 to 35 day s after the final 
dose of study  treatment .
Urine cultures, isolation of uropathogen(s), initial identification of pathogen(s) , susceptibility  
testing,and bacterial counts in urine will be conducted by  thelocal laboratory . The result sof 
urine cultures, initial identification of pathogen(s) ,and bacterial counts at the local laboratory  
will be recorded. The sites will also ship the isolated pathogen(s) to the central microbiology 
laboratory  forre-identification of uropathogen(s) and MICtesting. Further details of the 
procedures to be followed for sample collection, storage, and shipment will be provided in a 
laboratory  manual.
Blood Samples for Culture
Blood samples are collected for culture as specified in Section 6.0 – Trial Flow Chart. Blood 
samples for culture should be collected if signs of sepsis appear at any  time during the study . 
Further details of the procedures to be followed for sample collection, storage, and shipment 
will be provided in a laboratory manual. 
   05L60Q
Product:   MK-7625A 63
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialBlood samples for culture will be obtained for all subjects at Screening if clinically  indicated . 
Culture of the blood specimen, isolation of pathogen(s) ,initial identification of pathogen(s) , 
and susceptibility  testingwill be conducted by thelocal laboratory and recorded . The sites will
ship the isolated pathogen(s) to the central microbiology  laboratory  forre-identification and 
MIC testing. Further details of the procedures to be followed for sample collection, storage, 
and shipment will be provided in a laboratory manual.
Pharmacokinetic Evaluations
Whole blood to obtain plasma samples will be collected for population PK analysisof 
ceftolozane and tazobactam as specified in Section 6.0 –Trial Flow Chart. These samples may 
also be used in the assessment of the clinical relationship between ceftolozane and tazobactam 
plasma concentrations and efficacy , as appropriate.
Blood samples for ceftolozane , tazobactam , and tazobactam M1concentration assays and 
plasma PK parameters (for ceftolozane and tazobactam) will be collected from all subjects 
over one 8 -hour dosing period on Day 3 of the treatment period after administration of at leas t 
6 doses of IV study treatment. These blood sampleswill be collected at the following times: 
At the end of infusion (collected within 10 minutes after the end of total dose administration); 
between 2.5 and 3.5h post start of infusion; and between 5.0 and 6.0 hours post start of infusion 
but prior to the start of the next dose of study treatment.
Pharmacokinetic sample collection may occur on Day 4 if the last dosing period of Day 3 is 
selected for PK sample collection. Additionally , if sampling on Day 3 is logistically  difficult, 
sampling may be performed at comparable time points after Day 3 in subjects who are 
continuing to receive IV study treatment.
Plasma will be separated from blood and sent to the central laboratory  for PK testing. Details 
of the procedures for collection, processing, storage, and shipment of PK samples from blood 
(plasma) will be provided separately in a laboratory  manual. Actual whole blood sample 
collection dates and times must be recorded on the appropriate eCRF .
Other Procedures
Withdrawal/Discontinuation
Subjects who discontinue studytreatment prior to completion of the study treatment regimen
(IV only or IV + oral)should be encouraged to continue to be followed for all remaining stud y 
visits.
When a subject discontinues/withdraws from participation in the trial, all applicable activities 
scheduled for the EOIVorEOT Visit,as described in Section 7.1.5.9–Subjects Who 
Prematurel y Discontinue From Study  Treatment or the Trial, should be performed at the time 
of discontinuation.  Any adverse events which are present at the time of 
discontinuat ion/withdrawal should be followed in accordance with the safety requirements 
outlined in Section 7.2 - Assessing and Recording Adverse Events . 
   05L60Q
Product:   MK-7625A 64
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Lost to Follow -up
If a subject fails to return to the clinic for a required trial visit and/or if the site is unable to 
contact the subject, the following procedures willbe performed:
The site must attempt to contact the subject and reschedule the missed visi t. If the 
subject is contacted, the subject should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
The investigator or designee must make every effort to regain contact with the 
subject at each missed visit (e g,phone calls and/or a certified letter to the subject’s 
last known mailing address or locally equivalent methods). These contact attempts 
should be documented in the subject’s medical record.
NOTE: A subject is not considered lost to follow-up until the last scheduled visit for the 
individual subject. The amount of missing data for the subject will be managed viathe 
prespecified data handling and anal ysis guidelines.
Unblinded Pharmacist
Subjects will receive the IV study treatment,following preparation by an unblinded pharmacist
(Section 5.2.6–Trial Blinding ), for a maximum of 14 day s. Preparation of study drug by the 
unblinded pharmacist is detailed in the pharmacy  manual. Importantly, the unblinded 
pharmacist will be uninvolved in an y of the postinfusion evaluations for the subject . All study 
personnel involved with the postinfusion evaluations of safety andefficacy outcomes, 
including the study coordinator(s), investigator, or subinvestigator(s), must have no access to 
the treatment group assignment or the preparation of the study infusion.
Subject Blinding/Unblinding
When the investigator or delegate needsto identify  the drug used by  a subjectand the dosage 
administered in case of emergency  e.g., the occurrence of serious adverse events, he/she will 
contact the emergency  unblinding call center by  telephone and make a request for emergency  
unblinding.  As requested by the investigator or delegatethe emergency  unblinding call center 
will provide the information to him/her promptl y and report unblinding to the Sponsor.  Prior 
to contacting the emergency  unblinding call center to request unblinding of a subject’s 
treatment assignment, the investigator or delegatemust enter the intensity gradeof the adverse 
eventsobserved, the relation to study  drug, the reason thereof, etc., in the medical chart etc.
Subjects whose treatment assignment has been unblinded by the investigator/delegate and/or 
non-study treating ph ysician should continue to be monitored in the trial.
Additionally , the investigator must go into the IVRS system and perform the unblind in the 
IVRS system to update drug disposition.  In the event that the emergency  unblinding call center 
is not available for a given site in this trial, IVRS/IWRS should be used for emergency  
unblinding in the event that this is required for subject safet y.
Treatment/Vaccine identification information is to be unmasked ONLY if necessary  for the 
welfare of the subject.  Every effort should be made not to unblind the subject unless necessary .  
   05L60Q
Product:   MK-7625A 65
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialIn the event that unblinding has occurred, the circumstances around the unblinding (e.g., date, 
reason and person performing the unblinding) must be documented promptly, and the Sponsor 
Clinical Director notified as soon as possible. Once an emergency unblinding ha s taken place, 
the principal investigator, site personnel, and Sponsor personnel may  be unblinded so that the 
appropriate follow -up medical care can be provided to the participant.
Subjects whose treatment assignment has been unblinded should continue to receivestudy 
medication.
Calibration of Critical Equipment
The investigator or qualified designee has the responsibility  to ensure that any critical device
or instrument used for a clinical evaluation/test during a clinical trial that provides important 
information about inclusion/exclusion criteria and/or safety or efficacy parameters shall be 
suitably calibrated and maintained to ensure that the data obtained is reliable and/or 
reproducible.  Documentation of equipment calibration must be retained as source 
documentation at the trial site.
Critical Equipment for this trial includes:
Refrigerators or freezers used to store study medication or subject samples/specimens 
that will be sent to the central laboratory
Visit Requirements
Visit requirements are outlined in Section 6.0-Trial Flow Chart. Specific procedure -related 
details are provided above in Section 7.1 - Trial Procedures.
Screening
Screening assessments are performed within 48 hours prior to the start of administration of the 
first dose of IV study treatment. Assessments (eg, laboratory  procedures, vital signs) performed 
prior to providing documented informed consent may be used if collected during the routine 
care of the subject, so long as they were conducted within 48 hours prior to the start of 
administration of the first dose of IV study treatment. Potential subjects are evaluated at the 
Screening Visitto determine ifthey fulfill the entry requirements in Section 5.1–Entry 
Criteria. All Screening results must be available prior to randomization. Screening, 
randomization, and first dose of study  treatment may all occur on the same day .
Randomization Visit
The Randomization Visitis the date subjects are randomized to treatment arms, and may then 
receive the first dose of double-blind IV study treatment. Screening, randomization, and first 
dose of study  treatment may  all occur on the same day . 
   05L60Q
Product:   MK-7625A 66
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Clinical Asses smentVisitson Intravenous Study Treatment
Clinical Assessment Visitson IV study treatment occur daily beginning on Day 2 and 
continuing throughthe last dose of IV study treatment. At these visits, each subject’s 
assessment should be performed at a cons istent time eachday (eg, every morning), as much as 
possible. Safety laboratory tests and a directed physical examination should be completed on 
Day 3 (±24 hours) and then once weekly while the subject is receiving IV study treatment. 
Subjects cannot go h ome on IV study  treatment.
Blood iscollected for PK analyses on Day 3  (after ≥6 doses of IV study treatment). 
Pharmacokinetic sample collection mayoccur on Day 4 if the last dosing period of Day 3 is 
selected for PK sample collection. Additionally , if sampling on Day  3 is logistically  difficult, 
sampling may be performed at comparable timepoints after Day 3 in subjects who are 
continuing to receive IV study treatment .
End of IV Treatment Visit
The EOIV Visitoccurs in all subjects within 24 hours after the last dose of IV study treatment. 
For subjects who receive only IV study treatment and are notswitched to oral step-down 
therapy, the EOIV Visitserves as the EOT Visitand these subjects do not have a separate EOT 
Visit. Subjects who areswitched to oral step -down therapy will have both an EOIV and EOT 
Visit.If subjects are switched to oral step-down therapy, the oral step-down therapymust be 
initiated <24 hours after stopping IV study treatment. If blood samples for chemistry  and 
hematology  safety evaluations were collected within 24 hours prior to the EOIV Visit, blood 
samples for these evaluations are not required at this visit.
Clinical Asses sment Visit onOral Step -down Therapy
The Oral Clinical Assessment Visitis completed only for subjects who are switched to oral 
step-down therapy. If subjects are switched to oral step-down therapy, the oral step-down 
therapy must be initiated <24 hours after stopping IV study treatment. This visit should be 
performed once ifthe subject receives ≥7 days of oral step-down therapy. This visit can be 
performed ±24 hours after 7 day s on oral step- down therap y.Subjects who receive <7 day s of 
oral step-down therapy will not undergo this visit. Any AE that comes to the attention of the 
investigator before the Oral Clinical Assessment Visitshould be recorded at this visit, but an y 
SAE must be reported within 24 hours. This visit will be the same whether the subject is still 
in the hospital or has been discharged to home .If the Oral Clinical Assessment Visit and EOT 
Visit are on the same day, only the EOT V isitshould be completed .
End of Treatment Visit
The EOT Visitoccurs only in subjects who are switched to oral step-down therapy. These 
subjects will have both an EOIV and EOT Visit. This visit will occur within 48hours after the 
last dose of oral step-down therapy.If blood samples for chemistry  and hematology  safety 
evaluations were collected within 24 hours prior to the EOT Visit, blood samples for these 
evaluations are not required at this visit. 
   05L60Q
Product:   MK-7625A 67
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Test of Cure Visit
The TOC Visitoccurs in all subjects 5 to 9 day s after the final dose of study treatment (IV or 
oral).
Last Follow -up Visit
The LFU Visitoccurs in all subjects 28 to 35 days after the final dose of study treatment (IV 
or oral). The LFU Visitwill be conducted by  telephone; however,if the subject has abnormal 
laboratory  values or AEs that require follow -up, an in- person visit is required.
Subjects Who Prematurely Discontinue From Study Treatment or the Trial
Subjects who discontinue from study treatment prior to completion of the study treatment 
regimen (IV only or IV + oral) will continue to be monitored in the trial according to Section 
6.0 –Trial Flow Chart.
For subjects who prematurel y withdraw from the trial, see Section 7.1.4.1 –
Withdrawal/Discontinuation and Se ction 7.1.4.2 –Lost to Follow -up.
Assessing and Recording Adverse Events
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily 
have to have a causal relationship with this treatment. An adverse event can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory  finding, for example), 
symptom, or disease temporally  associated with the use of a medicinal product or protocol-
specified procedure, whether or not considered related to the medicinal product or protocol-
specified procedure.  Any worsening (i.e., any clinically significant adverse change in 
frequency  and/or intensity) of a preexisting condition that is temporally  associated with the use 
of the Sponsor’s product, is also an adverse event.
Changes resulting from normal growth and development that do not vary significantl y in 
frequency  or severity from expected levels are not to be considered adverse events.  Examples 
of this may include, but are not limited to, teething, ty pical crying in infants and children and 
onset of menses or menopause occurring at a ph ysiologicall y appropriate time.
Sponsor's product includes any pharmaceutical product, biological product, device, diagnostic 
agent or protocol-specified procedure, whether investigational (including placebo or active 
comparator medication) or marketed, manufactured by, licensed by, provided by or distributed 
by the Sponsor for h uman use.
Adverse events may occur during clinical trials, or as prescribed in clinical practice, from 
overdose (whether accidental or intentional), from abuse and from withdrawal.
All adverse events that occur after the subject provides documented informed consent but 
before treatment allocation/randomization must be reported by the investigator if they cause 
the subject to be excluded from the trial, or are the result of a protocol -specified intervention,  
   05L60Q
Product:   MK-7625A 68
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialincluding but not limited to washout or discontinu ation of usual therapy, diet, placebo 
treatment or a procedure. From the time of treatment allocation/ randomization through the last 
trial evaluation (Last Follow-up visit, 28to 35days after final dose), all adverse events must 
be reported by the investigator. Such events will be recorded at each examination on the 
Adverse Event case report forms/worksheets.  The reporting timeframe for adverse events 
meeting any serious criteria is described in section 7.2.3.1. The investigator will make every 
attempt to follow all subjects with non -serious adverse events for outcome.
Electronic reporting procedures can be found in the Electronic Data Capture ( EDC)data entry 
guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or 
equivalent).
Definition of an Overdose for This Protocol and Reporting of Overdose to the 
Sponsor
In this trial, an overdose is any dose greater than 1.5 times higher than the weight-based dosing 
specified for the subject’s age groupfor ceftolozane/tazobacta mand meropenem .Fororal step-
down antibiotic therapy , refer to the manufacturer’s label for overdose criteria.Additional 
details are described in the p harmacy manual.
If an adverse event(s) is associated with (“results from”) the overdose of Sponsor's product or 
vaccine, the adverse event(s) is reported as a non-serious adverse event, unless other serious
criteria are met.
If a dose of Sponsor's product or vaccine meeti ng the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory  results, the overdose is 
reported as a non-seriousadverse eventusing the terminology  “accidental or intentional 
overdose without adverse effec t.”
All reports of overdose with and without an adverse event must be reported by the investigator 
within 24 hours to the Sponsor either by electronic media or paper. Electronic reporting 
procedures can be found in the EDC data entry  guidelines. Paper repo rting procedures can be 
found in the Investigator Trial File Binder (or equivalent) .
Reporting of Pregnancy and Lactation to the Sponsor
Although pregnancy  and lactation are not considered adverse events, it is the responsibility  of 
investigators or their designees to report any pregnancy or lactation in a subject (spontaneousl y 
reported to them), including the pregnancy  of a male subject's female partner that occurs during 
the trial.
Pregnancies and lactations of subjects and female partners of male subjec ts from the time the 
documented informed consent form is provided but before treatment allocation/ randomization 
must be reported by  the investigator if they  cause the subject to be excluded from the trial, or 
are the result of a protocol-specified intervention, including but not limited to washout or 
discontinuation of usual therapy, diet, placebo treatment or a procedure.  Pregnancies and 
lactations of subjects and female partners of male subjects that occur from the time of treatment  
   05L60Q
Product:   MK-7625A 69
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialallocation/ randomizat ion through 14 days following cessation of Sponsor’s product must be 
reported. All reported pregnancies  must be followed to the completion/termination of the 
pregnancy . Pregnancy outcomes of spontaneous abortion, missed abortion, benign 
hydatidiform mole,blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth 
must be reported as serious events (Important Medical Events). If the pregnancy  continues to 
term, the outcome (health of infant) must also be reported.
Such events must be reported within 24 hours to the Sponsor either by electronic media or 
paper. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper 
reporting procedures can be found in the Investigator Trial File Binder (or equivalent).
Immediate Reporting of Adverse Events to the Sponsor
Serious Adverse Events
A serious adverse event is any  adverse event occurring at an y dose or during an y use of 
Sponsor's product that:
●Results in death;
●Is life threatening;
●Results in persistent or significant disability /incapacity ;
●Results in or prolongs an existing inpatient hospitalization;
●Is a congenital anomal y/birth defect;
●Is an other important medical event.
Note:In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor in the same timeframe 
as SAEs to meet certain local requirements. 
●Is a cancer;
●Is associated with an overdose .
Refer to Table 10for additional details regarding each of the above criteria.
For the time period beginning when the subject provides documented informed consent until 
treatment allocation/ randomization, any  serious adverse event, or follow- up to a serious 
adverse event, including death due to an y cause, that occurs to an y subject must be reported 
within 24 hours to the Sponsor if it cause s the subject to be excluded from the trial, or is the 
result of a protocol- specified intervention, including but not limited to washout or 
discontinuation of usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/randomization through the last trial 
evaluation (Last Follow -up visit, 28 to 35days after final dose) , any serious adverse event, or 
follow-up to a serious adverse event, including death due to an y cause, whether or not related 
to the Sponsor's product, must be reported within 24 hours to the Sponsor either by electronic 
media or paper. For the time period from the signing of informed consent through treatment 
allocation/randomization, only  serious adverse events that either cause the p articipant to be 
excluded from the trial or are the result of a protocol -specified intervention, must be reported 
within 24 hours to the Sponsor either b y electronic media or paper. Electronic reporting 
procedures can be found in the EDC data entry  guidelines. Paper reporting procedures can be  
   05L60Q
Product:   MK-7625A 70
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialfound in the Investigator Trial File Binder (or equivalent). All SAEswill be followed until 
resolution, stabilization, withdrawal of consent, or death.
Additionally , any serious adverse event, considered by an invest igator who is a qualified 
physician to be related to the Sponsor's product that is brought to the attention of the 
investigator at an y time outside of the time period specified in the previous paragraph also 
must be reported immediately  to the Sponsor.
All subjects with SAEs must be followed up for outcome.
Events of Clinical Interest
Selected non -serious and serious adverse events are also known as Eve nts of Clinical I nterest 
(ECI) and must be reported to the Sponsor.
For the time period beginning when th e subject provides documented informed c onsentuntil 
treatment allocation/ randomization, any  ECI, or follow up to an ECI , that occurs to an y 
subject must be reported within 24 hours to the Sponsor if it causes the subject to be 
excluded from the trial, or is the result of a protocol- specified intervention, including but not 
limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure.
For the time period begi nning at treatment allocation/randomization through the last trial 
evaluation (Last Follow -up visit, 28to 35days after final dose) , any ECI, or follow up to an 
ECI, whether or not related to the Sponsor’s product, must be reported within 24 hours to the 
Sponsor, either b y electronic media or paper.  Electroni c reporting procedures can be found 
in the EDC data entry  guidelines.  Paper reporting procedures can be found in the 
Investigator Trial File Binder (or equivalent).
Events of clinical interest for this trial include:
1. An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the upper lim it of normal, as determined by  way of protocol- specified laboratory  
testing or un scheduled laboratory  testing.*
*Note:  These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that may  require 
an additional evaluation for an underl ying etiology. The trial site guidance for assessment 
and follow up of these criteria can be found in the Investigator Trial File Binder (or 
equivalent).
2.An overdose of Sponsor's prod uct, as defined in Section 7.2.1 - Definition of an Overdose 
for This Protocol and Reporting of Overdose to the Sponsor, that is not associated with 
clinical symptoms or abnormal laboratory  results.
Evaluating Adverse Events
An investigator who is a qualified physician will evaluate all adverse events with respect to 
the elements outlined in Table 10.The investigator’s assessment of causality is required for 
each adverse event.  Refer to Table 10 for instructions in evaluating adverse events. 
   05L60Q
Product:   MK-7625A 71
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTable 10 Evaluating Adverse Events
Maximum Mild awareness of sign or symptom, but easily tolerated  (for pediatric trials, awareness of symptom, but easily tolerated)
Intensity Moderate discomfort enough to cause interference with usual activity (for pediatric trials, definitely acting like something is wrong)
Severe incapacitating with inability to work or do usual activity (for pediatric trials, extremely distressed or unable to do usual activities)
Seriousness A serious adverse event (AE) is any adverse event occurring at any dose or during any use of Sponsor's product that:
†Results in death ; or
†Is life threatening; or places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred [Note: This doe s not include an 
adverse event  that, had it occurred in a more severe form, might have caused death.]; or
†Results in a persistent or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay, even if the 
hospitalization is a precautionary measu re for continued observation.  (Note: Hospitalization for an elective procedure to treat a pre -existingcondition that has not 
worsened is not a serious adverse event.  A pre -existing condition is a clinical condition that is diagnosed prior to the use of a Merck product and is documented in the 
patient’s medical history. ); or
†Is a congenital anomaly/bir th defect  ( in offspring of subject taking the product regardless of time to diagnosis); or
Is a cancer (although not serious per IC Hdefinition, is reportable to the Sponsor within 24 hours to meet certain local requirements) ;or
Overdose, although not serious per ICH definition, whether accidental or intentional, with or without an accompanying adverse event/serious adverse event, i s 
reportable to the Sponsor within 24 hours to meet certain local requirements.
Other important medical events that may not result in death, not be life threatening, or not require hospitalization may be considered a serious adverse eve nt when, 
based upo n appropriate medical judgment, the event may jeopardize the subject and may require medical or surgical intervention to prev ent one of the outcomes listed 
previously (designated above by a †).
Duration Record the start and stop dates of the adverse event.  If less than 1 day, indicate the appropriate length of time and units
Action taken Did the adverse event cause the Sponsor's product to be discontinued?
Relationship to 
Sponsor's 
ProductDid the Sponsor's pr oduct cause the adverse event? The determination of the likelihood that the Sponsor's product caused the adverse event will be provided by an 
investigator who is a qualified physician.  The investigator’s signed/dated initials on the source document or worksheet that supports the caus ality noted on the AE 
form, ensures that a medically qualified assessment of causality was done.  This initialed document must be retained for the required regulatory time frame.  The 
criteria below are intended as reference guidelines to assist the invest igator in assessing the likelihood of a relationship between the test drug and the adverse event 
based upon the available information
The following components are to be used to assess the relationship between the Sponsor's product and the AE ; the greater the correlation with the components 
and their respective elements (in number and/or intensity), the more likely the Sponsor's product caused the adverse event:
Exposure Is there evidence that the subject was actually exposed to the Sponsor's product such as:  reliable history, acceptable compliance assessment (pill 
count, diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of the Sponsor's product? 
Is the time of onset of the AE compatible with a drug -induced effect (applies to trials with investigational medicinal product)?
Likely Cause Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or environmental
factors 
   05L60Q
Product:   MK-7625A 72
Protocol/Amendment No.: 034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialRelationship The following components are to be used to assess the relationship between the Sponsor's product and the AE:  (continued)
to Sponsor's 
Product
(continued) Dechallenge Was the Sponsor's product discontinued or dose/exposure/frequency reduced?
      If yes, did the AE resolve or improve?
           If yes, this is a positive dechallenge.    If no, this is a n egative dechallenge.
(Note:  This criterion is not applicable if:  (1) the AE resulted in death or permanent disability; (2) the AE resolved/impro ved despite 
continuation of the Sponsor's product; (3) the trial is a single -dose drug trial); or (4) Sponsor' s product(s) is/are only used one time.)
Rechallenge Was the subject re- exposed to the Sponsor's product in this trial?
      If yes, did the AE recur or worsen?
          If yes, this is a positive rechallenge.    If no, this is a negative rechallenge.
(Note:  This criterion is not applicable if:  (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single -dose drug trial); 
or (3) Sponsor's product(s) is/are used only one time.)
NOTE:  IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN 
CAUSED BY THE SPONSOR'S PRODUCT, OR IF RE -EXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL 
SIGNIFIC ANT RISK TO THE SUBJECT THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR
CLINICAL DIRECTOR AND THE INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE.
Consistency 
with Trial 
Treatment 
ProfileIs the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor's product or drug class
pharmacology or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by an investigat or who is a qualified physician according to his/her best clinical judgment, including 
consideration of the above elements.
Record one of the following : Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product relationship).
Yes, there is a reasonable 
possibility of Sponsor's product 
relationship.There is evidence of exposure to the Sponsor's product.  The temporal sequence of the AE onset relative to the administration of theSponsor's 
product is reasonable.  The AE is more likely explained by the Sponsor's product than by another cause. 
No, there is not a reasonable 
possibility of Sponsor's product 
relationshipSubject did not receive the Sponsor's product OR temporal seque nce of the AE onset relative to administration of the Sponsor's product is not 
reasonable OR the AE is more likely explained by another cause than the Sponsor’s product.  (Also entered for a subject with overdose without 
an associated AE.) 
   05L60Q
Product:   MK-7625A 73
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Sponsor Responsibility for Reporting Adverse Events
AllAdverse Eventswill be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations , i.e., per ICH Topic E6 (R1) 
Guidelines for Good Clinical Practice .
TRIAL GOVERNANCE AND OVERSIGHT
Executive Oversight Committee
The EOC comprises members of Sponsor Senior Management. The EOC will receive and 
decide upon an y recommendations made b y the DMC regarding the trial.
Data Monitoring Committee
To supplement the routine trial monitoring outlined in this protocol, an externalDMC will 
monitor the interim data from this trial.  The voting members of the committee are external to 
the Sponsor.  The members of the DMC must not be involved with the trial in any other way 
(e.g., they cannot be trial investigators) and must have no c ompeting interests that could affect 
their roles with respect to the trial.
The DMC will make recommendations to the EOC regarding steps to ensure both subject 
safety and the continued ethical integrity of the trial. Also, the DMC will review interim trial
results, consider the overall risk and benefit to trial participants (see Section 8.7 -Interim 
Analyses) and recommend to the EOC if the trial should continue in accordance with the 
protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team; meeting 
facilitation; the trial governance structure; and requirements for and proper documentation of 
DMC reports, minutes, and recommendations willbe described in the DMC charter that is 
reviewed and approved by all the DMC members.
8.0STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the trial. Changes to 
analyses made after the protocol has been finalized, but prior to final database lock, will be 
documented in a supplemental S tatistical Analy sis Plan(sSAP)and referenced in the Clinical 
Study Report (CSR) for the trial. For any analyses in the sSAP and protocol, the sSAP will 
supersede those described in the protocol. Post hoc exploratory anal yses will be detailed in the 
CSR.
Key elements of the Statistical Analysis Plan are summarized in Section 8.1. The 
comprehensive plan is provided in Sections 8.2 through 8.12. 
   05L60Q
Product:   MK-7625A 74
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Statistical Analysis Plan Summary
Trial Design Overview A Phase 2randomized, active comparator -controlled, multicenter, 
double-blind, clinical trial to study the safety and efficacy of 
ceftolozane/tazobactam (MK -7625A) versus meropenem in pediatric 
subjects with complicated urinary tract infection s (cUTIs) , including 
pyelonephritis.
Treatment Assignment Approximately 240 pediatric subjects (combined acrossMK-7625A-
034 andMK-7625A-035)in 5 age groups will be enrolled and 
randomized in a 3:1 ratio to receive IV ceftolozane/tazobactam or IV 
meropenem, respectively. T he total duration of study treatment will be 
a minimum of 7 days to a maximum of 14 days. Randomization will be 
stratified by agegroup. See Table 7for target enrollment sand IV 
dosage regimens for each age group.
Analysis Populations Safety: All Subjects as Treated (ASaT) Population
Pharmacokinetics: PK Population
Efficacy: Microbiolog ical Modified Intent -to-Treat (mMITT), 
Microbiologically Evaluable (ME), and Clinically Evaluable (CE) 
Populations
Primary Endpoints The primary safety parameters w ill include the following safety 
evaluations:
AEs
Clinical laboratory tests
Vital signs 
Key Secondary Endpoints Clinical successat the EOT and TOC Visits
Per-subject microbiological eradication atthe EOT and TOCVisits
Statistical Methods for Key 
Efficacy/P KAnalysesA 2-sided 95% confidence interval (CI) based on the M&N method [48]
stratified by age group will be provided to evaluate the treatment 
difference s forclinical successat the EOT and TOC Visit s and per-
subject microbiological eradication at the EOT and TOC Visits.
There will be no efficacy hypothesis testing in this estimation trial.
Statistical Methods for Key 
Safety AnalysesTier 2 endpoints include AEs of elevated laboratory values; the 
percentag e of subjects with any AE, any SAE, and any treatment -
related AE, any serious and study treatment -related AE; the percentage 
of subjects who discontinue due to an AE; and AEs (specific preferred 
terms), system organ classes, or values outside of the local laboratory’s 
reference range with frequency ≥6 subjects in the experimental 
treatment arm and/or ≥2 subjects in the comparator treatment arm . The 
95% CIs will be provided for betw een-treatment differences in the 
percentage of subjects with events; these an alyses will be performed 
using the unstrati fied M&N method [48], an unconditional, asymptotic 
method.
Changes in laboratory and vital sign values from baseline will be 
summarized as Tier 3 events using descriptive statistics.
Interim Analyses No interim analyses for efficacy are planned for this trial. However, an 
external DMC will convene to review  combined safety data from the 
present trial and the companion Phase 2 trial in pediatric subjects w ith 
cIAI (MK-7625A-035). Additional details are available in the external 
DMC charter. 
   05L60Q
Product:   MK-7625A 75
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialMultiplicity There will be no adjustment for multiplicity in this estimation trial.
Sample Size and Pow er Approximately 2 40 subjects (combined acrossMK-7625A-034 and
MK-7625A-035)will be enrolled, w ith approximately 180subjects in 
the ceftolozane/tazobactam arm and approximately 6 0 subjects in the 
meropenem arm. The estimated differen cesand 95% CI sfor event rate 
under various scenarios for the combined trials are presented in
Table15.For example, ifthe overall event rate is 10%across both 
treatment arms (18out of 180and 6out of 60 subjects ,respectively) , 
the 95% CI for the between-treatment difference is -1 3.4, 8.5.
Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this trialwill be the responsibility  of the 
Sponsor’s Clinical Biostatistics department.
This trialwill be conducted as a double-blind trial under in-house blinding procedures. The 
official, final database will not be unblinded until medical/scientific review has been 
performed, protocol deviations have been identified, and data have been declared final and 
complete.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study treatment assignment. Randomization will be impl emented via an IVRS/IWRS.
The interim review of the safety data will be performed by  the externalDMC(Section 7.3.2 –
Data Monitoring Committee ). Treatment level results will be provided by the external 
unblinded statistician to the external DMC. Limited additional Sponsor personnel may be 
unblinded to the treatment level results of the safety anal yses, if required, inorder to act on the 
recommendations of the external DMC. The extent to which individual s are unblinded with 
respect to results of safety review will be documented by the unblind ed statistician .
The external DMC will serve as the primar y reviewerof the safet y results from this study with 
respect to the safety reviews and will make recommenda tions for discontinuation of or 
modifications to the study to the EOCof the Sponsor(Section 7.3.1 – Executive Oversight 
Committee ). If the external DMC recommends modifications to the design of the protocol or 
discontinuation of the study , theEOC(internal to the Sponsor) may  be unblinded to results at 
the treatment level in order to act on these recommendations. Additional logistic details will 
be provided in the external DMC charter .
Prior to final study unblinding, the unblinded statistician will not be involved in any 
discussions regarding modifications to the protocol, statistical methods, identification of 
protocol violators, or data validation efforts after the interim safety review(s).
Pharmacokinetic data will be unblinded early for the purpose of preparing a population PK 
model. A separate Modeling and Simulation Plan authored by  the department of Quantitative 
Pharmacology  and Pharmacometrics will describe the modeling work to be performed. A small 
team, who are separate from the protocol team, will be unblinded for the purpose of preparing 
the population PK model. Efficacy and safety data will not be unblinded. Interim data or results 
will not be shared with the protocol team be fore study  unblinding . 
   05L60Q
Product:   MK-7625A 76
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Hypotheses/Estimation
Objectives of the trial are stated in Section 3.0 –Objectives & Hypothes is(es). No efficacy  or 
safety hypothesis testing will be conducted in this estimation trial.
Analysis Endpoints
Safety and efficacy endpoints that will be evaluated for between-treatment differences are 
listed below, followed b y the descriptions of the derivations of selected endpoints.
Safety Endpoints
In order to evaluate the safet y and tolerability of ceftolozane/tazobactam, the following safety 
endpoints will be summarized based on the ASaT population: AEs, laboratory data, and vital 
signs.
An initial description of safet y measures is provided in Section 4.2.3. 1 –Rationale for Safety 
Endpoints and Events of Clinical Interest (ECIs) are defined in Section 7.2.3.2 –ECIs.The 
proportion of subjects who experience AEs of elevated laboratory  values that are reported as 
ECIs during the stud y treatment period will be estimated .
Adverse Events
The proportion of subjects with AEs of the following types at any time from the first dose of 
study treatment to the last trial evaluation will be investigated : (1) Any AE, (2) any  SAE, (3) 
any drug-related AE,(4) any serious and drug-related AE,and (5) any AE leading to study 
treatment discontinuation.
Laboratory Data
For the summaries of laboratory  tests, subjects must have both a baseline and post-
randomization on-treatment measurement to be included. Subjects’ laboratory  values (based 
on their most abnormal laboratory  test values, in the direction of interest, while on study 
treatment) will be classified as to whether or not they fall outside of the local laboratory ’s 
reference range and are worse in grade (ie, more abnormal in the direction of interest) than at 
baseline.
Summaries of laborator y changes from baseline to the EOIV, EOT, and TOCVisits, and from 
baseline to the LFU Visit ,as data permit, will be presented.
The number and percentage of subjects in each treatment armwith an elevated AST or ALT
level (>3 × ULN, >5 × ULN, and >10 × ULN)andbilirubin level (>1.5 × ULN and >2 × ULN) 
will be presented by trialvisit (as specified in Section 6.0 - Trial Flow Chart) for the ASaT 
population.
A listing of subjects who meet the following predetermined laboratory  criteria will also be 
provided for the ASaT population, including 1) ALT or AST >3 × ULN, alkaline phosphatase  
   05L60Q
Product:   MK-7625A 77
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential≤2 × ULN, and total bilirubin >1.5 × ULN and 2) ALT or AST >3 × ULN, alkaline phosphatase 
≤2 × ULN and total bilirubin >2 × ULN .
Vital Signs
Vital sign parameters will includeheart rate (beats per minute),respiratory rate (breaths per 
minute),systolic and diastolic blood pressure (BP) in mm mercury (Hg), and temperature in 
degrees Celsius ( °C)by treatment group and trial day /visit.
Other safety parameters include phy sical examinations and standard laboratory  safety tests at 
time points specified in Section 6.0 –Trial Flow Chart.
Efficacy Endpoints
There are no primary efficacy endpoints for this study; the primary endpoints are safety 
parameters (Section 8.4.1 –Safety Endpoints).
Secondary Efficacy Endpoints
The secondary efficacy endpoints are as follows :
Clinical success rate at the EOT and TOC Visits, defined as the proportion of subjects 
in the anal ysis population who have a clinical response of cure .
Per-subject microbiological eradication rate at the EOT and TOC Visits, defined as 
the proportion of subjects in the analy sis population who have an overall outcome of 
microbiological eradication.
NOTE: For subjects who receive IV study treatment only (withoutoptional oral step-down 
therapy), a separate assessment does not need to be performed at the EOT Visit; the EOIV 
Visitwill serve as the EOT Visit.
Clinical outcome categories are defined in Table3and microbiological outcomecategories are 
defined in Table 4in Section 4.2.3.2 –Rationale for Efficacy  Endpoints.
Exploratory Efficacy Endpoints
The exploratory  efficacy endpoints are as follows :
Clinical success rate at the EOIV Visit , defined as the proportion of subjects in the 
analysispopulation who have a clinical resp onse of cure or partial improvement.
NOTE: At EOIV, clinical success is defi ned as cure or partial improvement. At EOT 
and TOC, clinical success is defined as cure. The definition for clinical success at the 
EOIV Visitincludes partial improvement to accommodate those subjects with partial 
improvement who are switched to oral step- down therap y at this time point. 
Per-subject microbiological eradication rate at the EOIV Visit. 
   05L60Q
Product:   MK-7625A 78
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialPer-pathogen microbiological eradication rate at the EOIV, EOT, and TOC Visits, 
defined as the proportion of pathogens in the analysis population that have an 
outcome of microbiological eradication.
Composite success (clinical success and per-subject microbiological eradication) rate 
at the EOIV, EOT, and TOC Visits.
NOTE: For subjects who receive IV study treatment only (without optional oral step-down 
therapy), a separate assessment does not need to be performed at the EOT Visit; the EOIV
Visitwill serve as the EOT Visit.
Clinical outcome categories are defined inTable3, microbiological outcome categories are 
defined in Table4, and composite clinical and microbiological outcomecategories are defined 
in Table5in Section 4.2.3.2 –Rationale for Efficacy  Endpoints.
The percentage of subjects with superinfection or new infection will also be estimated.
Emergent infection categories are defined in Table6in Section 4.2.3.2–Rationale for Efficacy 
Endpoints.
Pharmacokinetic Endpoints
Plasma concentration for ceftolozane ,tazobactam , and tazobactam M1will be determined. The 
data will be used to update the existing ceftolozane and tazobactam pediatric population PK 
models, which will be used to perform simulations to evaluate target attainment at suitable 
doses.
The PK target that best correlates with efficacy is % fT>MIC and % fT>Ct for ceftolozane and 
tazobactam, respectivel y. Therefore, in addition to plasma exposure (AUC0-8and Cmax), % 
fT>MIC and % fT>Ctwill be derived for ceftolozane and tazobactam, respectively .
Plasma concentrations for tazobactam M1 will be reported separatel y.
Analysis Populations
Safety Analysis Populations
The ASaT population will be used for the analysis of safety data in this trial. The ASaT 
population will consist of all randomized subjects who receive any amount of study treatment. 
Subjects will be included in the treatment armcorresponding to the IV study treatment they 
actually received, irrespective of the treatment to which they  were randomized . If any subject 
receives study  treatment from both treatment arms, he or she will be assigned to the treatment 
arm from which mo re study treatment was received .
Efficacy Analysis Populations
The efficacy analysis populations are defined in Table11.Additional details about evaluabilit y 
criteria for each efficacy analysis population will be provided in anevaluability  guideline 
document. 
   05L60Q
Product:   MK-7625A 79
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTable11Efficacy Analysis Populations
PopulationaDefinitiona
Microbiological Modified 
Intent-to-Treat(mMITT)The mMITT population w ill be the subset of randomized subjects who receive 
any amount of study treatment and have at least 1 acceptable causative 
uropathogen identified from a study -qualifying baseline urine culture. Subjects 
will be categorized based on the IV study treatment they were randomized to, 
irrespective of what they actually received.
Clinically Evaluable (CE) The CE population w ill be the subset of subjects in the mMITT population 
who adhere to trial procedures. An interpretable urine culture is not required at 
thevisitof interest . All subjects must have an evaluable clinical outcome at the 
visit of interest; subjects with an indeterminate clinical outcome are excluded 
from the CE pop ulation.
Microbiologically 
Evaluable (ME)The ME population will be the subset of subjects in the CE population who 
have an interpretable urine culture at the visit of interest.
aAdditional details about evaluability criteria for each efficacy analysis population will be provided in an 
evaluability guideline document.
Details on the approach to handling missing data for safety analyses are provided in Section 
8.6 -Statistical Methods.
Statistical Methods
Statistical Methods for Safety Analyses
Safety and tolerability  will be assessed by  clinical review of all relevant parameters including 
AEs, laboratory  tests, and vital signs measurements.
The analysis of safety results for this trial will follow a tiered approach (Table12). The tiers 
differ with respect to the analyses that will be performed. Based upon review of adult and 
pediatric trial safety data, no Tier 1AEs of interest have been identified for this trial. Therefore, 
all safety parameters will be considered Tier 2 or Tier 3. Tier 2 parameters will be assessed via 
point estimates with 95% CIs provided for between-group comparisons; only point estimates 
by treatment armare provided for Tier 3 safet y parameters.
Tier 2 endpoints for this trialinclude the percentage of subjects with AEsof elevated laboratory 
values, any AE, any treatment- related AE, an y SAE, any AE that is both tre atment-related and 
serious, and subjects who discontinued due to an AE. The 95% CIs will be provided for 
between-treatment differences in the percentage of subjects with events; these analyses will be 
performed using the unstratified M&N method [48], an unconditional, asymptotic method.
Adverse events (specific preferred terms), sy stem organ classes, or values outside of the local 
laboratory ’s reference range with at least 6 events in the experimental treatment arm and/or 
2 events in the comparator treatment arm will be classified as belonging to Tier 2. Adverse 
events (specific preferred terms), system organ classes, or values outside of the local 
laboratory ’s reference range with frequencies less than these criteria in both treatment arms 
combined will be classified as belonging to Tier 3. 
   05L60Q
Product:   MK-7625A 80
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialThese thresholds werechosen because the 95% CI for the between-group difference in 
percentage will include zero when these thresholds are not met and thus would add little to the 
interpretation of pote ntially meaningful differences.
Because many 95% CIs may be provided without adjustment for multiplicity , the CIs should 
be regarded as a helpful descriptive measure to be used in review, not a formal method for 
assessing the statistical significance of between -group differences in AEs.
Continuous measures such as changes from baseline in laboratory  parameter and vital sign 
values will be considered Tier 3 safety parameters. Summary  statistics for baseline, on-
treatment, and change from baseline values will be provided b y treatment arm in table format. 
In addition, summary statistics for bothtreatment swill be provided. Safety summaries by 
treatment methods (IV study treatment or oral step -down therap y) and age groups will also be 
generated.
Missing safet y parameters will be handled using the dataasobserved (DAO) approach, that is, 
any subject with a missing value will be excluded fromthe analysis. Change from baseline 
summaries require a baseline value. If a baseline value is missing, the latest pretreatment value 
will be used instead. If no pretreatment result is available, that subject will not be included in 
the summary. The safetysummarization of results will be presented by treatment armunless 
otherwise specified. Additional subgroup safety analysis summaries for the dosed subjects may 
be requested as needed. 
   05L60Q
Product:   MK-7625A 81
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTable12Analysis Strategy for Safety  Parameters
Safety Tier Safety Endpoint95% CI for 
Treatment 
ComparisonDescriptive 
Statistics
Tier 2 AEs of elevated laboratory values X X
Any AE X X
Any SAE X X
Any treatment -related AE X X
Any serious and treatment -related AE X X
Discontinuation from trial treatment due to AE X X
AEs (specific preferred terms), system organ classes, 
or values outside of the local laboratory’s reference 
range with frequency ≥6 subjects in the experimental 
treatment arm and/or ≥2 subjects in the co mparator 
treatment armX X
Tier 3 AEs (specific preferred terms), system organ classes, 
or values outside of the local laboratory’s reference 
range with frequency <6 subjects in the experimental 
treatment arm and frequency <2 subjects in the 
comparator treatment armX
Change from baseline in laboratory parameter and 
vital sign valuesX
AE =adverse event; CI = confidence interval; SAE = serious adverse event
Statistical Methods for Efficacy Analyses
For clinical and microbiological responses, missing data will be primarily handled with a 
treatment failure approach for the mMITT population and a DAOapproach for the ME andCE 
population s (Table13),with the following definitions:
For the analysis of clinical response ,microbiological response, andcomposite clinical 
and microbiological response in the mMI TT population, the subjects wi th a missing 
clinical response or microbiological response (eg, inde terminate) will be considered
treatment failures.
For the anal yses in the ME or CE population, the subjects with a missing clinical 
response or microbiological response (eg, indeterminate) will be excluded from the 
population.
A missing per -pathogen microbiological outcome at the TOC Visitwill be considered 
anindeterminate outcome unless the per -pathogen microbiological outcome at the 
EOIVor EOTVisitis persistence. A per -pathogen microbiological outcome of 
persistence at the EOIV or EOTVisitwill be carried forward to the TOC Visit. 
   05L60Q
Product:   MK-7625A 82
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialA missing clinical outc ome at the TOC Visitwill be considered an indeterminate 
outcome unless the clinical outcome at the EOIVor EOTVisitis failure. A clinical 
response of fa ilure at the EOIVor EOTVisitwill be carried forward to the TOC 
Visit.
The M&Nstatistical method[48]with data stratified by age group will be used to make 
between-group comparisons for binary outcomes (Table14)
, but no tests of hypotheses are 
planned in this estimation trial.
Table13Analysis Strategy  for Efficacy  Variables
Endpoint/Variablea
(Description, Timepoint)Primary (P) or 
Supportive (S) 
ApproachAnalysis 
Population Missing Data Approach
Secondary Endpoint s
Clinicalsuccessrate at the EOT and 
TOC VisitsP mMITT Treatment Failure
S CE Data As Observed
Per-subject microbiological eradication
rate at the EOT and TOC VisitsP mMITT Treatment Failure
S ME Data As Observed
Exploratory Endpoint s
Clinical successrate at the EOIV Visit P mMITT Treatment Failure
S CE Data As Observed
Per-subject microbiological eradication
rate at the EOIV VisitP mMITT Treatment Failure
S ME Data As Observed
Per-pathogen microbiological 
eradication rate at the EOIV, EOT, and 
TOC VisitsP mMITT Treatment Failure
S ME Data As Observed
Compositeresponse (clinical success
and per-subject microbiological
eradication ) rate at the EOIV, EOT, 
and TOC VisitsP mMITT Treatment Failure
S ME Data As Observed
CE = clinically evaluable; EOIV = End of IV Treatment; EOT = End of Treatment; LFU = Last Follow -up; 
ME =Microbiologically Evaluable; mMITT = microbiological Modified Intent -to-Treat; TOC = Test of 
Cure
aThe Miettinen and Nurimen statistical method [48]will be used for all analyses and will include 
stratification by age group.
NOTE: For subjects who receive IV study treatment only (without optional oral step -down therapy), a 
separate assessment does not need to be performed at the EOT Visit; the EOIV Visitwill serve as the EOT 
Visit. 
   05L60Q
Product:   MK-7625A 83
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTable14 Estimated Two-sided 95% Confidence Interval s Based on Different Assumed 
Observed Rates of Efficacy  Endpoints
Same Observed Clinical 
Success or Per- subject 
Microbiological Response 
RateAcross Both ArmsCeftolozane/tazobactam
(n=90)Meropenem
(n=30) Estimate (95% CI)
70% 63 (70.0%) 21 (70.0%) 0.00 (-17.20, 20.08)
80% 72 (80.0%) 24 (80.0%) 0.00 (-14.50, 18.88)
90% 81 (90.0%) 27 (90.0%) 0.00 (-10.60, 16.46)
CI = confidence interval
Summaries of Baseline Characteristics, Demographics, and Other Analyses
Analyses of Baseline Characteristics and Demographics
No statistical hy pothesis tests will be performed on demographic and baseline characteristics. 
The number and percentage of subjects screened, randomize d/allocated, the primary reasons 
for screening failure, and the primary reasonsfor discontinuation will be displayed. 
Demographic variables (as follows), baseline characteristics, primary diagnosis, prior and 
concomitant therapies, and medical history  will be summarized by  treatment usingdescriptive 
statistics for continuous or categorical variables, as appropriate . Summaries of baseline 
pathogens and signs and sy mptoms will also be provided.
Demographic variables include but are not limited to the following: Age, sex, race, body 
weight, body mass index (BMI) , and geographic region of enrollment .
Baseline characteristics include but are not limited to the following:
CrCL group (<50 mL/min, ≥50 to <80 mL /min, ≥80 mL /min)
Baseline diagnosis (py elonephritis or c LUTI)
Baseline clinical signs and sy mptoms for cUTI
Complicating factor(s) for c LUTI
Indwelling catheter (y es, no)
Numberof uropathogens present at baseline (1, 2, or ≥3)
Uropathogens group (gram -negative, gram -positive, Others)
Pretreatment with s ystemic gram -negative antibacterial agents (y es, no)
Presence of bacteremia at baseline (y es, no)
ESBL status of Enterobacteriac eae (ESBL, non -ESBL)
AmpC overexpression status
In addition, for randomized subjects, baseline characteristics will be presented by age category 
and treatment arm. 
   05L60Q
Product:   MK-7625A 84
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Population Pharmacokinetic Analyses
Based on PK data obtained within this study, a separate population PK analysis will be 
performed for ceftolozane and tazobactam . The prospective details of this analysis will be 
specified in a separate population PK analysis planand the results will be included in a separate 
report.
Interim Analyses
No interim analyses for efficacy are planned for this trial.However, an external DMCwill 
convene to review combined safet y datafrom the present tr ialand thecompanion Phase 2 trial 
in pediatric subjects with cIAI(MK-7625A-035). Additional details are available in the 
external DMC charter.
Multiplicity
There will be no multiplicity  adjustments in the analy ses of this estimation trial.
Sample Size and Power Calculations
This is an estimation trial; no formalstatistical testing will be performed for the efficacy or 
safety endpoints. In this trial, approximately  240 subjects (combined acrossMK-7625A-034 
and MK-7625A-035) will be enrolled with an expected 180 subjects in the 
ceftolozane/tazobactam treatment armand an expected 60 subjects in the meropenem treatment 
arm.With a sample size of 180 ceftolozane/tazobactam -treated subjectsin both this trial and 
the tandem cIAI trial (MK-7625A-035) (Section 4.2.1.1 –Rationale for Sample Size), AEs 
with an underlying true incidence of at least 2% in thetreatment arm areanticipated to occur 
with a probability  of at least 97%.
The primary  objective of this trialisassessment of the accumulated safet y data. Trial-specific 
safety assessments are described in Section 8.6.1–Statistical Methods for Safety Analyses. 
However, safet y data will be combined acrossMK-7625A-034 and MK- 7625A-035. Table15
shows estimated treatment differences and associated 2-sided 95% CIs for events under 
varying assumptions of the observed number of subjects having a certain eventcombined 
across trials . These calculations are based on t he unstratified M&Nmethod [48]. 
   05L60Q
Product:   MK-7625A 85
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialTable15 Estimated Treatment Differences and Two -sided 95% Confidence Intervals
Same Expected Event Rate 
Across Both Treatm ent 
GroupsCeftolozane/tazobactam
(n=180)Meropenem
(n=60) Estimate (95% CI)
2% 4 (2.2%) 2 (3.3%) -1.1 (-9.30, 3.05)
4% 8 (4.4%) 4 (6.7%) -2.2 (-1.18, 3.57)
10% 18 (10.0%) 6 (10.0%) 0.0 (-10.80, 7.64)
15% 28 (15.6%) 10 (16.7%) -1.1 (-13.42, 8.53)
CI =confidence interval
NOTE: Given the same expected event rate across both treatment groups, treatment difference estimates are 
not always zero given the discrete nature of events. The number of events within each treatment group is 
selected based on the mi nimum number of events required to match or exceed the expected event rate across 
both groups.
Subgroup Analyses
To assess the consistency of clinical and microbiological responseat the EOT and TOC Visits, 
the response rates with 95% CIs will be estimated for each treatment arm within each categor y 
listed below.
Age category  (birth to <3 months, 3 months to <2 y ears, 2 years to <6 y ears, 6 years 
to <12 years, 12 y ears to <18 y ears)
Sex (male, female)
Region of enrollment
Baseline diagnosis (cLUTI  or pyelonephritis)
Age category  by baseline diagnosis
Duration of IV stud y treatment
Presence of bacteremia at baseline (y es, no)
Urine sample collected via urinary  catheter (y es, no)
Subjects with meropenem -and ceftolozane/tazobactam -resistant baseline 
uropathogens and subjects with meropenem -and ceftolozane/tazobactam- susceptible 
baseline uropathogens
ESBL status of Enterobacteriaceae (ESBL, non- ESBL)
AmpC overexpression status
Additional subgroup analy sis summaries for randomized subje cts with regard to other factors 
may be considered as needed.
Compliance (Medication Adherence)
Each subject will be scheduled to receive IV study treatment every 8 hours ( 3 times dail y)for 
at least 9 doses . After that, subjects may be switched to open -label, standard- of-care oral step -
down antibiotic therap y at the investigator’s discretion.  Oral step -down therap y is considered 
study treatment.  The total duration of stud y treatment (IV onl y or IV + oral) is a minimum of 
7 days and a maximum of 14 day s.  
   05L60Q
Product:   MK-7625A 86
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialIn this study,the dosing of IV study treatment will be documented in the study intervention 
CRF pageby recording the date, time, and whether or not each dose of IV study treatment was 
completely  infused. The amount of oral step-down therapy taken by each subject will be 
recorded in the concomitant medication CRF page.  Th isinformation will be used to calculate 
the IV study treatment and overall study treatment compliance rates.  Details of the compliance 
calculations will be provided in the sSAP and/ or CSR. 
Extent of Exposure
The extent of exposure during IV study treatment and the total study treatment exposure will 
be summarized as both continuous and categorical variables alongside counts and percentages 
for the “Number of Days on Therapy” by treatment armin the ASaT population. The summary 
of exposure by  treatment armsand age group will also be provided.
9.0LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES
Investigational Product
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution and usage of 
investigational product in accordance with the protocol and any applicable laws and 
regulations. 
   05L60Q
Product:   MK-7625A 87
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialClinical Supplies will be pr ovided by the Sponsor as summarized in Table16.
Table16Product Descriptions
Treatment 
GroupProduct Name 
and Dosage 
FormDose Potency Total 
Dosage 
FormsAdditional 
Information
1 Ceftolozane/
tazobactam -IVCohort 
dose1 g/0.5 g 1.5 g/vialCommercial 
Zerbaxa product –
clinically labeled
2 Meropenem -IVCohort 
dose1.0g 1 .0g/vialCommercial 
meropenem 
product –
clinically labeled
Product Name & 
Potency Dosage Form Source/Additional Information
Ceftolozane 1 g/
tazobactam 0.5 g1 g/0.5 g l yophilized vial Provided centrall y by the Sponsor 
Meropenem 1 g 1 g lyophilized vial Provided centrall y by the Sponsor
All supplies indicated inTable16will be provided per the “Source/Additional Information” 
columndepending on local country  operational requirements .
Any commerciall y available product not included inTable16will be provided by the trial site, 
subsidiary  or designee.Every attempt should be made to source these supplies from a single 
lot/batch number. The trial site is responsible for r ecording the lot number, manufacturer, and 
expiry date for any locally purchased product as per local guidelines unless otherwise 
instructed by  the Sponsor.
Packaging and Labeling Information
Clinical supplies will be affixed with a clinical label in accordance with regulatory 
requirements.
The clinical supplies will be open-labeled and each vial/dosage formwill contain a component 
identification (CID) number for managem ent of the supplies through an IVRS/IWRS. Subjects 
will receive the IV stud y treatment following preparation by an unblinded pharmacist (Section 
5.2.6 – Trial Blinding) , for a maximum of 14 days. The subject's parent (or guardian) will 
remain blinded to the I V study treatment that the subjectreceives. Importantly, the unblinded 
pharmacist will be uninvolved in an y of the postinfusion evaluations for the subject . All study 
personnel involved with the postinfusion evaluations of safety and efficacy outcomes, 
including the study coordinator(s), investigator, or subinvestigator(s), must have no access to 
the treatment group assignment or the preparation of the study infusion. 
   05L60Q
Product:   MK-7625A 88
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Clinical Supplies Disclosure
The emergency  unblinding call center will use the treatment/ randomization schedule for the 
trial to unblind subjects and to unmask IV studytreatment identity.In the event that the 
emergency  unblinding call center is not available for a given site in this trial, the central 
electronic treatment allocation/randomization system (IVRS/IWRS) should be used in order to 
unblind subjects and to unmask treatment/vaccine identity. The Sponsor willnotprovide 
random code/disclosure envelopes or lists with the clinical supplies.
See Section 7.1.4.4, Subject Blinding/Unblinding, for a description of the method of 
unblinding a subject during the trial, should such action be warranted.
Storage and Handling Requirements
Clinical supplies must be stored in a secure, limited-access location under the storage 
conditions specified on the label.  
Receipt and dispensing of trial medication must be recorded by an authorized person at the 
trial site.
Clinical supplies may  not beused for an y purpose other than that stated in the protocol.
Discard/Destruction/ Returns and Reconciliation
The investigator is responsible for keeping accurate records of the clinical supplies received 
from the Sponsor or designee, the amount dispensed to and returned by the subjects and the 
amount remaining at the conclusion of the trial. For all trial sites, the local country Sponsor 
personnel or designee will provide appropriate documentation that must be completed for drug 
accountability  and return, or local discard and destruction if appropriate.  Where local discard 
and destruction is appropriate, the investigator is responsible for ensuring that a local 
discard/destruction procedure is documented.
Standard Policies
Trial site personnel will have acc ess to a central electronic treatment allocation/ randomization 
system (IVRS/I WRS system) to allocate subjects, to assign study treatmentto subjects and to 
manage the distribution of clinical supplies. Each person accessing the IVRS system must be 
assigned an individual unique PIN.  They must use only their assigned PIN to access the 
system, and they  must not share their assigned PIN with anyone.
10.0ADMINISTRATIVE AND R EGULATORY DETAILS
Confidentiality
Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will be 
divulged to the institutional review board, ethics review committee (IRB/ERC) or similar or  
   05L60Q
Product:   MK-7625A 89
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialexpert committee; affiliated institution and employees, only under an appropriate 
understanding of confidentiality  with such board or committee , affiliated institution and 
employees.  Data generated by this trial will be considered confidential by the investigator, 
except to the extent that it is included in a publication as provided in the Publications section 
of this protocol.
Confidentiality of Subject Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/ERC, or regulatory  authority representatives may consult and/or copy  trial documents in 
order to verify  worksheet/case report form data.  By  providing documented informed consent, 
the subject agrees to this process.  If trial documents will be photocopied during the process of 
verifying worksheet/case report form information, the subject will be identified by unique code 
only; full names/ini tials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all subject data used and disclosed in 
connection with this trial in accordance with all applicable privacy laws, rules and regulations.
Confidentiality of Investigator Information
By signing this protocol, the investigator recognizes that certain personal identifying 
information with respect to the investigator, and all subinvestigators and trial site personnel, 
may be used and disclosed fo r trial management purposes, as part of a regulatory submissions, 
and as required b y law.  This information may include:
1.name, address, telephone number and e -mail address;
2.hospital or clinic address and telephone number;
3.curriculum vitae or other summary of qualifications and credentials; and
4.other professional documentation.
Consistent with the purposes described above, this information may be transmitted to the 
Sponsor, and subsidiaries, affiliates and agents of the Sponsor, in your country and other 
countries, including countries that do not have laws protecting such information.  Additionally , 
the investigator’s name and business contact information may be included when reporting 
certain serious adverse events to regulatory  authorities or toother investigators.  By signing 
this protocol, the investigator expressly  consents to these uses and disclosures.
If this is a multicenter trial, in order to facilitate contact between investigators, the Sponsor 
may share an investigator’s name and contact information with other participating investigators 
upon request.
Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this trial.  The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements by requesting and maintaining records of the names and 
qualifications of the IRB/IEC members and to make these records available for regulatory  
agency review upon request by  those agencies. 
   05L60Q
Product:   MK-7625A 90
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Compliance with Financial Disclosure Requirements
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54).  It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required.  It is the investigator's/subinvestigator's 
responsibility  to comply  with any such request.  
The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements.  The 
investigator/subinvestigator( s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by 
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsorin the United States for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Compliance with Law, Audit and Debarment
By signing this protocol, the investigator agrees to conduct the trial in an efficient and diligent 
manner and in conformance with this protocol; generall y accepted standards of Good Clinical 
Practice (e.g., International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use Good Clinical Practice: Consolidated 
Guideline and other generally accepted standards of good clinical practice); and all applicable 
federal, state and local laws, rules and regulations relating to the conduct of the clinical trial.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by  Merck, is provided in Section12.1-
Merck Code of Conduct for Clinical Trials.
The investigator also agrees to allow monitoring, audits, IRB/IECreview and regulatory  
authority inspection of trial -related documents and procedures and provide for direct access to 
all trial-related source data and documents.
The investigator agrees not to seek reimbursement from subjects, their insurance providers or 
from government programs for procedures included as part of the trial reimbursed to the 
investigator b y the Sponsor.
The investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with Good Clinical Practice standards and applicable federal, state and local laws, 
rules and regulations; and, for each subject participating in the trial, provide all data, and, upon 
completion or termination of the clinical trial, submit any other reports to the Sponsor as 
required by this protocol or as otherwise required pursuant to any agreement with the Sponsor.
Trial documentation will be promptly and fully disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the trialsite upon request for inspection, 
copying, review and audit at reasonable times by representatives of the Sponsor or any  
   05L60Q
Product:   MK-7625A 91
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialregulatory  authorities.  The investigator agrees to promptly take any reasonable steps that are 
requested b y the Sponsor as a result o f an audit to cure deficiencies in the trial documentation 
and worksheets/case report forms.
The investigator must maintain copies of all documentation and records relating to the conduct 
of the trial in compliance with all applicable legal and regulatory  requirements.  This 
documentation includes, but is not limited to, the protocol, worksheets/case report forms, 
advertising for subject participation, adverse event reports, subject source data, correspondence 
with regulatory  authorities and IRBs/ERCs, consent forms, investigator’s curricula vitae, 
monitor visit logs, laboratory  reference ranges, laboratory  certification or quality control 
procedures and laboratory director curriculum vitae.  By signing this protocol, the investigator 
agrees that documentati on shall be retained until at least 2 years after the last approval of a 
marketing application in an ICH region or until there are no pending or contemplated 
marketing applications in an I CH region or until at least 2 y ears have elapsed since the formal 
discontinuation of clinical development of the investigational product.  Because the clinical 
development and marketing application process is variable, it is anticipated that the retention 
period can be up to 15 years or longer after protocol database lock.The Sponsor will determine 
the minimum retention period and notify  the investigator when documents may  be destroy ed.  
The Sponsor will determine the minimum retention period and upon request, will provide 
guidance to the investigator when documents no lon ger need to be retained.  The Sponsor also 
recognizes that documents may need to be retained for a longer period if required by local 
regulatory  requirements. All trial documents shall be made available if required by relevant 
regulatory  authorities. The investigator must consult with and obtain written approval by the 
Sponsor prior to destroying trial and/or subject files.  
ICH Good Clinical Practice guidelines recommend that the investigator inform the subject’s 
primary physician about the subject’s participation in the trial if the subject has a primary 
physician and if the subject agrees to the primary  physician being informed.
The investigator will promptly inform the Sponsor of any regulatory  authority inspection 
conducted for this trial.
Persons debarred from conducting or working on clinical trials by any court or regulatory 
authority will not be allowed to conduct or work on this Sponsor’s trials.  The investigator will 
immediately  disclose in writing to the Sponsor if any person who is involved in conducting the 
trial is debarred or if any proceeding for debarment is pending or, to the best of the 
investigator’s knowledge, threatened.
In the event the Sponsor prematurel y terminates a particular trial site, the Sponsor will 
promptly notify that trial site’s IRB/IEC.
According to European legislation, a Sponsor must designate an overall coordinating 
investigator for a multi -center trial (including multinational).  When more than one trial site is 
open in an EU country, Merck, as the Sponsor, will designate, per country, a national principal 
coordinator (Protocol CI), responsible for coordinating the work of the principal investigators 
at the different trial sites in that Member State, according to national regulations.  For a single -
center trial, the Protocol CI is the principal investigator.  In addition, the Sponsor must  
   05L60Q
Product:   MK-7625A 92
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidentialdesignate a principal or coordinating investigator to review the trial report that summarizes the 
trial results and confirm that, to the best of his/her knowledge, the report accuratel y describes 
the conduct and results of the trial [Clinical Study Report (CSR) CI].  The Sponsor may 
consider one or more factors in the selection of the individual to serve as the Protocol CI and 
or CSR CI (e.g., availability  of the Protocol/CSR CI during the anticipated review process, 
thorough understanding of clinical trial methods, appropriate enrollment of subject cohort, 
timely achievement of trial milestones).  The Protocol CI must be a participating trial 
investigator.
Compliance with Trial Registra tion and Results Posting Requirements
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency  (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the trial is solely responsible for determining whether the trial and its results are subject to 
the requirements for submission to http://www.clinicaltrials.gov, www.clinicaltrialsregister.eu 
or other local registries.  Merck, as Sponsor of this trial, will review this protocol and submit 
the information necessary  to fulfill these requirements. Merck entries are not limited to 
FDAAA or the EMA clinical trial directive mandated trials.  Information posted will allow 
subjects to identify potentially  appropriate trials for their disease conditions andpursue 
participation by calling a central contact number for further information on appropriate trial 
locations and trial site contact information.  
By signing this protocol, the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive or other locally mandated registries are that of the 
Sponsor and agrees not to submit any information about this trial or its results to those 
registries.
Quality Management System
By signing this protocol, the Sponsor agrees to be responsible for implementing and 
maintaining a quality management system with written development procedures and functional 
area standard operating procedures (SOPs) to ensure that trials are conducted and data are 
generated, documented, and reported in compliance with the protocol, accepted standards of 
Good Clinical Practice, and all applicable federal, state, and local laws, rules and regulations 
relating to the conduct of the clinical trial.
Data Management
The investigator or qualified designee is responsible for recording and verify ing the accuracy 
of subject data.  By signing this protocol, the investigator acknowledges that his/her electronic 
signature is the legally binding equivalent of a written signature.  By entering his/her electronic 
signature, the investigator confirms that all recorded data have been verified as accurate.
Detailed information regarding Data Management procedures for this protocol will be provided 
separately . 
   05L60Q
Product:   MK-7625A 93
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Publications
This trial is intended for publication, even if terminated prematurel y. Publication may  include 
any or all of the following: posting of a synopsis online, abstract and/or presentation at a 
scientific conference, or publication of a full manuscript.  The Sponsor will work with the 
authors to submit a manuscript describing trial results within 12 months after the last data 
become available, which may take up to several months after the last subject visit in some 
cases such as vaccine trials.  However, manuscript submission timelines ma y be extended on 
OTC trials.  For trials intended for pediatric-related regulatory  filings, the investigator agrees 
to delay publication of the trial results until the Sponsor notifies the investigator that all 
relevant regulatory  authority decisions on the trial drug have been made with regard to 
pediatric-related regulatory  filings. Merck will post a synopsis of trial results for approved 
products on www.clinicaltrials.gov by 12 months after the last subject's last visit for the 
primary outcome, 12 monthsafter the decision to discontinue development, or product 
marketing (dispensed, administered, delivered or promoted), whichever is later.
These timelines may be extended for products that are not yet marketed, if additional time is 
needed for analysis, toprotect intellectual property, or to comply with confidentiality 
agreements with other parties.  Authors of the primary results manuscript will be provided the 
complete results from the Clinical Study Report, subject to the confidentiality  agreement. 
Whena manuscript is submitted to a biomedical journal, the Sponsor's policy is to also include 
the protocol and statistical analysis plan to facilitate the peer and editorial review of the 
manuscript.  If the manuscript is subsequentl y accepted for publicatio n, the Sponsor will allow 
the journal, if it so desires, to post on its website the key sections of the protocol that are 
relevant to evaluating the trial, specificall y those sections describing the trial objectives and 
hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures, the 
efficacy and safety measures, the statistical analysis plan, and any amendments relating to 
those sections.  The Sponsor reserves the right to redact proprietary information.
For multicenter trials, subsequent to the multicenter publication (or after public disclosure of 
the results online at www.clinicaltrials.gov if a multicenter manuscript is not planned), an 
investigator and his/her colleagues may publish their data independentl y.  In most cases, 
publication of individual trial site data does not add value to complete multicenter results, due 
to statistical concerns.  In rare cases, publication of single trial site data prior to the main paper 
may be of value.  Limitations of single trial site observations in a multicenter trial should 
always be described in such a manuscript.
Authorship credit should be based on 1) substantial contributions to conception and design, or 
acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it 
critically for important intellectual content; and 3) final approval of the version to be published. 
Authors must meet conditions 1, 2 and 3.  Significant contributions to trial execution may also 
be taken into account to determine authorship, provided that contributions have also been made 
to all three of the preceding authorship criteria.  Although publication planning may begin 
before conducting the trial, final decisions on authorship and the order of authors’ names will 
be made based on participation and actual contributions to the trial and writing, as discussed 
above. The first author is responsible for defending the integrity of the data, method(s) of data 
analysis and the scientific content of the manuscript. 
   05L60Q
Product:   MK-7625A 94
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialThe Sponsor must have the opportunity  to review all proposed abstracts, manuscripts or 
presentations regarding this trial 45days prior to submission for publication/presentation. Any 
information identified by the Sponsor as confidential must be deleted prior to submission; this 
confidentiality  does not include efficacy and safety results. Sponsor review can be expedited 
to meet publication timelines. 
   05L60Q
Product:   MK-7625A 95
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential11.0LIST OF REFERENCES
[1]Becknell B, Schober M, Korbel L, Spencer JD. The diagnosis, evaluation and 
treatment of acute and recurrent pediatric urinary  tract infections. Expert Rev 
Anti Infect Ther. 2015 Jan;1 3(1):81-90.
[2]Grabe M, Bjerklund -Johansen TE, Botto H, Wullt B, Cek M, Naber KG, et al. 
Guidelines on urological infections. Netherlands: European Association of 
Urology; 2012. 110 p.
[3]Stamm WE, Norrby  SR. Urinary  tract infections: disease panorama and 
challenges. J I nfect Dis. 2001 Mar 1;183 Suppl 1:S1 -4.
[4]Foxman B. The epidemiology  of urinary  tract infection. Nat Rev Urol. 2010 
Dec;7(12):653 -60.
[5] Stein R, Dogan HS, Hoebeke P, Kocvara R, Nijman RJ, Radmay r C, et al. 
Urinary tract infections in children: EAU/ESPU guidelines. Eur Urol. 2015 
Mar;67(3):546-58.
[6]Ma JF, Shortliffe L M. Urinary  tract infection in children: etiology  and 
epidemiology . Urol Clin North Am. 2004 Aug;31(3):517-26.
[7]Bader MS, Hawboldt J, Brooks A. Management of complicated urinary  tract 
infections in the era of antimicrobial resistance. Postgrad Med. 2010 
Nov;122(6):7-15.
[8]Center for Drug Evaluation and Research (CDER). Guidance for industry : 
Complicated urinary  tract infections: developing drugs for t reatment [I nternet]. 
Maryland: Department of Health and Human Services Food and Drug 
Administration; 2015 Available from: 
http://www.fda.gov/downloads/Drugs/Guidances/ucm070981.pdf .
[9]Al Hasan MN, Eckel -Passow JE, Baddour LM. Bacteremia complicating gr am-
negative urinary  tract infections: a population- based study . J Infect 2010;60:278 -
85.
[10]Smellie JM, Prescod NP, Shaw PJ, Risdon RA, Bryant TN. Childhood reflux and 
urinary infection: a follow -up of 10-41 years in 226 adults. Pediatr Nephrol. 1998 
Nov; 12(9):727 -36.
[11]Benador D, Benador N, Slosman D, Mermillod B, Girardin E. Are younger 
children at highest risk of renal sequelae after p yelonephritis? Lancet. 1997 Jan 
4;349(9044):17 -9.
[12] Larcombe J. Urinary  tract infection in children: recurren t infections. BMJ Clin 
Evid. 2015 Jun 12;2015. pii: 0306. 
   05L60Q
Product:   MK-7625A 96
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential[13]Schulman SL . Voiding dy sfunction in children. Urol Clin North Am. 2004 
Aug;31(3):481 -90.
[14]Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary  
tract infections. Clin Microbiol Rev. 2005 Apr;18(2):417 -22.
[15]Foxman B. Epidemiology of urinary  tract infections: incidence, morbidity , and 
economic costs. Dis Mon 2003;49:53 -70.
[16]Jacobson SH, Eklof O, Eriksson CG, Lins LE, Tidgren B, Winberg J. 
Development of h ypertension and uraemia after p yelonephritis in childhood: 27 
year follow up. BMJ. 1989 Sep 16;299(6701):703-6.
[17]Spahiu L, Hasbahta V. Most frequent causes of urinary  tract infections in 
children. Med Arh. 2010;64(2):88 -90.
[18]Lo DS, Shie h HH, Ragazzi SL , Koch VH, Martinez MB, Gilio AE. Community -
acquired urinary  tract infection: age and gender- dependent etiology . J Bras 
Nefrol. 2013 Apr -Jun;35(2):93-8.
[19]Katsarolis I, Poulakou G, Athanasia S, Kourea- Kremastinou J, L ambri N, 
Karaiskos E, et al. Acute uncomplicated cy stitis: from surveillance data to a 
rationale for empirical treatment. Int J Antimicrob Agents. 2010 Jan;35(1):62 -7.
[20]Nicolle LE. Complicated urinary  tract infection in adults. Can J I nfect Dis Med 
Microbiol. 2005 Nov-Dec; 16(6): 349–360.
[21]Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane -
tazobactam compared with levofloxacin in the treatment of complicated urinary -
tract infections, including pyelonephritis: a randomised, double-blind, phase 3 
trial (ASPECT -cUTI). Lancet. 2015 May  16;385(9981):1949-56.
[22]Bradley JS, Ang JY, Arrieta AC, Larson KB, Rizk ML , Caro L, et al. 
Pharmacokinetics and safety  of single intravenous doses of 
ceftolozane/tazobactam in children with pr oven or suspected Gram -negative 
infection. Pediatr Infect Dis J. 2018 Nov;37(11):1130-6.
[23]E.U. Product Circular: Meropenem 500 mg, 1g powder for solution for injection 
or infusion: November 2009.
[24]Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaske l F, Warady  BA, et al. 
New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009 
Mar;20(3):629-37. 
   05L60Q
Product:   MK-7625A 97
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential[25]Craig W, Andes D. In Vivo Activities of Ceftolozane, a New Cephalosporin, with 
and without Tazobactam against Pseudomonas aeruginosa a nd 
Enterobacteriaceae, Including Strains with Extended- Spectrum  - Lactamases, in 
the Thighs of Neutropenic Mice.  Antimicrob Agents Chemother 2013, 57(4): p. 
1577–1582
[26]Xiao AJ, Caro L , Popejoy  MW, Huntington JA, Kullar R. PK/PD Target 
Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in 
Patients With Various Degrees of Renal Function, I ncluding Augmented Renal 
Clearance and End -Stage Renal Disease. Infect Dis Ther. 2016 Dec 24. doi: 
10.1007/s40121 -016-0143-9.
[27]Blumer JL. Meropen em: evaluation of a new generation carbapenem. Int J 
Antimicrob Agents. 1997 Mar;8(2):73 -92.
[28]Romanelli G, Cravarezza P. I ntramuscular meropenem in the treatment of 
bacterial infections of the urinary  and lower respiratory  tracts. Italian 
Intramuscular Meropenem Study  Group. J Antimicrob Chemother. 1995 Jul;36 
Suppl A:109-19.
[29]Cox CE, Holloway  WJ, Geckler RW. A multicenter comparative study  of 
meropenem and imipenem/cilastatin in the treatment of complicated urinary  tract 
infections in hospitalized patients. Clin I nfect Dis. 1995 Jul;21(1):86 -92.
[30]Mouton YJ, Beuscart C. Empirical monotherap y with meropenem in serious 
bacterial infections. Meropenem Study  Group. J Antimicrob Chemother. 1995 
Jul;36 Suppl A:145-56.
[31]Schuler D, Me ropenem Paediatric Study  Group. Safet y and efficacy of 
meropenem in hospitalised children: randomised comparison with cefotaxime, 
alone and combined with metronidazole or amikacin. J Antimicrob Chemother 
1995;36(Suppl A):99-108.
[32]Bradley JS, Faulkner KL, Klaugman KP. Efficacy, safet y and tolerability of 
meropenem as empiric antibiotic therapy  in hospitalized pediatric patients. 
Pediatr Infect Dis J. 1996 Aug;15(8):749-57.
[33]Hanna-Wakim RH, Ghanem ST, El Helou MW, Khafaja SA, Shaker RA, Hassan 
SA, et al. Epidemiology and characteristics of urinary  tract infections in children 
and adolescents. Front Cell I nfect Microbiol. 2015 May  26;5:45.
[34]Principi N, Marchisio P. Meropenem compared with ceftazidime in the empiric 
treatment of acute severe infec tions in hospitalized children. Italian Pediatric 
Meropenem Stud y Group. J Chemother. 1998 Apr;10(2):108 -13. 
   05L60Q
Product:   MK-7625A 98
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential[35]Ahonkhai V, Cy han GM, Wilson SE, Brown KR. Imipenem -cilastatin in pediatric 
patients: an overview of safet y and efficacy in studies conducted in the United 
States. Pediatr I nfect Dis J 1989;8:740 -4.
[36]Lee B, Kang SY, Kang HM, Yang NR, Kang HG, Ha IS, et al. Outcome of 
Antimicrobial Therap y of Pediatric Urinary  Tract Infections Caused b y  
Extended -Spectrum β -Lactamase Producing Enterobacteriaceae. Infect 
Chemother. 2013 Dec;45(4):415 -21.
[37]Karaaslan A, Kaday ifci EK, Atici S, Akkoc G, Yakut N, Ocal Demir S, et al. The 
Clinical Efficacy  and Safety  of Ertapenem for the Treatment of Complicated 
Urinary Tract Infections Caused by  ESBL-Producing Bacteria in Children. Int J 
Nephrol. 2015;2015:595840.
[38]Younis N, Quol K, Al -Momani T, Al -Awaisheh F, Al -Kayed D. Antibiotic 
resistance in children with recurrent or complicated urinary  tract infection. JNMA 
J Nepal Med Assoc. 2009 Jan -Mar;48(173):14-9.
[39]Yildiz B, Kural N, Durmaz G, Yarar C, Ak I, Akcar N. Antibiotic resistance in 
children with complicated urinary  tract infection. Saudi Med J. 2007 
Dec;28(12):1850 -4.
[40] Norrby SR, Newell PA, Faulkner KL, Lesk y W. Safety  profile of meropenem: 
international clinical experience based on the first 3125 patients treated with 
meropenem. J Antimicrob Chemother 1995;36(Suppl A):207-23.
[41]Solomkin JS, Ristagno RL, Das AF, Cone JB, Wilson SE, Rotstein OD, et al. 
Source control review in clinical trials of anti -infective agents in complicated 
intra-abdominal infections. Clin I nfect Dis. 2013 Jun;56(12):1765-73.
[42]Bradley JS, Jackson MA, Committee on I nfectious Diseases, American Academy  
of Pediatrics.The use of sy stemic and topical fl uoroquinolones. Pediatrics. 2011 
Oct;128(4):e1034 -45.
[43]Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G. Ciprofloxacin resistance 
in community -and hospital -acquired Escherichia coli urinary  tract infections: a 
systematic review and meta anal ysis of observational studies. BMC Infect Dis. 
2015 Nov 25;15:545.
[44]Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL , 
Randolph DA, et al. Safety  and effectiveness of meropenem in infants with 
suspected or complicated intra-abdominal infections. Clin I nfect Dis. 2012 
Dec;55(11):1495 -502. 
   05L60Q
Product:   MK-7625A 99
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential[45]Smith PB, Cohen- Wolkowiez M, Castro L M, Poindexter B, Bidegain M, 
Weitkamp JH, et al. Population pharmacokinetics of meropenem in plasma and 
cerebrospinal fluid of infants with su spected or complicated intra -abdominal 
infections. Pediatr Infect Dis J. 2011 Oct;30(10):844-9.
[46]Lee LS, Kinzig -Schippers M, Nafziger AN, Ma L, Sörgel F, Jones RN, Drusano 
GL, Bertino JS Jr. Comparison of 30-min and 3-h infusion regimens for 
imipenem/ cilastatin and for meropenem evaluated by  Monte Carlo simulation. 
Diagn Microbiol Infect Dis. 2010 Nov;68(3):251-8.
[47]Lancefield RC. A serological differentiation of human and other groups of 
hemolytic streptococci. J Exp Med. 1933 Mar 31;57(4):571 -95.
[48]Miettinen O, Nurminen M. Comparative anal ysis of two rates. Stat Med 
1985;4:213-26. 
   05L60Q
Product:   MK-7625A 100
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential12.0 APPENDICES
Merck Code of Conduct for Clinical Trials
Merck*
Code of Conduct for Clinical Trials
I. Introduction
A. Purpose
Merck, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the high est ethical and scientific standards. Protection of subject safety is the overriding concern in 
the design of clinical trials. In all cases, Merck clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by Merck irrespective of the 
party (parties) employed for their execution (e. g., contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator -initiated trials which are n ot under the control of Merck.
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of Merck or comparator products.  Alternatively, Merck may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
subject preferences, etc.  
The design (i.e., subject population, duration, statistical power) must be adequate to address the specific purpose 
of the trial.  Research subjects must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
Merck selects investigative sites based on medical expertise, access to appropriate subjects, adequacy of facilities 
and staff, previous performance in Merck trials, as well as budgetary considerations.  Prior to trial initiation, sites 
are evaluated by Merck personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  Merck reviews clinical data for accuracy, completeness and consistency. Data are verified versu s source 
documentation according to standard operating procedures.  Per Merck policies and procedures, if fraud, 
misconduct or serious GCP -non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be closed, the responsible regulatory authorities and ethics review committees notified and 
data disclosed accordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, Merck seeks to publish the results of trials it conducts.  Some early pha se or 
pilot trials are intended to be hypothesis -generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues 
of multiplicity .
Merck’s policy on authorship is consistent with the requirements outlined in the ICH -Good Clinical Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, 
performance or interpretation of the analysis, and/or writing of the manuscript.  All named authors must be able to 
defend the trial results and conclusions.  Merck funding of a trial will be acknowledged in publications.  
   05L60Q
Product:   MK-7625A 101
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialIII. Subject Protection
A.IRB/ERC review
All clinical trials will be reviewed and approved by an independent IRB/ERC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by the IRB/ERC prior to implementation, except that 
changes required urgently to protect subject saf ety and well -being may be enacted in anticipation of IRB/ERC 
approval. For each site, the IRB/ERC and Merck will approve the subject informed consent form. 
B.Safety
The guiding principle in decision -making in clinical trials is that subject welfare is of primary importance.  Potential 
subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial 
designs will take into account the local standard of care.  Subjects are never denied access to app ropriate medical care 
based on participation in a Merck clinical trial. 
All participation in Merck clinical trials is voluntary.  Subjects are enrolled only after providing informed consent for 
participation.  Subjects may withdraw from a Merck trial at a ny time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C.Confidentiality
Merck is committed to safeguarding subject confidentiality, to the greatest extent possible.  Unless required by law,
only the investigator, Sponsor (or representative) and/or regulatory authorities will have access to confidential medical 
records that might identify the research subject by name.  
D.Genomic Research
Genomic Research will only be conducted in accordance with informed consent and/or as specifically authorized by 
an Ethics Committee.
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time -and labor -intensive.  It is Merck’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performe d in support of Merck trials.  Merck does not pay incentives to 
enroll subjects in its trials.  However, when enrollment is particularly challenging, additional payments may be made 
to compensat e for the time spent in extra recruiting efforts.
Merck does not pay for subject referrals.  However, Merck may compensate referring physicians for time spent on 
chart review to identify potentially eligible subjects.
B.Clinical Research Funding 
Informed consent forms will disclose that the trial is sponsored by Merck, and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/ERC may wish to alter 
the wording of the disclosure s tatement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from Merck trials will indicate Merck as a source of funding.
C.Funding for Travel and Other Requests
Funding of travel by investigators and su pport staff (e.g. ,to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by the American Medical 
Association (AMA). 
V. Investigator Commit ment
Investigators wi ll be expected to review Merck’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "Merck" refers to Merck Sharp & Dohme Corp. and Schering Corpor ation, each of which is a 
subsidiary of Merck & Co., Inc.  Merck is known as MSD outside of the United States and Canada.  As warranted by 
context, Merck also includes affiliates and subsidiaries of Merck & Co., Inc." 
   05L60Q
Product:   MK-7625A 102
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
Approximate Blood Volumes Drawn/Col lected by Trial Visit
The approximate maximum blood volumes to be collected at each trial visit are summarized 
in Table17.
Table17Approximate Blood Volumes Collected by  Trial Visit
Approximate Blood Sample Volume ( mL)
Trial Period: Screening Treatment (7to 14 days) Follow-up
Visit Number: 1 3 to 16 17 18 19 20 21
Trial Visit: ScreeningIV Clinical 
AssessmentsEOIV 
(all 
subjects)Oral 
Clinical 
Assessment
(only for IV 
to oral 
switch)EOT
only for 
IV to oral 
switch)TOC
(all 
subjects)LFUa
(all 
subjects)
Safety hematology 
and chemistry , 
serum creatinine3.5 3.5b3.5 3.5 3.5 3.5 3.5c,d
Coombs test 
(direct)1.0 0 1.0 0 0 0 0
Serum pregnancy 
teste 3.0 0 0 0 0 3.0e0
Blood for culture 7.0c7.0c,f0 0 0 0 0
Blood for PK 
analyses(Day 3 
only)g0 0.75g0 0 0 0 0
Maximum 
expected total 
blood volume14.5 11.25 4.5 3 .5 3.5 6.5 3.5
EOIV = End of IV Treatment; EOT = End of Treatment; IV = intravenous; LFU = Last Follow -up; PK = 
pharmacokinetics; TOC = Test of Cure
aAt the discretion of the investigator, the LFU Visitmay be conducted by telephone, unless the subject has abnormal 
laboratory values or AEs that require follow -up.
bTo be completed on Day 3 and then once weekly while the subject is receiving IV study treatment.
cIf clinically indicated.
dTo be performed only if LFU Visitis conducted in person instead of by telephone.
eFemale subjects of child -bearing potential only. A urine pregnancy test instead of a serum pregnancy test may be 
done at the TOC Visit, if deemed clinically appropriate by the investigator.
fBlood samples for culture should be collected if signs of sepsis appear at any time during the study.
gBlood samples for ceftolozane , tazobactam , and tazobactam M1 concentration assays will be collected from all 
subjects over one 8 -hourdosing period on Day 3 of the treatment period after administration of at least 6 doses of IV 
study treatment (see Section 7.1.3. 7–Pharmacokinetic Evaluations ). 
   05L60Q
Product:   MK-7625A 103
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential
List of Abbre viations and Definitions of Terms
Abbreviation or 
Term Definition
%CV Coefficient of variation
% fT>MIC Percentage of dosing interval during which free concentration of drug 
(ceftolozane) exceeds the MI C
% fT>Ct Percentage of dosing interval during which free concentration of drug 
(tazobactam) exceeds the Ct
AE Adverse event
ALT Alanine aminotransferase
ANC Absolute neutrophil count
ASaT All Subjects as Treated
AST Aspartate aminotransferase
AUC Area under the concentration -time curve
BLI β-lactamase inhibitor
BP Blood pressure
CE Clinically  evaluable
CI Confidence interval
cIAI Complicated intra -abdominal infection
CID Component identification
CL Clearance
CLSI Clinical and Laboratory  Standards Institute
cLUTI Complicated lower urinary  tract infection
Cmax Maximum observed concentration
CrCL Creatinine clearance
CRF Case report form
CSR Clinical study  report
Ct Threshold drug concentration
CT Computed tomograph y
CVA Costovertebral angle
CYP450 Cytochrome P450
cIAI Complicated intra -abdominal infection
cUTI Complicated urinary  tract infection 
   05L60Q
Product:   MK-7625A 104
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialAbbreviation or 
Term Definition
DAO Data as observed
DMC Data Monitoring Committee
ECI Events of clinical interest
eCRF Electronic case report form
EDC Electronic data capture
eGFR Estimated glomerular filtration rate
EMA European Medicines Association
EOC Executive Oversight Committee
EOIV End of IV Treatment (Visit)
EOT End of Treatment (Visit)
ERC Ethics Review Committee
ESBL Extended -spectrum β -lactamase
EU European Union
FDA Food and Drug Administration
FDAAA FDA Amendments Act
GCP Good Clinical Practice
Hg Mercury (for BP, mm Hg)
IAI Intra-abdominal infection
IB Investigator’s Brochure
ICH International Council for Harmonisation
IRB Institutional Review Board
IV Intravenous
IVRS Interactive voice response sy stem
IWRS Integrated web response sy stem
LFU Last Follow -up (Visit)
M&N Miettinen and Nurminen (statistical method)
MDR Multidrug -resistant
ME Microbiologically  evaluable
MIC Minimuminhibitory  concentration
mMITT Microbiological Modified I ntent-to-Treat
MRI Magnetic resonance imaging 
   05L60Q
Product:   MK-7625A 105
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
ConfidentialAbbreviation or 
Term Definition
MRSA Methicillin -resistant Staphylococcus aureus
NP Nosocomial pneumonia
PCS Potentially  clinically  significant
PD Pharmacod ynamic
PIN Personal identification number
PK Pharmacokinetic(s)
PTA Probability  of target attainment
Q Intercompartmental clearance
RBC Red blood cell
SAE Serious adverse event
SD Standard deviation
SOP Standard operating procedure
sSAP Supplemental Statistical Analysis P lan
T>MIC Time above MIC
t½ Elimination half-life
TEAE Treatment -emergent adverse event
TOC Test of Cure (Visit)
ULN Upper limit of normal
US United States (of America)
UTI Urinary tract infection
Vc Central volume of distribution
Vp Peripheral volume of distribution
WBC White blood cell 
   05L60Q
Product:   MK-7625A 106
Protocol/Amendment No.:   034-03 
MK-7625A-034-03 Final Protocol 14-Sep-2020
Confidential13.0SIGNATURES
Sponsor's Representative
TYPED NAME
TITLE
SIGNATURE
DATE SIGNED
Investigator
I agree to conduct this clinical trial in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol (including other manuals and documents 
referenced from this protocol).  I agree to conduct the trial in accordance with gene rally 
accepted standards of Good Clinical Practice.  I also agree to report all information or data in 
accordance with the protocol and, in particular, I agree to report an y serious adverse events 
as defined in Section 7 .0–TRIAL PROCEDURES ( Assessing and Recording Adverse 
Events).  I also agree to handle all clinical supplies provided b y the Sponsor and collect and 
handle all clinical specimens in accordance with the protocol.  I understand that information 
that identifies me will be used and disclosed as described in the protocol, and that such 
information may  be transferred to countries that do not have laws protecting such 
information.  Since the information in this protocol and the referenced Investigator’s 
Brochure is confidential, I understand that its disclosure to an y third parties, other than those 
involved in approval, supervision, or conduct of the trial is prohibited.  I will ensure that the 
necessary  precautions are taken to protect such information from loss, inadvertent disclosure 
or access b y third parties.
TYPED NAME
TITLE
SIGNATURE
DATE SIGNED 
   05L60Q